0001683168-24-00570810-Q AETHLON MEDICAL INC 20240814202408141710201710201710201710 0 0001683168-24-005708 10-Q 58 20240630 20240814 20240814 AETHLON MEDICAL INC 0000882291 3841 133632859 NV 0331 10-Q 34 001-37487 241209441 11555 SORRENTO VALLEY ROAD, SUITE 203 SAN DIEGO CA 92121 619-941-0360 11555 SORRENTO VALLEY ROAD, SUITE 203 SAN DIEGO CA 92121 BISHOP EQUITIES INC 19930602 10-Q 1 aethlon_i10q-063024.htm FORM 10-Q FOR JUNE 2024 Aethlon Medical, Inc. 10-Q false --03-31 2025 Q1 0000882291 0000882291 2024-04-01 2024-06-30 0000882291 2024-08-14 0000882291 2024-06-30 0000882291 2024-03-31 0000882291 2023-04-01 2023-06-30 0000882291 us-gaap:CommonStockMember 2024-03-31 0000882291 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000882291 us-gaap:RetainedEarningsMember 2024-03-31 0000882291 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000882291 us-gaap:NoncontrollingInterestMember 2024-03-31 0000882291 us-gaap:CommonStockMember 2023-03-31 0000882291 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000882291 us-gaap:RetainedEarningsMember 2023-03-31 0000882291 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000882291 us-gaap:NoncontrollingInterestMember 2023-03-31 0000882291 2023-03-31 0000882291 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000882291 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000882291 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000882291 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000882291 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0000882291 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000882291 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000882291 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000882291 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000882291 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0000882291 us-gaap:CommonStockMember 2024-06-30 0000882291 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000882291 us-gaap:RetainedEarningsMember 2024-06-30 0000882291 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000882291 us-gaap:NoncontrollingInterestMember 2024-06-30 0000882291 us-gaap:CommonStockMember 2023-06-30 0000882291 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000882291 us-gaap:RetainedEarningsMember 2023-06-30 0000882291 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000882291 us-gaap:NoncontrollingInterestMember 2023-06-30 0000882291 2023-06-30 0000882291 2023-10-03 2023-10-04 0000882291 us-gaap:LetterOfCreditMember 2024-06-30 0000882291 aemd:ATM2022AgreementMember 2022-03-24 0000882291 aemd:ATM2022AgreementMember 2024-04-01 2024-06-30 0000882291 aemd:ATM2022AgreementMember 2023-04-01 2023-06-30 0000882291 aemd:ATM2022AgreementMember aemd:WainwrightMember 2023-04-01 2023-06-30 0000882291 aemd:May2024PublicOfferingMember us-gaap:CommonStockMember 2024-05-16 2024-05-17 0000882291 aemd:May2024PublicOfferingMember aemd:ClassAWarrantsMember 2024-05-17 0000882291 aemd:May2024PublicOfferingMember aemd:ClassBWarrantsMember 2024-05-17 0000882291 aemd:May2024PublicOfferingMember aemd:PrefundedWarrantsMember 2024-05-17 0000882291 aemd:May2024PublicOfferingMember aemd:PlacementAgentMember 2024-05-16 2024-05-17 0000882291 aemd:May2024PublicOfferingMember aemd:PlacementAgentWarrantsMember 2024-05-17 0000882291 aemd:May2024PublicOfferingMember 2024-05-16 2024-05-17 0000882291 aemd:May2024PublicOfferingMember aemd:ClassAWarrantsMember 2024-06-01 2024-06-30 0000882291 aemd:May2024PublicOfferingMember aemd:ClassBWarrantsMember 2024-06-01 2024-06-30 0000882291 aemd:May2024PublicOfferingMember aemd:ClassAAndClassBWarrantsMember 2024-06-01 2024-06-30 0000882291 aemd:Director1Member us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0000882291 aemd:Director2Member us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0000882291 aemd:Director3Member us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0000882291 aemd:Director4Member us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0000882291 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0000882291 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000882291 aemd:NonEmployeeDirectorsMember 2024-06-30 0000882291 aemd:EmployeeMember aemd:SeparationAgreementMember 2024-04-01 2024-06-30 0000882291 aemd:EmployeeMember aemd:SeparationAgreementMember 2024-06-30 0000882291 srt:ChiefExecutiveOfficerMember aemd:SeparationAgreementMember 2024-06-30 0000882291 aemd:AccruedBoardFeesMember 2024-06-30 0000882291 aemd:AccruedBoardFeesMember 2024-03-31 0000882291 aemd:AccruedVacationMember 2024-06-30 0000882291 aemd:AccruedVacationMember 2024-03-31 0000882291 aemd:AccruedSeparationExpensesMember 2024-06-30 0000882291 aemd:AccruedSeparationExpensesMember 2024-03-31 0000882291 aemd:StockBasedCompensationMember 2024-04-01 2024-06-30 0000882291 aemd:StockBasedCompensationMember 2023-04-01 2023-06-30 0000882291 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0000882291 us-gaap:StockOptionMember 2024-04-01 2024-06-30 0000882291 us-gaap:StockOptionMember 2024-06-30 0000882291 us-gaap:OptionMember 2024-03-31 0000882291 us-gaap:OptionMember 2024-04-01 2024-06-30 0000882291 us-gaap:OptionMember 2024-06-30 0000882291 us-gaap:OptionMember aemd:ExercisePrice1Member 2024-06-30 0000882291 us-gaap:OptionMember aemd:ExercisePrice1Member 2024-04-01 2024-06-30 0000882291 us-gaap:OptionMember aemd:ExercisePrice2Member 2024-06-30 0000882291 us-gaap:OptionMember aemd:ExercisePrice2Member 2024-04-01 2024-06-30 0000882291 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0000882291 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0000882291 us-gaap:OptionMember 2023-04-01 2023-06-30 0000882291 us-gaap:WarrantMember 2024-03-31 0000882291 us-gaap:WarrantMember 2024-04-01 2024-06-30 0000882291 us-gaap:WarrantMember 2024-06-30 0000882291 aemd:OfficeAndLaboratorySpaceMember 2024-04-01 2024-06-30 0000882291 aemd:ManufacturingSpaceMember 2024-04-01 2024-06-30 0000882291 aemd:ManufacturingSpaceMember 2024-06-30 0000882291 aemd:OfficeLabAndManufacturingLeasesMember 2024-06-30 0000882291 aemd:OfficeAndLaboratorySpaceMember 2024-06-30 0000882291 aemd:RestrictedCashMember 2024-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Table of Contents Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â (Mark One) Â â˜’Â Â Â Â Â QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended June 30, 2024 Â OR Â â˜Â Â Â Â Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from _____to_____ Â COMMISSION FILE NUMBER 001-37487 Â Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Â nevada 13-3632859 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Â Â 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO, CA 92121 (Address of principal executive offices) (Zip Code) Â (619) 941-0360 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â TITLE OF EACH CLASS COMMON STOCK, $0.001 PAR VALUE TRADING SYMBOL AEMD NAME OF EACH EXCHANGE ON WHICH REGISTERED NASDAQ CAPITAL MARKET Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YesÂ Â â˜’ NoÂ Â â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filerâ€, â€œsmaller reporting companyâ€, and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated Filer â˜ Accelerated Filer â˜ Non-accelerated Filer â˜’ Smaller reporting company â˜’ Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Â As of August 14, 2024, the registrant had outstanding 13,937,327 shares of common stock, $0.001 par value. Â Â Â Â Â Â Â Â TABLE OF CONTENTS Â PART I. FINANCIAL INFORMATION 4 Â Â Â Â ITEM 1. FINANCIAL STATEMENTS 4 Â Â Â Â Â CONDENSED CONSOLIDATED BALANCE SHEETS AT JUNE 30, 2024 (UNAUDITED) AND MARCH 31, 2024 4 Â Â Â Â Â CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) 5 Â Â Â Â CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) 6 Â Â Â Â Â CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) 7 Â Â Â Â NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 8 Â Â Â Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 19 Â Â Â Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 26 Â Â Â Â ITEM 4. CONTROLS AND PROCEDURES 26 Â Â Â PART II. OTHER INFORMATION 27 Â Â Â Â ITEM 1. LEGAL PROCEEDINGS 27 Â Â Â Â ITEM 1A. RISK FACTORS 27 Â Â Â Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 28 Â Â Â Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES 28 Â Â Â Â ITEM 4. MINE SAFETY DISCLOSURES 28 Â Â Â Â ITEM 5. OTHER INFORMATION 28 Â Â Â ITEM 6. EXHIBITS 29 Â Â Â Â Â SIGNATURES 30 Â Â Â Â 2Â Â Â CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS Â This Quarterly Report on Form 10-Q, or Quarterly Report, contains â€œforward-looking statementsâ€ within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by those sections. Â We may, in some cases, use words such as â€œanticipate,â€ â€œbelieve,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œintend,â€ â€œmay,â€ â€œplan,â€ â€œpotential,â€ â€œpredict,â€ â€œproject,â€ â€œshould,â€ â€œwill,â€ â€œwouldâ€ or the negative of these terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Such statements, include, but are not limited to, statements contained in this Quarterly Report relating to our business, business strategy, products and services we may offer in the future, the timing and results of future clinical trials, and capital outlook, successful completion of our clinical trials, our ability to raise additional capital, our ability to maintain our Nasdaq listing, U.S. Food and Drug Administration, or FDA, approval of our products candidates, our ability to comply with changing government regulations, patent protection of our proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors detailed herein and in other of our filings with the Securities and Exchange Commission, or the SEC. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statement of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward looking statements include, but are not limited to, a decline in general economic conditions nationally and internationally, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, inability to raise capital to fund continuing operations, changes in government regulation, and other factors (including the risks contained in Item 1A of our most recent Annual Report on Form 10-K under the heading â€œRisk Factorsâ€) relating to our industry, our operations and results of operations and any businesses that may be acquired by us. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Â Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, we undertake no obligation to and do not intend to update any of the forward-looking statements to conform these statements to actual results. Â Â Â Â Â 3Â Â Â PART I. FINANCIAL INFORMATION Â ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Â AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Â Â Â Â Â Â Â June 30, 2024Â Â March 31, 2024Â Â Â (Unaudited)Â Â Â Â ASSETSÂ Â Â Â Â Â Current assetsÂ Â Â Â Â Â Cash and cash equivalentsÂ $9,072,379Â Â $5,441,978Â Deferred Offering CostÂ Â â€“Â Â Â 277,827Â Prepaid expenses and other current assetsÂ Â 478,058Â Â Â 505,983Â Total current assetsÂ Â 9,550,437Â Â Â 6,225,788Â Â Â Â Â Â Â Â Property and equipment, netÂ Â 929,306Â Â Â 1,015,229Â Operating lease right-of-use assetÂ Â 813,900Â Â Â 883,054Â Patents, netÂ Â 963Â Â Â 1,100Â Restricted cashÂ Â 87,506Â Â Â 87,506Â DepositsÂ Â 33,305Â Â Â 33,305Â Total assetsÂ $11,415,417Â Â $8,245,982Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITYÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Current liabilitiesÂ Â Â Â Â Â Â Â Accounts payableÂ $1,068,134Â Â $777,862Â Due to related partiesÂ Â 732,518Â Â Â 546,434Â Operating lease liability, current portionÂ Â 296,093Â Â Â 290,565Â Other current liabilitiesÂ Â 32,203Â Â Â 215,038Â Total current liabilitiesÂ Â 2,128,948Â Â Â 1,829,899Â Â Â Â Â Â Â Â Operating lease liability, less current portionÂ Â 573,852Â Â Â 649,751Â Total liabilitiesÂ Â 2,702,801Â Â Â 2,479,650Â Â Â Â Â Â Â Â Stockholdersâ€™ EquityÂ Â Â Â Â Â Â Â Common stock, par value $0.001 per share; 60,000,000 shares authorized as of June 30, 2024 and March 31, 2024; 13,937,327 and 2,629,725 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectivelyÂ Â 13,937Â Â Â 2,629Â Additional paid-in capitalÂ Â 165,844,620Â Â Â 160,337,371Â Accumulated other comprehensive lossÂ Â (7,773)Â Â (6,940) Accumulated deficitÂ Â (157,138,168)Â Â (154,566,728) Â Â Â Â Â Â Â Â Total stockholdersâ€™ equityÂ Â 8,712,616Â Â Â 5,766,332Â Â Â Â Â Â Â Â Total liabilities and stockholdersâ€™ equityÂ $11,415,417Â Â $8,245,982Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â Â Â Â 4Â Â Â AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Month Periods Ended June 30, 2024 and 2023 (Unaudited) Â Â Â Â Â Â Â Â Three Months Ended June 30, 2024Â Â Three Months Ended June 30, 2023Â Â Â Â Â Â Â Â OPERATING EXPENSESÂ Professional feesÂ $614,082Â Â $976,638Â Payroll and related expensesÂ Â 1,254,802Â Â Â 1,123,239Â General and administrativeÂ Â 751,974Â Â Â 1,308,283Â Total operating expensesÂ Â 2,620,858Â Â Â 3,408,160Â OPERATING LOSSÂ Â (2,620,858)Â Â (3,408,160) Â Â Â Â Â Â Â Â Â Â OTHER INCOMEÂ Â Â Â Â Â Â Â Â Interest incomeÂ Â 49,418Â Â Â 125,981Â Â Â Â Â Â Â Â Â Â Â Â NET LOSSÂ Â (2,571,440)Â Â (3,282,179) Â Â Â Â Â Â Â Â Â Â NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.Â Â (2,571,440)Â Â (3,282,179) Â Â Â Â Â Â Â Â Â Â OTHER COMPREHENSIVE LOSSÂ Â (833)Â Â (994) Â Â Â Â Â Â Â Â Â Â COMPREHENSIVE LOSSÂ $(2,572,273)Â $(3,283,173) Â Â Â Â Â Â Â Â Â Â Basic and diluted net loss per share attributable to common stockholdersÂ $(0.34)Â $(1.35) Â Â Â Â Â Â Â Â Â Â Weighted average number of common shares outstanding â€“ basic and dilutedÂ Â 7,457,888Â Â Â 2,431,476Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â Â Â Â 5Â Â Â AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY For the Three Months Ended June 30, 2024 and 2023 (Unaudited) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Â Â â€“ Â Â Â (3,282,179) Other comprehensive loss Â Â â€“ Â Â Â â€“ Â Â Â â€“ Â Â Â (994) Â Â â€“ Â Â Â (994) BALANCE â€“ JUNE 30, 2023 Â Â 2,483,547 Â Â $ 2,484 Â Â $ 158,754,282 Â Â $ (145,640,734) Â $ (7,135) Â $â€“ Â Â $ 13,108,897 Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â Â Â Â 6Â Â Â AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS For the Three Months Ended June 30, 2024 and 2023 (Unaudited) Â Â Â Â Â Â Â Â Three months Ended June 30, 2024Â Â Three months Ended June 30, 2023Â Â Â Â Â Â Â Â Cash flows used in operating activities:Â Â Â Â Â Â Â Net lossÂ $(2,571,440)Â $(3,282,179) Adjustments to reconcile net loss to net cash used in operating activities:Â Â Â Â Â Â Â Depreciation and amortizationÂ Â 86,060Â Â Â 90,325Â Stock based compensationÂ Â 139,328Â Â Â 250,114Â Accretion of right-of-use operating lease assetÂ Â (1,217)Â Â 1,238Â Changes in operating assets and liabilities:Â Â Â Â Â Â Â Prepaid expenses and other current assetsÂ Â 89,872Â Â Â 146,409Â Accounts payable and other current liabilitiesÂ Â 323,776Â Â Â 334,613Â Deferred revenueÂ Â â€“Â Â Â â€“Â Due to related partiesÂ Â 186,084Â Â Â (22,907) Net cash used in operating activitiesÂ Â (1,747,537)Â Â (2,482,387) Â Â Â Â Â Â Â Â Cash flows used in investing activities:Â Â Â Â Â Â Â Purchases of property and equipmentÂ Â â€“Â Â Â (230,383) Net cash used in investing activitiesÂ Â â€“Â Â Â (230,383) Â Â Â Â Â Â Â Â Cash flows provided by financing activities:Â Â Â Â Â Â Â Â Proceeds from the issuance of common stock, netÂ Â 3,539,907Â Â Â 1,086,119Â Proceeds from the issuance of common stock upon Class A and Class B warrant exercisesÂ Â 1,844,400Â Â Â â€“Â Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expenseÂ Â (5,078)Â Â (8,372) Net cash provided by financing activitiesÂ Â 5,379,229Â Â Â 1,077,747Â Â Â Â Â Â Â Â Effect of exchange rate on changes on cashÂ Â (1,290)Â Â (186) Â Â Â Â Â Â Â Â Net increase (decrease) in cash, cash equivalents and restricted cashÂ Â 3,630,402Â Â Â (1,635,209) Â Â Â Â Â Â Â Â Cash, cash equivalents and restricted cash at beginning of periodÂ Â 5,529,483Â Â Â 14,620,449Â Â Â Â Â Â Â Â Cash, cash equivalents and restricted cash at end of periodÂ $9,159,885Â Â $12,985,240Â Â Â Â Â Â Â Â Supplemental disclosures of cash flow information:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Supplemental disclosures of non-cash investing and financing activities:Â Â Â Â Â Â Â Par value of shares issued for vested restricted stock units and net stock option exerciseÂ $28Â Â $64Â Â Â Â Â Â Â Â Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:Â Â Â Â Â Â Â Â Cash and cash equivalentsÂ $9,072,379Â Â $12,897,734Â Restricted cashÂ Â 87,506Â Â Â 87,506Â Cash, cash equivalents and restricted cashÂ $9,159,885Â Â $12,985,240Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â Â Â Â 7Â Â Â AETHLON MEDICAL, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) June 30, 2024 Â Â 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION Â Aethlon Medical, Inc., or Aethlon, the Company, we or us, is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients, the Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and metastasis, and in life-threatening infectious diseases. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a â€œBreakthrough Deviceâ€ for two independent indications: Â Â Â· the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes or exosomal particles have been shown to participate in the development or severity of the disease; and Â Â· the treatment of life-threatening viruses that are not addressed with approved therapies. Â We believe the Hemopurifier may be a substantial advancement in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove harmful exosomes and exosomal particles that promote the growth and spread of tumors. In October 2022, we formed a wholly-owned subsidiary in Australia to initially conduct oncology-related clinical research, then seek regulatory approval and commercialize our Hemopurifier in Australia. We are currently working with our contract research organization, or CRO, on preparations to conduct a clinical trial in Australia in patients with solid tumors, including head and neck cancer, and gastrointestinal cancers. Â In January 2023, we entered into an agreement with North American Science Associates, LLC, or NAMSA, a world leading medical technology CRO offering global end-to-end development services, to oversee our planned clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA agreed to manage our planned clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors. Â We recently completed an in vitro binding study of relevant oncology targets, to provide pre-clinical evidence to support our trial design and translational endpoints. Our study indicated positive results, providing evidence that our Hemopurifier removes extracellular vesicles, or EVs, from plasma. This translational study provides pre-clinical evidence to support our planned phase 1 safety, feasibility and dose-finding clinical trials of our Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as KeytrudaÂ® or OpdivoÂ®. In addition to an interested initial trial site in India, we had three interested sites in Australia that were awaiting our completion of this in vitro binding study. We added the data from this study to our Clinical Investigator Brochure and submitted that brochure to the Ethics Committee of Royal Adelaide Hospital in Australia and in June 2024, we received approval for our proposed phase 1 oncology trial from the Ethics Committee from Royal Adelaide Hospital. We are currently in the process of applying to the Ethics Committees of the two additional interested clinical trial sites in Australia and the site in India. Â We also believe that the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola. Â Â Â Â 8Â Â Â Additionally,Â in vitro,Â the Hemopurifier has been demonstrated to capture H5N1 bird flu virus, H1N1 swine flu virus, Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, Monkeypox virus and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research institutes. Â On June 17, 2020, the FDA approved a supplement to our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19, or COVID-19, in a new feasibility study.Â That study was designed to enroll up to 40 subjects at up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19, be admitted to an ICU and have acute lung injury and/or severe or life-threatening disease, among other criteria. Endpoints for this study, in addition to safety, included reduction in circulating virus, as well as clinical outcomes (NCT # 04595903). In January 2021, the Hemopurifier was used to treat a viremic patient, under our emergency use approval, with a predicted risk of mortality of 80% and the Hemopurifier was able to reduce the patientâ€™s SARS-CoV-2 plasma viral load by 58.4%.Â In June 2022, the first patient in this study was enrolled and completed the Hemopurifier treatment phase of the protocol. Due to the lack of COVID-19 patients in the ICUs of our trial sites, we terminated this study in 2022. However, our IDE for this indication remains open, as we have an active COVID-19 trial in India and wish to preserve the option of enrolling patients if the situation with COVID-19 changes. Â Under Single Patient Emergency Use regulations, Aethlon has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated with our Hemopurifier in our COVID-19 clinical trial discussed above. Â In October 2022, we launched a wholly owned subsidiary in Australia, formed to conduct clinical research, seek regulatory approval and commercialize our Hemopurifier in that country. The subsidiary will initially focus on the planned oncology trials in Australia. Â In August 2024, the Bellberry Human Research Ethics Committee granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the HemopurifierÂ® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia. Â In June 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for the same safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as KeytrudaÂ® (pembrolizumab) or OpdivoÂ® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia. Â We also obtained ethics review board, or ERB, approval from and entered into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi NCR, India, for a COVID-19 clinical trial at that location. Â In May 2023, we received ERB approval from the MAMC, for a second site for our clinical trial in India to treat severe COVID-19. MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government. Â We now have two sites in India for this trial with the Medanta Medicity Hospital and Maulana Azad Medical College, or MAMC. One patient has been treated to date; however, we have been informed by our CRO that a new COVID-19 subvariant was detected in India recently. Our COVID-19 trial in India remains open in the event that there are COVID-19 admissions to the ICUs at our sites in India. Â Â Â Â 9Â Â Â Additionally, based on preclinical data with acellular kidney perfusates, we believe that the Hemopurifier has potential applications in organ transplantation. We are investigating whether the Hemopurifier, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses, exosomes, RNA molecules, cytokines, chemokines and other inflammatory molecules from recovered organs. We initially are focused on recovered kidneys from deceased donors. We have previously demonstrated the removal of multiple viruses and exosomes and exosomal particles from buffer solutions, in vitro, utilizing a scaled-down version of our Hemopurifier and believe this process could reduce transplantation complications by improving graft function, reducing graft rejection, maintaining or improving organ viability prior to transplantation, and potentially reducing the number of kidneys rejected for transplant. Â Successful outcomes of human trials will also be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology. Â In addition to the foregoing, we are monitoring closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and the surrounding areas, as well as related political and economic responses and counter-responses by various global factors on our business. Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing military conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical research will depend on future developments, as well as the economic impact on national and international markets that are highly uncertain. Â We incorporated in Nevada on March 10, 1999. Our executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our website address is www.aethlonmedical.com. Â Our common stock is listed on the Nasdaq Capital Market under the symbol â€œAEMD.â€ Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â During the three months ended June 30, 2024, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024. Â REVERSE STOCK SPLIT Â On October 4, 2023, we effected a 1-for-10 reverse stock split of our then outstanding shares of common stock. Accordingly, each 10 shares of outstanding common stock then held by our stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock remained at 60,000,000 shares following the stock split. The accompanying unaudited condensed consolidated financial statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred on April 1, 2023. All shares and per share amounts have been revised accordingly. Â Â Â Â 10Â Â Â Basis of Presentation and Use of Estimates Â Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended March 31, 2024, included in our Annual Report on Form 10-K filed with the SEC on June 27, 2024. The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements, taken as a whole, contain all adjustments that are of a normal recurring nature necessary to present fairly our operating results, cash flows, and financial position as of and for the period ended June 30, 2024. Estimates were made relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2024 has been derived from the audited consolidated balance sheet at March 31, 2024, contained in the above referenced 10-K. The results of operations for the three months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full year or any future interim periods. Â Reclassifications Â Certain prior year balances within the unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation, including the impact of the reverse stock split. Â LIQUIDITY AND GOING CONCERN Â Management expects existing cash as of June 30, 2024 to be sufficient to fund the Companyâ€™s operations for at least twelve months from the issuance date of these condensed consolidated financial statements. In previous filings, we disclosed substantial doubt about our ability to continue as a going concern due to recurring losses and negative cash flows. We have addressed these concerns by raising $5,379,229, net, through the combination of an equity offering and warrant exercises, combined with our recent financial performance which has shown a significant decrease in expenses and use of cash. For the three-month period ended June 30, 2024, expenses decreased by approximately $787,000 compared to June 30, 2023, accompanied by an approximate $964,000 decrease in cash used in operating and investing activities. As a result of these actions, management believes that the substantial doubt regarding our ability to continue as a going concern has been alleviated. Â The accompanying unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. Â Restricted Cash Â To comply with the terms of our laboratory and office lease and our lease for our manufacturing space (see Note 10), we caused our bank to issue two standby letters of credit, or L/Cs, in the aggregate amount of $87,506 in favor of our landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs, we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit. We have classified that amount as restricted cash, a long-term asset, on our balance sheet. Â Â Â Â 11Â Â Â 2. LOSS PER COMMON SHARE Â Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded, as their effect would be antidilutive. Â As of June 30, 2024 and 2023, an aggregate of 13,523,429 and 2,291,234 potential common shares, respectively, consisting of shares underlying outstanding stock options, warrants, and restricted stock units were excluded, as their inclusion would be antidilutive. Â 3. RESEARCH AND DEVELOPMENT EXPENSES Â Our research and development costs are expensed as incurred. We incurred research and development expenses during the three-month periods ended June 30, 2024 and 2023, which are included in various operating expense line items in the accompanying condensed consolidated statements of operations. Our research and development expenses in those periods were as follows: Â Schedule of research and development expensesÂ Â Â Â Â Â Â Â Â June 30,Â Â June 30,Â Â 2024Â Â 2023Â Three months endedÂ $414,658Â Â $678,922Â Â 4. RECENT ACCOUNTING PRONOUNCEMENTS Â In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued ASU 2023-07 â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€). ASU 2023-07 intends to improve reportable segment disclosure requirements, enhance interim disclosure requirements and provide new segment disclosure requirements for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods with fiscal years beginning after December 15, 2024. ASU 2023-07 is to be adopted retrospectively to all prior periods presented. We are currently assessing the impact this guidance will have on our consolidated financial statements; however, we do not expect a material impact. Â In December 2023, the FASB issued Accounting Standards Update 2023-09, Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which requires enhanced annual disclosures for specific categories in the rate reconciliation and income taxes paid disaggregated by federal, state and foreign taxes. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. The Company is evaluating if the adoption of this new standard will have a material effect on our

disclosures. Â In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The adoption of ASU No. 2016-13 for smaller reporting companies that did not previously early adopt was January 1, 2023. The Company maintained US Treasury bills with maturities of less than three months and expects zero credit losses from these securities. As a result, the Company did not record an allowance for expected credit losses. Â Â Â Â 12Â Â Â 5. EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 Â 2022 At The Market Offering Agreement with H.C. Wainwright & Co., LLC Â On March 24, 2022, we entered into an At The Market Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, which established an at-the-market equity program pursuant to which we may offer and sell shares of our common stock from time to time, as set forth in the 2022 ATM Agreement. Â The offering was registered under the Securities Act of 1933, as amended, or the Securities Act, pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-259909), as previously filed with the SEC and declared effective on October 21, 2021. We filed a prospectus supplement, dated March 24, 2022, with the SEC that provides for the sale of shares of our common stock having an aggregate offering price of up to $15,000,000, or the 2022 ATM Shares. Â Under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares by any method permitted by law and deemed to be an â€œat the market offeringâ€ as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the 2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if the sales cannot be effected at or above the price designated by us from time to time. Â We are not obligated to make any sales of the 2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate upon the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein. Â The 2022 ATM Agreement contains customary representations, warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement. Â During the three months ended June 30, 2024, we did not raise proceeds under the 2022 ATM Agreement. During the three months ended June 30, 2023, we raised net proceeds of $1,086,119, net of $27,999 in commissions to Wainwright and $5,846 in other offering expenses, through the sale of 177,890 shares of our common stock at an average price of $6.11 per share under the 2022 ATM Agreement. Â May 2024 Public Offering Â On May 17, 2024, we closed a public offering pursuant to which we sold an aggregate of: (i) 2,450,000 shares of our common stock and accompanying Class A warrants to purchase up to 2,450,000 shares of common stock and Class B warrants to purchase up to 2,450,000 shares of common stock, at a combined public offering price of $0.58 per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase 5,650,000 shares of common stock and accompanying Class A warrants to purchase up to 5,650,000 shares of common stock and Class B warrants to purchase up to 5,650,000 shares of common stock, at a combined public offering price of $0.579 per pre-funded warrant and accompanying warrants, which is equal to the public offering price per share of common stock, and accompanying warrants less the $0.001 per share exercise price of each such pre-funded warrant. Â All pre-funded warrants issued in the offering were exercised in the quarter ended June 30, 2024. The Class A and Class B warrants each have an exercise price of $0.58 per share, are immediately exercisable, and, in the case of Class A warrants, will expire on May 17, 2029, and in the case of Class B warrants, will expire on May 19, 2025. The exercise price of the Class A and Class B warrants is also subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in such warrants. Â Maxim Group LLC (â€œMaximâ€), served as the exclusive placement agent in connection with the offering. We paid Maxim a cash fee of 6.5% of the aggregate gross proceeds raised at the closing of the offering, and reimbursement of certain expenses and legal fees in the amount of $100,000. We also issued to designees of Maxim warrants to purchase up to an aggregate of 324,000 shares of common stock (the â€œPlacement Agent Warrantsâ€). The Placement Agent Warrants have an exercise price of $0.58 per share and have substantially the same terms as the Class A warrants, except the Placement Agent Warrants are not subject to an exercise price reset, are non-exercisable until November 15, 2024, and will expire on May 15, 2029. Â Â Â Â 13Â Â Â The gross proceeds from the offering, before deducting the placement agentâ€™s fees and other offering expenses, were approximately $4.7 million. Net proceeds, of the offering, after deducting the placement agent fees and expenses and other offering expenses payable by us, were are approximately $3.5 million. In June 2024, and holders of Class A and Class B warrants exercised 300,000 shares and 2,880,000 shares, respectively, for additional proceeds of $1,844,400. Â The shares of Common Stock, the Class A and Class B warrants, the pre-funded warrants and the Placement Agent Warrants described above and the underlying shares of Common Stock were offered pursuant to a Registration Statement on Form S-1, as amended (File No. 333-278188) (the â€œRegistration Statementâ€), which was declared effective by the Securities and Exchange Commission (the â€œSECâ€) on May 15, 2024. Â Restricted Stock Unit Grants Â On April 16, 2024, our Board of Directors approved, pursuant to the terms of the Director Compensation Policy, the grant of the annual RSUs under the Director Compensation Policy to each of the four non-employee directors of the Company then serving on the Board of Directors. The Director Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs at the beginning of each fiscal year for current non-employee directors then serving on the Board of Directors, and for a grant of stock options or $75,000 worth of RSUs for a newly elected non-employee director, with each RSU priced at the average of the closing prices for the five trading days preceding and including the date of grant, or $1.52 per share for the RSUs granted in April 2024. As a result, in April 2024, the four eligible directors were each granted 32,894 RSUs under the Companyâ€™s 2020 Equity Incentive Plan, as amended, or the 2020 Plan. The RSUs are subject to vesting in four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2024, September 30, 2024, December 31, 2024, and March 31, 2025, subject in each case to the directorâ€™s Continuous Service (as defined in the 2020 Plan), through such dates. Vesting will automatically terminate upon the directorâ€™s termination of Continuous Service prior to any vesting date. Â During the three-months ended June 30, 2024, 27,602 shares were issued upon settlement of 37,779 RSUs. Â 6. RELATED PARTY TRANSACTIONS Â During the three months ended June 30, 2024, we accrued unpaid fees of $68,250 owed to our non-employee directors. Â As a result of entering into a Separation Agreement effective July 1, 2024 with a former employee, we paid out accrued vacation of $9,688 in the three months ended June 30, 2024. That accrued vacation was previously recorded in the due to related parties account. In addition, pursuant to the terms of the Separation Agreement, we accrued $323,534 for salary and related expenses connected with the Separation Agreement. Accrued separation expenses includes a balance of approximately $186,000 owed to our former Chief Executive Officer, as stipulated in his Separation Agreement. Â Amounts due to related parties were comprised of the following items: Â Schedule of amounts due to related partiesÂ Â Â Â Â Â Â Â Â June 30, 2024Â Â March 31, 2024Â Accrued Board feesÂ $68,250Â Â $68,250Â Accrued vacation to all employeesÂ Â 154,816Â Â Â 167,973Â Accrued separation expensesÂ Â 509,452Â Â Â 310,211Â Total due to related partiesÂ $732,518Â Â $546,434Â Â Â Â Â Â 14Â Â Â 7. OTHER CURRENT LIABILITIES Â Other current liabilities were comprised of the following items: Â Schedule of other current liabilitiesÂ Â Â Â Â Â Â Â June 30,Â Â March 31,Â Â Â 2024Â Â 2024Â Accrued professional feesÂ $32,203Â Â $215,038Â Total other current liabilitiesÂ $32,203Â Â $215,038Â Â 8. STOCK COMPENSATION Â The following tables summarize share-based compensation expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three month periods ended June 30, 2024 and 2023: Â Schedule of share-based compensation expensesÂ Â Â Â Â Â Â June 30, 2024Â Â June 30, 2023Â Vesting of stock options and restricted stock unitsÂ $139,328Â Â $250,114Â Total stock-based compensation expenseÂ $139,328Â Â $250,114Â Â Â Â Â Â Â Â

2023, we entered into an agreement with North American Science Associates, LLC, or NAMSA, a world leading MedTech CRO offering global end-to-end development services, to oversee our planned clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA agreed to manage our planned clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors. We anticipate that the initial clinical trials will begin in Australia. Â In August 2024, the Bellberry Human Research Ethics Committee granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the HemopurifierÂ® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia. Â In June 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for the same safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as KeytrudaÂ® (pembrolizumab) or OpdivoÂ® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia. Â Â Â Â 19Â Â Â We also believe the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola. Â Additionally, in vitro, the Hemopurifier has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research institutes. Â On June 17, 2020, the FDA approved a supplement to our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19, or COVID-19, in a New Feasibility Study. That study was designed to enroll up to 40 subjects at up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19, be admitted to an intensive care unit, or ICU, and have acute lung injury and/or severe or life-threatening disease, among other criteria. Endpoints for this study, in addition to safety, included reduction in circulating virus as well as clinical outcomes (NCT # 04595903). In June 2022, the first patient in this study was enrolled and completed the Hemopurifier treatment phase of the protocol. Due to lack of COVID-19 patients in the ICUs of our trial sites, we terminated this study in 2022. Â Under Single Patient Emergency Use regulations, the Company has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated with our Hemopurifier in our COVID-19 clinical trial discussed above. Â We previously reported a disruption in our Hemopurifier supply, as our then existing supply of Hemopurifiers expired on September 30, 2022 and, also as previously disclosed, we are dependent on FDA approval of qualified suppliers to manufacture our Hemopurifier. Our intended transition to a new supplier for galanthus nivalis agglutinin, or GNA, a component of our Hemopurifier, continues to be delayed as we work with the FDA for approval of our supplement to our IDE, which is required to make this manufacturing change. We are working with the FDA to qualify this second supplier of our GNA. We also are in the process of completing final testing in order to begin manufacturing Hemopurifiers at our new manufacturing facility in San Diego, California for use in planned U.S. clinical trials, using GNA from our current supplier. The first manufacturing lot that incorporates the GNA from our original supplier was approved and released at the end of December 2023. We also have sufficient Hemopurifiers on hand for use in our planned Australia and India oncology trials. Â In October 2022, we launched a wholly owned subsidiary in Australia, formed to conduct clinical research, seek regulatory approval and commercialize our Hemopurifier in that country. The subsidiary will initially focus on the planned oncology trials in Australia. Â We also obtained ethics review board, or ERB, approval from and entered into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi NCR, India, for a COVID-19 clinical trial at that location. One patient has completed participation in the Indian COVID-19 study. The relevant authorities in India have accepted the use of our Hemopurifiers made with the GNA from our new supplier. Â In May 2023, we also received ERB approval from the Maulana Azad Medical College, or MAMC, for a second site for our clinical trial in India to treat severe COVID-19. MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government. Â In October 2023, we announced that we received clearance from the Drug Controller General of India, the central drug authority in India, to conduct a Phase 1 safety, feasibility and dose-finding trial of the Companyâ€™s HemopurifierÂ in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as KeytrudaÂ® or OpdivoÂ®. The trial is expected to begin following completion of an internal in vitro binding study of relevant targets, and subsequent approval by the respective Ethics Boards of interested sites in India. Â Â Â Â 20Â Â Â Additionally, we announced that we have begun investigating the use of our Hemopurifier in the organ transplant setting. Our objective is to confirm that the Hemopurifier, in our translational studies, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes from recovered organs. We initially are focused on recovered kidneys, in a research collaboration with 34 Lives, PBC. We have previously demonstrated the removal of multiple viruses and exosomes from buffer solutions, in vitro, utilizing a scaled-down version of our Hemopurifier. This process potentially may reduce complications following transplantation of the recovered organ, which can include viral infection, delayed graft function and rejection. We believe this new approach could be additive to existing technologies that currently are in place to increase the number of viable kidneys for transplant. Â Successful outcomes of human trials will also be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology. Â In addition to the foregoing, we are monitoring closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and the surrounding areas, as well as related political and economic responses and counter-responses by various global factors on our business. Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing military conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical research will depend on future developments, as well as the economic impact on national and international markets that are highly uncertain. Â We incorporated in Nevada on March 10, 1999. Our executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our website address is www.aethlonmedical.com. Â Our common stock is listed on the Nasdaq Capital Market under the symbol â€œAEMD.â€ Â WHERE YOU CAN FIND MORE INFORMATION Â We are subject to the informational requirements of the Exchange Act, and must file reports, proxy statements and other information with the SEC. The SEC maintains a website (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding registrants, like us, which file electronically with the SEC. Â RESULTS OF OPERATIONS Â THREE MONTHS ENDED JUNE 30, 2024 COMPARED TO THE THREE MONTHS ENDED JUNE 30, 2023 Â Operating Expenses Â Consolidated operating expenses for the three months ended June 30, 2024 were $2,620,858 compared to $3,408,7160 for the three months ended June 30, 2023. This decrease of $787,302, or 23.1%, in the 2024 period was due to a decrease of $556,309 in general and administrative expenses and a decrease of $362,556 in professional fees, partially offset by an increase in payroll and related expenses of $131,563. Â The $556,309 decrease in general and administrative expenses in the three months ended June 30, 2024 was due to a $447,393 decrease in supplies related to the purchase of raw materials for manufacturing of the Hemopurifier and for lab supplies, a $39,017 decrease in repairs and maintenance associated with the certification of the cleanroom, a $29,092 decrease in travel related to former employee and consultant, $11,226 in insurance expense, a $7,572 decrease in clinical trial expense and $22,000 in various other general operating expenses. Â Â Â Â 21Â Â Â The decrease in professional fees of $362,556 was related to a $136,481 decrease in consulting expenses primarily related to termination of services with a contract manufacturing organization, a $110,418 decrease in scientific consulting, an $83,865 decrease in investor relations expenses associated with more widespread awareness and dissemination of Company news, a $77,920 decrease in legal fees relating to general corporate matters and a decrease of $16,063 associated with a reduction in website services. These decreases were partially offset by a $50,940 increase in audit and accounting expense, and $11,250 increase in board of director fees associated with the addition of a new board member. Â Payroll expenses increased by $131,563 due to an increase in separation expenses of $320,604 related to the termination of an employee and a $16,172 increase in payroll expense associated with an increase in manufacturing headcount. These increases were offset by a decrease of $110,786 in stock based compensation and an $89,152 decrease in general and administration headcount. Â Â Net Loss Â As a result of the changes in expenses noted above, our net loss decreased to $2,571,440 in the three months ended June 30, 2024 from $3,282,179 in the three months ended June 30, 2023. Â Basic and diluted loss attributable to common stockholders was ($0.34) for the three months ended June 30, 2024, compared to ($1.35) for the three-month period ended June 30, 2023. Â LIQUIDITY AND CAPITAL RESOURCES Â As of June 30, 2024, we had a cash balance of $9,072,379 and working capital of $7,421,489. This compares to a cash balance of $5,441,978 and working capital of $4,395,889 at March 31, 2024. Â On May 17, 2024, we closed a public offering of our equity, pursuant to which we sold an aggregate of: (i) 2,450,000 shares of our common stock and accompanying Class A warrants to purchase up to 2,450,000 shares of common stock and Class B warrants to purchase up to 2,450,000 shares of common stock, at a combined public offering price of $0.58 per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase 5,650,000 shares of common stock and accompanying Class A warrants to purchase up to 5,650,000 shares of common stock and Class B warrants to purchase up to 5,650,000 shares of common stock, at a combined public offering price of $0.579 per pre-funded warrant and accompanying warrants, which is equal to the public offering price per share of common stock, and accompanying warrants less the $0.001 per share exercise price of each such pre-funded warrant. The gross proceeds from the offering, before deducting the placement agentâ€™s fees and other offering expenses, were approximately $4.7 million. Net proceeds, of the offering, after deducting the placement agent fees and expenses and other offering expenses payable by us, were are approximately $3.5 million. In June 2024, holders of Class A and Class B warrants exercised 300,000 shares and 2,880,000 shares, respectively, for additional total proceeds of $1,844,400. See the section entitled â€œMay 2024 Public Offering,â€ below, for additional information regarding this offering. Â We expect our existing cash as of June 30, 2024 to be sufficient to fund our operations for at least twelve months from the issuance date of these financial statements. In previous filings, we disclosed substantial doubt about our ability to continue as a going concern due to recurring losses and negative cash flows. We have addressed these concerns by raising $5,379,229, net, through a combination of a equity offering and warrant exercises, combined with our recent financial performance which has shown a significant decrease in expenses and use of cash. For the three-month period ended June 30,2024, expenses decreased by approximately $787,000 compared to June 30, 2023 accompanied by an approximate $964,000 decrease in cash used in operating and investing activities. As a result of these actions, management believes that the substantial doubt regarding our ability to continue as a going concern has been alleviated. Â As we expand our activities, our overhead costs to support personnel, laboratory materials and infrastructure will increase and significant additional financing must be obtained to provide a sufficient source of operating capital. Should the financing we require to sustain our working capital needs be unavailable to us on reasonable terms, if at all, when we require it, we may be unable to support our research and our planned clinical trials. The failure to implement our research and clinical trials would have a material adverse effect on our ability to conduct planned clinical trials and commercialize our products. Â Â Â Â 22Â Â Â Future capital requirements will depend upon many factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinical programs, the time and costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary rights, the time and costs involved in obtaining regulatory approvals, competing technological and market developments, as well as our ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements. We expect to continue to incur increasing negative cash flows and net losses for the foreseeable future. Â 2022 At The Market Offering Agreement with H.C. Wainwright & Co., LLC Â On March 24, 2022, we entered into the 2022 ATM Agreement with Wainwright, which established an at-the-market equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the 2022 ATM Agreement. Â The offering was registered under the Securities Act pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-259909), as previously filed with the SEC and declared effective on October 21, 2021. We filed a prospectus supplement, dated March 24, 2022, with the SEC that provides for the sale of shares of our common stock, or the 2022 ATM Shares, having an aggregate offering price of up to $15,000,000, which was subsequently and most recently updated pursuant to our prospectus supplement, dated September 29, 2022, filed with the SEC that provides for the sale of 2022 ATM Shares having an aggregate offering price of up to $6,625,000. As of June 30, 2024, $5,302,617 of 2022 ATM Shares remained available for sale under the 2022 ATM Agreement. Â Under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares by any method permitted by law and deemed to be an â€œat the market offeringâ€ as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the 2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if the sales cannot be effected at or above the price designated by us from time to time. Â We are not obligated to make any further sales of the 2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate upon the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein. Â The 2022 ATM Agreement contains customary representations, warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement Â During the three months ended June 30, 2024, we did not sell shares of our common stock under the 2022 ATM Agreement. Â May 2024 Public Offering Â On May 17, 2024, we closed a public offering pursuant to which we sold an aggregate of: (i) 2,450,000 shares of our common stock and accompanying Class A warrants to purchase up to 2,450,000 shares of common stock and Class B warrants to purchase up to 2,450,000 shares of common stock, at a combined public offering price of $0.58 per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase 5,650,000 shares of common stock and accompanying Class A warrants to purchase up to 5,650,000 shares of common stock and Class B warrants to purchase up to 5,650,000 shares of common stock, at a combined public offering price of $0.579 per pre-funded warrant and accompanying warrants, which is equal to the public offering price per share of common stock, and accompanying warrants less the $0.001 per share exercise price of each such pre-funded warrant. Â Â Â Â 23Â Â Â All pre-funded warrants issued in the offering were exercised in the quarter ended June 30, 2024. The Class A and Class B warrants each have an exercise price of $0.58 per share, are immediately exercisable, and, in the case of Class A warrants, will expire on May 17, 2029, and in the case of Class B warrants, will expire on May 19, 2025. The exercise price of the Class A and Class B warrants is also subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in such warrants. Â Maxim Group LLC (â€œMaximâ€), served as the exclusive placement agent in connection with the offering. We paid Maxim a cash fee of 6.5% of the aggregate gross proceeds raised at the closing of the offering, and reimbursement of certain expenses and legal fees in the amount of $100,000. We also issued to designees of Maxim warrants to purchase up to an aggregate of 324,000 shares of common stock (the â€œPlacement Agent Warrantsâ€). The Placement Agent Warrants have an exercise price of $0.58 per share and have substantially the same terms as the Class A warrants, except the Placement Agent Warrants are not subject to an exercise price reset, are non-exercisable until November 15, 2024, and will expire on May 15, 2029. Â The gross proceeds from the offering, before deducting the placement agentâ€™s fees and other offering expenses, were approximately $4.7 million.Â Net proceeds, of the offering, after deducting the placement agent fees and expenses and other offering expenses payable by us, were are approximately $3.5 million. In June 2024, and holders of Class A and Class B warrants exercised 300,000 shares and 2,880,000 shares, respectively, for additional proceeds of $1,844,400. Â The shares of Common Stock, the Class A and Class B warrants, the pre-funded warrants and the Placement Agent Warrants described above and the underlying shares of Common Stock were offered pursuant to a Registration Statement on Form S-1, as amended (File No. 333-278188) (the â€œRegistration Statementâ€), which was declared effective by the Securities and Exchange Commission (the â€œSECâ€) on May 15, 2024. Â Cash Flows Â Cash flows from operating, investing and financing activities, as reflected in the accompanying Condensed Consolidated Statements of Cash Flows, are summarized as follows: Â Â Â (In thousands) For the three months endedÂ Â Â June 30, 2024Â Â June 30, 2023Â Cash (used in) provided by:Â Â Â Â Â Â Â Â Â Operating activitiesÂ $(1,748)Â $(2,482) Investing activitiesÂ Â â€“Â Â Â (230) Financing activitiesÂ Â 5,379Â Â Â 1,077Â Effect of exchange rate changes on cashÂ Â (1)Â Â â€“Â Net decrease in cash and restricted cashÂ $3,630Â Â $(1,635) Â Â Â Â 24Â Â Â NET CASH USED IN OPERATING ACTIVITIES. We used cash in our operating activities due to our losses from operations.

Net cash used in operating activities was approximately $1,748,000 in the three months ended June 30, 2024, compared to approximately $2,482,000 in the three months ended June 30, 2023. The primary components in the $734,000 decrease in cash used in our operating activities in the 2024 period was a decrease in our net loss of approximately $711,000 offset by a decrease in non-cash components of approximately $118,000 and a positive net change in other working capital components of $141,000. Â NET CASH USED IN INVESTING ACTIVITIES. We did not use cash for investing activities in the three months ended June 30, 2024, compared to approximately $230,000 in the three months ended June 30, 2023. The $230,000 decrease in the 2024 period was primarily a result of equipment purchase for our laboratory incurred in the three months ended June 2023. Â NET CASH PROVIDED BY FINANCING ACTIVITIES. During the three months ended June 30, 2024, we raised approximately $5,384,000, net of placement agent fees and offering costs, from the sale and issuance of our common stock and warrants in connection with a public offering and the exercise of 300,000 and 1,880,000 Class A and Class B warrants, respectively, by holders thereof. The source of cash from our financing activities was partially offset by the use of approximately $5,000 to pay for the tax withholding upon settlement of on restricted stock units, for a net aggregate amount of cash provided by financing activities of approximately $5,379,000. Â Material Cash Requirements Â We expect our clinical trial expenses for the planned oncology trials in Australia and India to increase for the foreseeable future. Those increases in clinical trial expenses include the cost of manufacturing additional Hemopurifiers. Â In addition, we have entered into leases for our headquarters, laboratory and manufacturing facilities. We expect our rent payments to continue to increase for the foreseeable future. Â Future capital requirements will depend upon many factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinical programs, the time and costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary rights, the time and costs involved in obtaining regulatory approvals, competing technological and market developments, as well as our ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements. We expect to continue to incur increasing negative cash flows and net losses for the foreseeable future. We will continue to need to raise additional capital either through equity and/or debt financing for the foreseeable future. Â We do plan to access the equity markets for additional capital, however, there can be no assurance that we will be able to access such additional capital on favorable terms, or at all. Â Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States, including due to bank failures, actual or perceived changes in interest rates and economic inflation, and worldwide resulting from macroeconomic factors. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and we may never be profitable or generate positive cash flow from operating activities. Â CRITICAL ACCOUNTING POLICIES AND ESTIMATES Â Managementâ€™s discussion and analysis of financial condition and results of operations is based on our interim condensed consolidated financial statements, that we prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Preparing these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosures. We base our estimates on historical experience and on various assumptions we believe to be reasonable under the circumstances. We believe our judgment is applied consistently and produces financial information that fairly depicts our results of operations for all periods. Actual results may differ materially from these estimates. Â Â Â Â 25Â Â Â We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require the most difficult, subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These critical accounting estimates relate to long lived assets, stock compensation, deferred tax asset valuation allowance, contingencies and clinical trial accruals. Â There were no accounting estimates in the three months ended June 30, 2024 with a high degree of uncertainty or amounts that are with a high likelihood to change from period to period that would materially impact the presentation of our financial statements for the three months ended June 30, 2024. Â Â Â There have been no changes to our critical accounting policies and estimates as disclosed in our Form 10-K for the year ended March 31, 2024. Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Â As a smaller reporting company, as defined by Item 10(f)(1) of Regulation S-K, we are not required to provide the information required by this item. Â ITEM 4. CONTROLS AND PROCEDURES. Â DISCLOSURE CONTROLS AND PROCEDURES Â We maintain â€œdisclosure controls and proceduresâ€ (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed, in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our Interim Chief Executive Officer and Chief Financial Officer (who is our principal executive officer and principal financial officer), to allow timely decisions regarding required disclosures. Â Under the supervision and with the participation of our management, including our Interim Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report. Â Based on such evaluation, our Interim Chief Executive Officer and Chief Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Interim Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Â As previously reported in our Annual Report on Form 10-K for the year ended March 31, 2024, we identified a material weakness in our internal control over financial reporting related to segregation of duties within our financial systems. Specifically, user access controls were not sufficiently maintained to properly restrict both user and privileged access to financial applications within our accounting software system to initiate, record and approve entries. Also noted that check stock was secured in an authorized signatoryâ€™s office. Â Since identifying the material weakness, we have been actively engaged in implementing measures to remediate the weakness and enhance our internal control over financial reporting. These measures include but are not limited to updating the accounting software and creating distinct user roles. Transactions are recorded by personnel who are independent of those who initiate them and are approved by separate personnel who are independent of those who record them. Additionally, check stock had been relocated in November 2023. Â We believe that these measures, once fully implemented and operational for a sufficient period of time, will effectively remediate the material weakness. We are committed to maintaining a strong internal control environment and will continue to monitor the effectiveness of these controls and procedures. Â CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING Â Other than the changes to remediate the material weakness noted above, there were not changes in our internal control over financial reporting during the quarter ending June 30, 2024 that have materially affected, or reasonably likely to materially affect, our internal control over financial reporting. Â Â Â Â 26Â Â Â PART II. OTHER INFORMATION Â ITEM 1. LEGAL PROCEEDINGS. Â From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. Â The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. We are not presently a party to any pending or threatened legal proceedings. Â ITEM 1A. RISK FACTORS. Â RISK FACTOR SUMMARY Â Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found under the heading â€œRisk Factorsâ€ in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024, filed with the SEC on June 27, 2024, or Annual Report, and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC before making investment decisions regarding our securities. Â Â Â· We have incurred significant losses and expect to continue to incur losses for the foreseeable future. Â Â Â Â Â· We will require additional financing to sustain our operations, achieve our business objectives and satisfy our cash obligations, which may dilute the ownership of our existing stockholders. Â Â Â Â Â· We have limited experience in identifying and working with large-scale contracts with medical device manufacturers; manufacture of our devices must comply with good manufacturing practices in the United States. Â Â Â Â Â· Delays, interruptions or the cessation of production by our third-party suppliers of important materials or delays in qualifying new materials, has and may continue to prevent or delay our ability to manufacture our Hemopurifier. Â Â Â Â Â· Our Hemopurifier technology may become obsolete. Â Â Â Â Â· If we fail to comply with extensive regulations of U.S. and foreign regulatory agencies, the commercialization of our products could be delayed or prevented entirely. Â Â Â Â Â· If we are unable to regain compliance with the listing requirements of the Nasdaq Capital Market, our common stock may be delisted from the Nasdaq Capital Market, which could have a material adverse effect on our financial condition and could make it more difficult for you to sell your shares. Â Â Â Â Â· As a public company with limited financial resources undertaking the launch of new medical technologies, we may have difficulty attracting and retaining executive management and directors. Â Â Â· We plan to expand our operations, which may strain our resources; our inability to manage our growth could delay or derail implementation of our business objectives. Â Â Â· Our success is dependent in part on our executive officers. Â Â Â· Delays in successfully commencing or completing our planned clinical trials could jeopardize our ability to obtain regulatory approval and sustain our operations. Â Â Â Â 27Â Â Â There have been no material changes to the risk factors previously disclosed under the heading â€œRisk Factorsâ€ in our Annual Report. The risks described in our Annual Report are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. Â We did not issue or sell any unregistered securities during the three months ended June 30, 2024. Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES. Â None. Â ITEM 4. MINE SAFETY DISCLOSURES. Â Not applicable. Â ITEM 5. OTHER INFORMATION. Â Rule 10b5-1 Trading Plans Â During the three months ended June 30, 2024, none of our directors or officers entered into, modified or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ that were intended to satisfy the affirmative defense conditions of Rule 10b5-1, in each case as defined in Item 408 of Regulation S-K. Â Â Â Â Â Â Â Â Â Â Â Â 28Â Â Â ITEM 6. EXHIBITS. Â (a) Exhibits. The following documents are filed as part of this report: Â Â Â Â Â Â Â Incorporated by Reference Exhibit Number Â Exhibit Description Â Form Â SEC File No. Â Exhibit Number Â Date Â Filed Herewith Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3.1 Articles of Incorporation, as amended. Â 8-K Â 001-37487 Â 3.1 Â September 19, 2022 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3.2 Â Amended and Restated Bylaws of the Company. Â 8-K Â 001-37487 Â 3.1 Â September 12, 2019 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.1 Â Form of Common Stock Certificate. Â S-1 Â 333-201334 Â 4.1 Â December 31, 2014 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.2 Â Form of Warrant to Purchase Common Stock. Â S-1/A Â 333-234712 Â 4.14 Â December 11, 2019 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.3 Â Form of Underwriter Warrant. Â S-1/A Â 333-234712 Â 4.15 Â December 11, 2019 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.4 Â Form of Common Stock Purchase Warrant. Â 8-K Â 001-37487 Â 4.1 Â January 17, 2020 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.5 Â Form of Class A Warrant to Purchase Common Stock, issued on May 17, 2024. Â 8-K Â 001-37487 Â 4.1 Â May 17, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.6 Â Form of Class B Warrant to Purchase Common Stock, issued on May 17, 2024. Â 8-K Â 001-37487 Â 4.2 Â May 17, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.7 Â Form of Pre-Funded Warrant to Purchase Common Stock, issued on May 17, 2024. Â 8-K Â 001-37487 Â 4.3 Â May 17, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10.1 Â Form of Securities Purchase Agreement. Â S-1/A Â 333-278188 Â 10.20 Â May 13, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 31.1 Â Certification of the Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. Â Â Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â 32.1^ Â Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350. Â Â Â Â Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.INS Â Inline XBRL Instance Document with Embeded Linkbase Documents Â Â Â Â Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema Document Â Â Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â 104 Â Cover Page Interactive Data File (formatted in XBRL, and included in exhibit 101) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995512 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 995513 - Disclosure - LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 995514 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 995516 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 995518 - Disclosure - OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 995519 - Disclosure - STOCK COMPENSATION link:presentationLink link:calculationLink link:definitionLink 995520 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 995521 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995522 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 995523 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies) link:presentationLink link:calculationLink link:definitionLink 995524 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 995526 - Disclosure - OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - STOCK COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 995528 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 995529 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995530 - Disclosure - LOSS PER COMMON SHARE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995531 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 995532 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995533 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 995534 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 995536 - Disclosure - STOCK COMPENSATION (Details - Stock compensation) link:presentationLink link:calculationLink link:definitionLink 995537 - Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest) link:presentationLink link:calculationLink link:definitionLink 995538 - Disclosure - STOCK COMPENSATION (Details - Option activity) link:presentationLink link:calculationLink link:definitionLink 995539 - Disclosure - STOCK COMPENSATION (Details - Nonvested shares) link:presentationLink link:calculationLink link:definitionLink 995540 - Disclosure - STOCK COMPENSATION (Details - Options exercisable) link:presentationLink link:calculationLink link:definitionLink 995541 - Disclosure - STOCK COMPENSATION (Details - RSU activity) link:presentationLink link:calculationLink link:definitionLink 995542 - Disclosure - STOCK COMPENSATION (Details - Stockbased compensation) link:presentationLink link:calculationLink link:definitionLink 995543 - Disclosure - STOCK COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995544 - Disclosure - WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 aemd-20240630_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 aemd-20240630_def.xml XBRL DEFINITION FILE EX-101.LAB 7 aemd-20240630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Noncontrolling Interest [Member] Pledging Purpose [Axis] Letter of Credit [Member] Securities Financing Transaction [Axis] ATM 2022 Agreement [Member] Counterparty Name [Axis] Wainwright [Member] May 2024 Public Offering [Member] Class of Stock [Axis] Class A Warrants [Member] Class B Warrants [Member] Prefunded Warrants [Member] Placement Agent [Member] Placement Agent Warrants [Member] Class A And Class B Warrants [Member] Director 1 [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Director 2 [Member] Director 3 [Member] Director 4 [Member] Non Employee Directors [Member] Related and Nonrelated Parties [Axis] Employee [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Separation Agreement [Member] Chief Executive Officer [Member] Related Party Transaction [Axis] Accrued Board Fees [Member] Accrued Vacation [Member] Accrued Separation Expenses [Member] Transaction Type [Axis] Stock Based Compensation [Member] Equity Option [Member] Options Held [Member] Exercise Price Range [Axis] Exercise Price $6.90 - $16.80 [Member] Exercise Price $25.20 [Member] Warrant [Member] Property Subject to or Available for Operating Lease [Axis] Office And Laboratory Space [Member] Manufacturing Space [Member] Office Lab And Manufacturing Leases [Member] Statement of Financial Position Location, Balance [Axis] Restricted Cash [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Deferred Offering Cost Prepaid expenses and other current assets Total current assets Property and equipment, net Operating lease right-of-use asset Patents, net Restricted cash Deposits Total assets LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Current liabilities Accounts payable Due to related parties Operating lease liability, current portion Other current liabilities Total current liabilities Operating lease liability, less current portion Total liabilities Stockholdersâ€™ Equity Common stock, par value $0.001 per share; 60,000,000 shares authorized as of June 30, 2024 and March 31, 2024; 13,937,327 and 2,629,725 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total stockholdersâ€™ equity Total liabilities and stockholdersâ€™ equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES Professional fees Payroll and related expenses General and administrative Total operating expenses OPERATING LOSS OTHER INCOME Interest income NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC. OTHER COMPREHENSIVE LOSS COMPREHENSIVE LOSS Basic net loss per share attributable to common stockholders Diluted net loss per share attributable to common stockholders Weighted average number of common shares outstanding, basic Weighted average number of common shares outstanding, diluted Statement [Table] Statement [Line Items] BALANCE â€“ MARCH 31, 2023 Beginning balance, shares Issuances of common stock for cash under at the market program BALANCE â€“ JUNE 30, 2023 Issuances of common stock for public offering Issuances of common stock for cash under at the market program, shares Issuances of common stock for Class A and Class B warrant exercises Issuances of common stock for Class A and Class B warrant exercises, shares Issuance of common shares upon vesting of restricted stock units and net stock option exercises Issuance of common shares upon vesting of restricted stock units and net stock option exercises, shares Stock-based compensation expense Net loss Other comprehensive loss Ending balance, shares Statement of Cash Flows [Abstract] Cash flows used in operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock based compensation Accretion of right-of-use operating lease asset Changes in operating assets and liabilities: Prepaid expenses and other current assets Accounts payable and other current liabilities Deferred revenue Due to related parties Net cash used in operating activities Cash flows used in investing activities: Purchases of property and equipment Net cash used in investing activities Cash flows provided by financing activities: Proceeds from the issuance of common stock, net Proceeds from the issuance of common stock upon Class A and Class B warrant exercises Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense Net cash provided by financing activities Effect of exchange rate on changes on cash Net increase (decrease) in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash Supplemental disclosures of cash flow information: Supplemental disclosures of non-cash investing and financing activities: Par value of shares issued for vested restricted stock units and net stock option exercise Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: Cash and cash equivalents Restricted cash Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Accounting Policies [Abstract] NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION Earnings Per Share [Abstract] LOSS PER COMMON SHARE Research and Development [Abstract] RESEARCH AND DEVELOPMENT EXPENSES Accounting Changes and Error Corrections [Abstract] RECENT ACCOUNTING PRONOUNCEMENTS Equity [Abstract] EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Other Liabilities Disclosure [Abstract] OTHER CURRENT LIABILITIES STOCK COMPENSATION Warrants WARRANTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS REVERSE STOCK SPLIT Basis of Presentation and Use of Estimates Reclassifications LIQUIDITY AND GOING CONCERN Restricted Cash Schedule of research and development expenses Schedule of amounts due to related parties Schedule of other current liabilities Schedule of share-based compensation expenses Schedule of stock options outstanding Schedule of stock option activity Schedule of non vested stock options Schedule of options outstanding and exercisable Schedule of restricted stock units restricted stock units Schedule of stock-based compensation Schedule of warrant activity Variable Interest Entity [Table] Variable Interest Entity [Line Items] Reverse stock split Net cash used in financing activities Decrease in expenses Decrease in cash used in operating and investing activities Potential common shares Research and development expense Stock, Class of Stock [Table] Class of Stock [Line Items] Aggregate offering price Proceeds from sale of equity Payment of offering costs Payment of other stock issuance costs Stock issued new, shares Average per share sale price Warrants issued Warrants exercise price Warrants maturity date Gross proceeds from sale of equity Warrants exercised Proceeds from warrant exercises RSU's granted Terms of awards Conversion of Stock, Shares Issued Conversion of Stock, Shares Converted Related Party Transaction [Table] Related Party Transaction [Line Items] Due to related parties Accrued director fees Accrued vacation paid Accrued salary and related expenses Accrued professional fees Total other current liabilities Offsetting Assets [Table] Offsetting Assets [Line Items] Vesting of stock options and restricted stock units Total stock-based compensation expense Weighted average number of common shares outstanding - basic Weighted average number of common shares outstanding - diluted Basic loss per common share attributable to stock-based compensation expense Diluted loss per common share attributable to stock-based compensation expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of shares vested Weighted average exercise price vested Weighted average remaining contractual term in years vested Number of shares expected to vest Weighted average exercise price expected to vest Weighted average remaining contractual term in years expected to vest Number of shares total Stock options outstanding, beginning balance Range of exercise prices, beginning balance Weighted average exercise price outstanding, beginning balacne Stock options, granted Range of exercise prices, granted Weighted average exercise price, granted Stock options, cancelled/expired Range of exercise prices, cancelled/expired Weighted average exercise price, cancelled/expired Stock options outstanding, ending balance Range of exercise prices, ending balance Weighted average exercise price outstanding, ending balance Stock options, exercisable Range of exercise prices, exercisable Weighted average exercise price, exercisable Nonvested shares outstanding, beginning balance Weighted average grant date fair value nonvested shares outstanding, beginning balance Options vested Weighted average grant date fair value nonvested shares outstanding, vested Options forfeited Nonvested shares outstanding, ending balance Stock options outstanding Weighted average remaining life (years) Weighted average exercise price, outstanding Stock options exercisable RSUs nonvested RSU's vested Tax withholding payments, shares Stock-based compensation expense Change in earnings per share, basic Change in earnings per share, diluted Options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Intrinsic value per share Unrecognized compensation cost to share based Weighted average period Warrants outstanding Warrants outstanding, range of exercise prices Warrants outstanding, weighted average exercise price Warrants granted Warrants grantedrange of exercise prices Warrants granted, weighted average exercise price Warrants exercised Warrants exercised, range of exercise prices Warrants exercised, weighted average exercise price Warrants cancelled or expired Warrants cancelled or expired, range of exercise prices Warrants cancelled or expired, weighted average exercise price Class of Warrant or Right, Outstanding [custom:ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRights1] Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercisable Warrants exercisable, range of exercise prices Warrants exercisable, weighted average exercise price Loss Contingencies [Table] Loss Contingencies [Line Items] Lease description Lease frequency of periodic payment Lease periodic payment Operating lease liabilities Remaining lease term Lease weighted average discount rate Right of use lease asset Letter of credit Operating lease expense Range of exercise prices, Option beginning Range of exercise prices, Option cancelled/expired Range of exercise prices, Option ending Range of exercise prices, Option exercisable Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Tax Shares, Outstanding Other Comprehensive Income

(Loss), Net of Tax AccretionOfRightofuseOperatingLeaseAsset Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable, Related Parties Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payment, Tax Withholding, Share-Based Payment Arrangement Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Due to related parties current 1 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Class of Warrant or Right, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised EX-101.PRE 8 aemd-20240630_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 3 Months Ended Jun. 30, 2024 Aug. 14, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Jun. 30, 2024 Â Document Fiscal Period Focus Q1 Â Document Fiscal Year Focus 2025 Â Current Fiscal Year End Date --03-31 Â Entity File Number 001-37487 Â Entity Registrant Name Aethlon Medical, Inc. Â Entity Central Index Key 0000882291 Â Entity Tax Identification Number 13-3632859 Â Entity Incorporation, State or Country Code NV Â Entity Address, Address Line One 11555 SORRENTO VALLEY ROAD Â Entity Address, Address Line Two SUITE 203 Â Entity Address, City or Town SAN DIEGO Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 92121 Â City Area Code 619 Â Local Phone Number 941-0360 Â Title of 12(b) Security COMMON STOCK, $0.001 PAR VALUE Â Trading Symbol AEMD Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 13,937,327 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) Jun. 30, 2024 Mar. 31, 2024 Current assets Â Â Cash and cash equivalents $ 9,072,379 $ 5,441,978 Deferred Offering Cost 0 277,827 Prepaid expenses and other current assets 478,058 505,983 Total current assets 9,550,437 6,225,788 Property and equipment, net 929,306 1,015,229 Operating lease right-of-use asset 813,900 883,054 Patents, net 963 1,100 Restricted cash 87,506 87,506 Deposits 33,305 33,305 Total assets 11,415,417 8,245,982 Current liabilities Â Â Accounts payable 1,068,134 777,862 Due to related parties 732,518 546,434 Operating lease liability, current portion 296,093 290,565 Other current liabilities 32,203 215,038 Total current liabilities 2,128,948 1,829,899 Operating lease liability, less current portion 573,852 649,751 Total liabilities 2,702,801 2,479,650 Stockholdersâ€™ Equity Â Â Common stock, par value $0.001 per share; 60,000,000 shares authorized as of June 30, 2024 and March 31, 2024; 13,937,327 and 2,629,725 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively 13,937 2,629 Additional paid-in capital 165,844,620 160,337,371 Accumulated other comprehensive loss (7,773) (6,940) Accumulated deficit (157,138,168) (154,566,728) Total stockholdersâ€™ equity 8,712,616 5,766,332 Total liabilities and stockholdersâ€™ equity $ 11,415,417 $ 8,245,982 X - ReferencesNo definition available. + Details Name: aemd_DueToRelatedParties Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSpecific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.A) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1 + Details Name: us-gaap_DeferredOfferingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Jun. 30, 2024 Mar. 31, 2024 Statement of Financial Position [Abstract] Â Â Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 60,000,000 60,000,000 Common stock, shares issued 13,937,327 2,629,725 Common stock, shares outstanding 13,937,327 2,629,725 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 OPERATING EXPENSES Â Â Professional fees $ 614,082 $ 976,638 Payroll and related expenses 1,254,802 1,123,239 General and administrative 751,974 1,308,283 Total operating expenses 2,620,858 3,408,160 OPERATING LOSS (2,620,858) (3,408,160) OTHER INCOME Â Â Interest income 49,418 125,981 NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC. (2,571,440) (3,282,179) OTHER COMPREHENSIVE LOSS (833) (994) COMPREHENSIVE LOSS $ (2,572,273) $ (3,283,173) Basic net loss per share attributable to common stockholders $ (0.34) $ (1.35) Diluted net loss per share attributable to common stockholders $ (0.34) $ (1.35) Weighted average number of common shares outstanding, basic 7,457,888 2,431,476 Weighted average number of common shares outstanding, diluted 7,457,888 2,431,476 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income earned from interest bearing assets classified as other. + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LaborAndRelatedExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoninterestIncomeOtherAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_ProfessionalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Noncontrolling Interest [Member] Total BALANCE â€" MARCH 31, 2023 at Mar. 31, 2023 $ 2,299 $ 157,426,606 $ (142,358,555) $ (6,141) $ 15,064,209 Beginning balance, shares at Mar. 31, 2023 2,299,259 Â Â Â Â Â Issuances of common stock for cash under at the market program $ 178 1,085,941 1,086,119 BALANCE â€" JUNE 30, 2023 at Jun. 30, 2023 $ 2,484 158,754,282 (145,640,734) (7,135) 13,108,897 Issuances of common stock for cash under at the market program, shares 177,891 Â Â Â Â Â Issuance of common shares upon vesting of restricted stock units and net stock option exercises $ 7 (8,379) (8,372) Issuance of common shares upon vesting of restricted stock units and net stock option exercises, shares 6,397 Â Â Â Â Â Stock-based compensation expense 250,114 250,114 Net loss (3,282,179) (3,282,179) Other comprehensive loss (994) (994) Ending balance, shares at Jun. 30, 2023 2,483,547 Â Â Â Â Â BALANCE â€" MARCH 31, 2023 at Mar. 31, 2024 $ 2,629 160,337,371 (154,566,728) (6,940) 5,766,332 Beginning balance, shares at Mar. 31, 2024 2,629,725 Â Â Â Â Â BALANCE â€" JUNE 30, 2023 at Jun. 30, 2024 $ 13,937 165,844,620 (157,138,168) (7,733) 8,712,616 Issuances of common stock for public offering $ 8,100 3,531,807 3,539,907 Issuances of common stock for cash under at the market program, shares 8,100,000 Â Â Â Â Â Issuances of common stock for Class A and Class B warrant exercises $ 3,180 1,841,220 1,844,400 Issuances of common stock for Class A and Class B warrant exercises, shares 3,180,000 Â Â Â Â Â Issuance of common shares upon vesting of restricted stock units and net stock option exercises $ 28 (5,106) (5,078) Issuance of common shares upon vesting of restricted stock units and net stock option exercises, shares 27,602 Â Â Â Â Â Stock-based compensation expense 139,328 139,328 Net loss (2,571,440) (2,571,440) Other comprehensive loss $ (833) $ (833) Ending balance, shares at Jun. 30, 2024 13,937,327 Â Â Â Â Â X - ReferencesNo definition available. + Details Name: aemd_IssuancesOfCommonStockForPublicOffering Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionValue, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 30 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 30 -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480843/718-30-35-1 + Details Name: us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4:

http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows used in operating activities: Â Â Net loss $ (2,571,440) $ (3,282,179) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 86,060 90,325 Stock based compensation 139,328 250,114 Accretion of right-of-use operating lease asset (1,217) 1,238 Changes in operating assets and liabilities: Â Â Prepaid expenses and other current assets 89,872 146,409 Accounts payable and other current liabilities 323,776 334,613 Deferred revenue 0 0 Due to related parties 186,084 (22,907) Net cash used in operating activities (1,747,537) (2,482,387) Cash flows used in investing activities: Â Â Purchases of property and equipment 0 (230,383) Net cash used in investing activities 0 (230,383) Cash flows provided by financing activities: Â Â Proceeds from the issuance of common stock, net 3,539,907 1,086,119 Proceeds from the issuance of common stock upon Class A and Class B warrant exercises 1,844,400 0 Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense (5,078) (8,372) Net cash provided by financing activities 5,379,229 1,077,747 Effect of exchange rate on changes on cash (1,290) (186) Net increase (decrease) in cash, cash equivalents and restricted cash 3,630,402 (1,635,209) Cash, cash equivalents and restricted cash at beginning of period 5,529,483 14,620,449 Cash, cash equivalents and restricted cash 9,159,885 12,985,240 Supplemental disclosures of non-cash investing and financing activities: Â Â Par value of shares issued for vested restricted stock units and net stock option exercise 28 64 Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: Â Â Cash and cash equivalents 9,072,379 12,897,734 Restricted cash $ 87,506 $ 87,506 X - ReferencesNo definition available. + Details Name: aemd_AccretionOfRightofuseOperatingLeaseAsset Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ProceedsFromIssuanceOfCommonStockUponClassAndClassBWarrantExercises Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure [Table] Â Â Net Income (Loss) $ (2,571,440) $ (3,282,179) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Insider Trading Arrangements [Line Items] Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace

Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION 3 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION Â Aethlon Medical, Inc., or Aethlon, the Company, we or us, is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients, the Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and metastasis, and in life-threatening infectious diseases. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a â€œBreakthrough Deviceâ€ for two independent indications: Â Â Â· the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes or exosomal particles have been shown to participate in the development or severity of the disease; and Â Â· the treatment of life-threatening viruses that are not addressed with approved therapies. Â We believe the Hemopurifier may be a substantial advancement in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove harmful exosomes and exosomal particles that promote the growth and spread of tumors. In October 2022, we formed a wholly-owned subsidiary in Australia to initially conduct oncology-related clinical research, then seek regulatory approval and commercialize our Hemopurifier in Australia. We are currently working with our contract research organization, or CRO, on preparations to conduct a clinical trial in Australia in patients with solid tumors, including head and neck cancer, and gastrointestinal cancers. Â In January 2023, we entered into an agreement with North American Science Associates, LLC, or NAMSA, a world leading medical technology CRO offering global end-to-end development services, to oversee our planned clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA agreed to manage our planned clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors. Â We recently completed an in vitro binding study of relevant oncology targets, to provide pre-clinical evidence to support our trial design and translational endpoints. Our study indicated positive results, providing evidence that our Hemopurifier removes extracellular vesicles, or EVs, from plasma. This translational study provides pre-clinical evidence to support our planned phase 1 safety, feasibility and dose-finding clinical trials of our Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as KeytrudaÂ® or OpdivoÂ®. In addition to an interested initial trial site in India, we had three interested sites in Australia that were awaiting our completion of this in vitro binding study. We added the data from this study to our Clinical Investigator Brochure and submitted that brochure to the Ethics Committee of Royal Adelaide Hospital in Australia and in June 2024, we received approval for our proposed phase 1 oncology trial from the Ethics Committee from Royal Adelaide Hospital. We are currently in the process of applying to the Ethics Committees of the two additional interested clinical trial sites in Australia and the site in India. Â We also believe that the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola. Â Additionally,Â in vitro,Â the Hemopurifier has been demonstrated to capture H5N1 bird flu virus, H1N1 swine flu virus, Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, Monkeypox virus and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research institutes. Â On June 17, 2020, the FDA approved a supplement to our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19, or COVID-19, in a new feasibility study.Â That study was designed to enroll up to 40 subjects at up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19, be admitted to an ICU and have acute lung injury and/or severe or life-threatening disease, among other criteria. Endpoints for this study, in addition to safety, included reduction in circulating virus, as well as clinical outcomes (NCT # 04595903). In January 2021, the Hemopurifier was used to treat a viremic patient, under our emergency use approval, with a predicted risk of mortality of 80% and the Hemopurifier was able to reduce the patientâ€™s SARS-CoV-2 plasma viral load by 58.4%.Â In June 2022, the first patient in this study was enrolled and completed the Hemopurifier treatment phase of the protocol. Due to the lack of COVID-19 patients in the ICUs of our trial sites, we terminated this study in 2022. However, our IDE for this indication remains open, as we have an active COVID-19 trial in India and wish to preserve the option of enrolling patients if the situation with COVID-19 changes. Â Under Single Patient Emergency Use regulations, Aethlon has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated with our Hemopurifier in our COVID-19 clinical trial discussed above. Â In October 2022, we launched a wholly owned subsidiary in Australia, formed to conduct clinical research, seek regulatory approval and commercialize our Hemopurifier in that country. The subsidiary will initially focus on the planned oncology trials in Australia. Â In August 2024, the Bellberry Human Research Ethics Committee granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the HemopurifierÂ® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia. Â In June 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for the same safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as KeytrudaÂ® (pembrolizumab) or OpdivoÂ® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia. Â We also obtained ethics review board, or ERB, approval from and entered into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi NCR, India, for a COVID-19 clinical trial at that location. Â In May 2023, we received ERB approval from the MAMC, for a second site for our clinical trial in India to treat severe COVID-19. MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government. Â We now have two sites in India for this trial with the Medanta Medicity Hospital and Maulana Azad Medical College, or MAMC. One patient has been treated to date; however, we have been informed by our CRO that a new COVID-19 subvariant was detected in India recently. Our COVID-19 trial in India remains open in the event that there are COVID-19 admissions to the ICUs at our sites in India. Â Additionally, based on preclinical data with acellular kidney perfusates, we believe that the Hemopurifier has potential applications in organ transplantation. We are investigating whether the Hemopurifier, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses, exosomes, RNA molecules, cytokines, chemokines and other inflammatory molecules from recovered organs. We initially are focused on recovered kidneys from deceased donors. We have previously demonstrated the removal of multiple viruses and exosomes and exosomal particles from buffer solutions, in vitro, utilizing a scaled-down version of our Hemopurifier and believe this process could reduce transplantation complications by improving graft function, reducing graft rejection, maintaining or improving organ viability prior to transplantation, and potentially reducing the number of kidneys rejected for transplant. Â Successful outcomes of human trials will also be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology. Â In addition to the foregoing, we are monitoring closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and the surrounding areas, as well as related political and economic responses and counter-responses by various global factors on our business. Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing military conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical research will depend on future developments, as well as the economic impact on national and international markets that are highly uncertain. Â We incorporated in Nevada on March 10, 1999. Our executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our website address is www.aethlonmedical.com. Â Our common stock is listed on the Nasdaq Capital Market under the symbol â€œAEMD.â€ Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â During the three months ended June 30, 2024, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024. Â REVERSE STOCK SPLIT Â On October 4, 2023, we effected a 1-for-10 reverse stock split of our then outstanding shares of common stock. Accordingly, each 10 shares of outstanding common stock then held by our stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock remained at 60,000,000 shares following the stock split. The accompanying unaudited condensed consolidated financial statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred on April 1, 2023. All shares and per share amounts have been revised accordingly. Â Basis of Presentation and Use of Estimates Â Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended March 31, 2024, included in our Annual Report on Form 10-K filed with the SEC on June 27, 2024. The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements, taken as a whole, contain all adjustments that are of a normal recurring nature necessary to present fairly our operating results, cash flows, and financial position as of and for the period ended June 30, 2024. Estimates were made relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2024 has been derived from the audited consolidated balance sheet at March 31, 2024, contained in the above referenced 10-K. The results of operations for the three months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full year or any future interim periods. Â Reclassifications Â Certain prior year balances within the unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation, including the impact of the reverse stock split. Â LIQUIDITY AND GOING CONCERN Â Management expects existing cash as of June 30, 2024 to be sufficient to fund the Companyâ€™s operations for at least twelve months from the issuance date of these condensed consolidated financial statements. In previous filings, we disclosed substantial doubt about our ability to continue as a going concern due to recurring losses and negative cash flows. We have addressed these concerns by raising $5,379,229, net, through the combination of an equity offering and warrant exercises, combined with our recent financial performance which has shown a significant decrease in expenses and use of cash. For the three-month period ended June 30, 2024, expenses decreased by approximately $787,000 compared to June 30, 2023, accompanied by an approximate $964,000 decrease in cash used in operating and investing activities. As a result of these actions, management believes that the substantial doubt regarding our ability to continue as a going concern has been alleviated. Â The accompanying unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. Â Restricted Cash Â To comply with the terms of our laboratory and office lease and our lease for our manufacturing space (see Note 10), we caused our bank to issue two standby letters of credit, or L/Cs, in the aggregate amount of $87,506 in favor of our landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs, we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit. We have classified that amount as restricted cash, a long-term asset, on our balance sheet. Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LOSS PER COMMON SHARE 3 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â LOSS PER COMMON SHARE 2. LOSS PER COMMON SHARE Â Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded, as their effect would be antidilutive. Â As of June 30, 2024 and 2023, an aggregate of 13,523,429 and 2,291,234 potential common shares, respectively, consisting of shares underlying outstanding stock options, warrants, and restricted stock units were excluded, as their inclusion would be antidilutive. Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESEARCH AND DEVELOPMENT EXPENSES 3 Months Ended Jun. 30, 2024 Research and Development [Abstract] Â RESEARCH AND DEVELOPMENT EXPENSES 3. RESEARCH AND DEVELOPMENT EXPENSES Â Our research and development costs are expensed as incurred. We incurred research and development expenses during the three-month periods ended June 30, 2024 and 2023, which are included in various operating expense line items in the accompanying condensed consolidated statements of operations. Our research and development expenses in those periods were as follows: Â Schedule of research and development expensesÂ Â Â Â Â Â Â Â June 30,Â Â June 30,Â Â Â 2024Â Â 2023Â Three months endedÂ $414,658Â Â $678,922Â Â X - ReferencesNo definition available. + Details Name: us-gaap_ResearchAndDevelopmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or

technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details Name: us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RECENT ACCOUNTING PRONOUNCEMENTS 3 Months Ended Jun. 30, 2024 Accounting Changes and Error Corrections [Abstract] Â RECENT ACCOUNTING PRONOUNCEMENTS 4. RECENT ACCOUNTING PRONOUNCEMENTS Â In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued ASU 2023-07 â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€). ASU 2023-07 intends to improve reportable segment disclosure requirements, enhance interim disclosure requirements and provide new segment disclosure requirements for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods with fiscal years beginning after December 15, 2024. ASU 2023-07 is to be adopted retrospectively to all prior periods presented. We are currently assessing the impact this guidance will have on our consolidated financial statements; however, we do not expect a material impact. Â In December 2023, the FASB issued Accounting Standards Update 2023-09, Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which requires enhanced annual disclosures for specific categories in the rate reconciliation and income taxes paid disaggregated by federal, state and foreign taxes. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. The Company is evaluating if the adoption of this new standard will have a material effect on our disclosures. Â In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The adoption of ASU No. 2016-13 for smaller reporting companies that did not previously early adopt was January 1, 2023. The Company maintained US Treasury bills with maturities of less than three months and expects zero credit losses from these securities. As a result, the Company did not record an allowance for expected credit losses. Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 250 -Publisher FASB -URI https://asc.fasb.org/250/tableOfContentReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 + Details Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 3 Months Ended Jun. 30, 2024 Equity [Abstract] Â EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 5. EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 Â 2022 At The Market Offering Agreement with H.C. Wainwright & Co., LLC Â On March 24, 2022, we entered into an At The Market Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, which established an at-the-market equity program pursuant to which we may offer and sell shares of our common stock from time to time, as set forth in the 2022 ATM Agreement. Â The offering was registered under the Securities Act of 1933, as amended, or the Securities Act, pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-259909), as previously filed with the SEC and declared effective on October 21, 2021. We filed a prospectus supplement, dated March 24, 2022, with the SEC that provides for the sale of shares of our common stock having an aggregate offering price of up to $15,000,000, or the 2022 ATM Shares. Â Under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares by any method permitted by law and deemed to be an â€œat the market offeringâ€ as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the 2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if the sales cannot be effected at or above the price designated by us from time to time. Â We are not obligated to make any sales of the 2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate upon the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein. Â The 2022 ATM Agreement contains customary representations, warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement. Â During the three months ended June 30, 2024, we did not raise proceeds under the 2022 ATM Agreement. During the three months ended June 30, 2023, we raised net proceeds of $1,086,119, net of $27,999 in commissions to Wainwright and $5,846 in other offering expenses, through the sale of 177,890 shares of our common stock at an average price of $6.11 per share under the 2022 ATM Agreement. Â May 2024 Public Offering Â On May 17, 2024, we closed a public offering pursuant to which we sold an aggregate of: (i) 2,450,000 shares of our common stock and accompanying Class A warrants to purchase up to 2,450,000 shares of common stock and Class B warrants to purchase up to 2,450,000 shares of common stock, at a combined public offering price of $0.58 per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase 5,650,000 shares of common stock and accompanying Class A warrants to purchase up to 5,650,000 shares of common stock and Class B warrants to purchase up to 5,650,000 shares of common stock, at a combined public offering price of $0.579 per pre-funded warrant and accompanying warrants, which is equal to the public offering price per share of common stock, and accompanying warrants less the $0.001 per share exercise price of each such pre-funded warrant. Â All pre-funded warrants issued in the offering were exercised in the quarter ended June 30, 2024. The Class A and Class B warrants each have an exercise price of $0.58 per share, are immediately exercisable, and, in the case of Class A warrants, will expire on May 17, 2029, and in the case of Class B warrants, will expire on May 19, 2025. The exercise price of the Class A and Class B warrants is also subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in such warrants. Â Maxim Group LLC (â€œMaximâ€), served as the exclusive placement agent in connection with the offering. We paid Maxim a cash fee of 6.5% of the aggregate gross proceeds raised at the closing of the offering, and reimbursement of certain expenses and legal fees in the amount of $100,000. We also issued to designees of Maxim warrants to purchase up to an aggregate of 324,000 shares of common stock (the â€œPlacement Agent Warrantsâ€). The Placement Agent Warrants have an exercise price of $0.58 per share and have substantially the same terms as the Class A warrants, except the Placement Agent Warrants are not subject to an exercise price reset, are non-exercisable until November 15, 2024, and will expire on May 15, 2029. Â The gross proceeds from the offering, before deducting the placement agentâ€™s fees and other offering expenses, were approximately $4.7 million. Net proceeds, of the offering, after deducting the placement agent fees and expenses and other offering expenses payable by us, were are approximately $3.5 million. In June 2024, and holders of Class A and Class B warrants exercised 300,000 shares and 2,880,000 shares, respectively, for additional proceeds of $1,844,400. Â The shares of Common Stock, the Class A and Class B warrants, the pre-funded warrants and the Placement Agent Warrants described above and the underlying shares of Common Stock were offered pursuant to a Registration Statement on Form S-1, as amended (File No. 333-278188) (the â€œRegistration Statementâ€), which was declared effective by the Securities and Exchange Commission (the â€œSECâ€) on May 15, 2024. Â Restricted Stock Unit Grants Â On April 16, 2024, our Board of Directors approved, pursuant to the terms of the Director Compensation Policy, the grant of the annual RSUs under the Director Compensation Policy to each of the four non-employee directors of the Company then serving on the Board of Directors. The Director Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs at the beginning of each fiscal year for current non-employee directors then serving on the Board of Directors, and for a grant of stock options or $75,000 worth of RSUs for a newly elected non-employee director, with each RSU priced at the average of the closing prices for the five trading days preceding and including the date of grant, or $1.52 per share for the RSUs granted in April 2024. As a result, in April 2024, the four eligible directors were each granted 32,894 RSUs under the Companyâ€™s 2020 Equity Incentive Plan, as amended, or the 2020 Plan. The RSUs are subject to vesting in four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2024, September 30, 2024, December 31, 2024, and March 31, 2025, subject in each case to the directorâ€™s Continuous Service (as defined in the 2020 Plan), through such dates. Vesting will automatically terminate upon the directorâ€™s termination of Continuous Service prior to any vesting date. Â During the three-months ended June 30, 2024, 27,602 shares were issued upon settlement of 37,779 RSUs. Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50

-Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS 3 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Â RELATED PARTY TRANSACTIONS 6. RELATED PARTY TRANSACTIONS Â During the three months ended June 30, 2024, we accrued unpaid fees of $68,250 owed to our non-employee directors. Â As a result of entering into a Separation Agreement effective July 1, 2024 with a former employee, we paid out accrued vacation of $9,688 in the three months ended June 30, 2024. That accrued vacation was previously recorded in the due to related parties account. In addition, pursuant to the terms of the Separation Agreement, we accrued $323,534 for salary and related expenses connected with the Separation Agreement. Accrued separation expenses includes a balance of approximately $186,000 owed to our former Chief Executive Officer, as stipulated in his Separation Agreement. Â Amounts due to related parties were comprised of the following items: Â Schedule of amounts due to related partiesÂ Â Â Â Â Â Â Â June 30, 2024Â Â March 31, 2024Â Accrued Board feesÂ $68,250Â Â $68,250Â Accrued vacation to all employeesÂ Â 154,816Â Â Â 167,973Â Accrued separation expensesÂ Â 509,452Â Â Â 310,211Â Total due to related partiesÂ $732,518Â Â $546,434Â Â Â Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 OTHER CURRENT LIABILITIES 3 Months Ended Jun. 30, 2024 Other Liabilities Disclosure [Abstract] Â OTHER CURRENT LIABILITIES 7. OTHER CURRENT LIABILITIES Â Other current liabilities were comprised of the following items: Â Schedule of other current liabilitiesÂ Â Â Â Â Â Â Â June 30,Â Â March 31,Â Â Â 2024Â Â 2024Â Accrued professional feesÂ $32,203Â Â $215,038Â Total other current liabilitiesÂ $32,203Â Â $215,038Â Â X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405/tableOfContent + Details Name: us-gaap_OtherLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION 3 Months Ended Jun. 30, 2024 Equity [Abstract] Â STOCK COMPENSATION 8. STOCK COMPENSATION Â The following tables summarize share-based compensation expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three month periods ended June 30, 2024 and 2023: Â Schedule of share-based compensation expensesÂ Â Â Â Â Â Â Â June 30, 2024Â Â June 30, 2023Â Vesting of stock options and restricted stock unitsÂ $139,328Â Â $250,114Â Total stock-based compensation expenseÂ $139,328Â Â $250,114Â Â Â Â Â Â Â Â Â Â Â Weighted average number of common shares outstanding â€” basic and dilutedÂ Â 7,457,888Â Â Â 2,431,476Â Â Â Â Â Â Â Â Â Â Basic and diluted loss per common share attributable to stock-based compensation expenseÂ $(0.10)Â $(0.16) Â Â All of the stock-based compensation expense recorded during the three months ended June 30, 2024 and 2023, an aggregate of $139,328 and $250,114, respectively, is included in payroll and related expense in the accompanying condensed consolidated statements of operations. Stock-based compensation expense recorded during each of the three months ended June 30, 2024 and 2023 represented an impact on basic and diluted loss per common share of $(0.02) and $(0.16), respectively. Â Stock Option Activity Â We did not issue any stock options during the three months ended June 30, 2024 and 2023. Â Stock options outstanding that have vested as of June 30, 2024 and stock options that are expected to vest subsequent to June 30, 2024 are as follows: Â Schedule of stock options outstandingÂ Â Â Â Â Â Â Â Â Â Â Number of SharesÂ Â Weighted Average Exercise PriceÂ Â Weighted Average Remaining Contractual Term in YearsÂ VestedÂ Â 61,977Â Â $17.37Â Â Â 6.81Â Expected to vestÂ Â 23,873Â Â $14.60Â Â Â 7.60Â TotalÂ Â 85,850Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â A summary of stock option activity during the three months ended June 30, 2024 is presented below: Â Schedule of stock option activityÂ Â Â Â Â Â Â Â Â Â Â AmountÂ Â Range of Exercise PriceÂ Â Weighted Average Exercise PriceÂ Outstanding at beginning of yearÂ Â 86,466Â Â $6.90 â€“ 25.20Â Â $22.40Â GrantedÂ Â â€“Â Â $â€“Â Â $â€“Â Cancelled/ExpiredÂ Â 616Â Â $14.10-1,425.00Â Â $206.34Â Outstanding June 30, 2024Â Â 85,850Â Â $6.90 â€“ 25.20Â Â $16.60Â Exercisable, June 30, 2024Â Â 61,977Â Â $6.90 â€“ 25.20Â Â $17.37Â Â There were no stock option grants during the three months ended June 30, 2024 and 2023. There were 131,576 RSUs granted during the three months June 30, 2024. The weighted average grant date fair value of RSUs granted during the three months ended June 30, 2024 was $1.52. There were no stock option exercises during the three months ended June 30, 2024 and 2023. On June 30, 2024, our outstanding stock options had no intrinsic value, since the closing share price on that date of $0.50 per share was below the exercise price of our outstanding stock options. Â The table below summarizes nonvested stock options as of June 30, 2024 and changes during the three months ended June 30, 2024. Â Schedule of non vested stock optionsÂ Â Â Â Â Â Â Â Â SharesÂ Â Weighted Average Grant Date Fair ValueÂ Nonvested stock options at April 1, 2024Â Â 28,653Â Â $1.44Â VestedÂ Â (4,780)Â $1.62Â ForfeitedÂ Â â€“Â Â Â Â Â Nonvested stock options at June 30, 2024Â Â 23,873Â Â Â Â Â Â Â The detail of the options outstanding and exercisable as of June 30, 2024 is as follows: Â Schedule of options outstanding and exercisable Â Â Â Â Â Â Â Â Â Â Â

treatment (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia. Â X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies) 3 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â REVERSE STOCK SPLIT REVERSE STOCK SPLIT Â On October 4, 2023, we effected a 1-for-10 reverse stock split of our then outstanding shares of common stock. Accordingly, each 10 shares of outstanding common stock then held by our stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock remained at 60,000,000 shares following the stock split. The accompanying unaudited condensed consolidated financial statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred on April 1, 2023. All shares and per share amounts have been revised accordingly. Â Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates Â Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended March 31, 2024, included in our Annual Report on Form 10-K filed with the SEC on June 27, 2024. The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements, taken as a whole, contain all adjustments that are of a normal recurring nature necessary to present fairly our operating results, cash flows, and financial position as of and for the period ended June 30, 2024. Estimates were made relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2024 has been derived from the audited consolidated balance sheet at March 31, 2024, contained in the above referenced 10-K. The results of operations for the three months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full year or any future interim periods. Â Reclassifications Reclassifications Â Certain prior year balances within the unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation, including the impact of the reverse stock split. Â LIQUIDITY AND GOING CONCERN LIQUIDITY AND GOING CONCERN Â Management expects existing cash as of June 30, 2024 to be sufficient to fund the Companyâ€™s operations for at least twelve months from the issuance date of these condensed consolidated financial statements. In previous filings, we disclosed substantial doubt about our ability to continue as a going concern due to recurring losses and negative cash flows. We have addressed these concerns by raising $5,379,229, net, through the combination of an equity offering and warrant exercises, combined with our recent financial performance which has shown a significant decrease in expenses and use of cash. For the three-month period ended June 30, 2024, expenses decreased by approximately $787,000 compared to June 30, 2023, accompanied by an approximate $964,000 decrease in cash used in operating and investing activities. As a result of these actions, management believes that the substantial doubt regarding our ability to continue as a going concern has been alleviated. Â The accompanying unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. Â Restricted Cash Restricted Cash Â To comply with the terms of our laboratory and office lease and our lease for our manufacturing space (see Note 10), we caused our bank to issue two standby letters of credit, or L/Cs, in the aggregate amount of $87,506 in favor of our landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs, we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit. We have classified that amount as restricted cash, on a long-term asset, on our balance sheet. Â X - ReferencesNo definition available. + Details Name: aemd_LiquidityAndGoingConcernPolicyTextBlock Namespace Prefix: aemd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ReverseStockSplitPolicyTextBlock Namespace Prefix: aemd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESEARCH AND DEVELOPMENT EXPENSES (Tables) 3 Months Ended Jun. 30, 2024 Research and Development [Abstract] Â Schedule of research and development expenses Schedule of research and development expensesÂ Â Â Â Â Â Â Â Â June 30,Â Â June 30,Â Â Â Â 2024Â Â 2023Â Three months endedÂ $414,658Â Â $678,922Â Â X - ReferencesNo definition available. + Details Name: us-gaap_ResearchAndDevelopmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of capitalized cost and amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 + Details Name: us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS (Tables) 3 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Â Schedule of amounts due to related parties Schedule of amounts due to related partiesÂ Â Â Â Â Â Â Â June 30, 2024Â Â March 31, 2024Â Accrued Board feesÂ $68,250Â Â $68,250Â Accrued vacation to all employeesÂ Â 154,816Â Â Â 167,973Â Accrued separation expensesÂ Â 509,452Â Â Â 310,211Â Total due to related partiesÂ $732,518Â Â $546,434Â Â X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 OTHER CURRENT LIABILITIES (Tables) 3 Months Ended Jun. 30, 2024 Other Liabilities Disclosure [Abstract] Â Schedule of other current liabilities Schedule of other current liabilitiesÂ Â Â Â Â Â Â June 30,Â Â March 31,Â Â Â 2024Â Â 2024Â Accrued professional feesÂ $32,203Â Â $215,038Â Total other current liabilitiesÂ $32,203Â Â $215,038Â X - DefinitionTabular disclosure of other current liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION (Tables) 3 Months Ended Jun. 30, 2024 Equity [Abstract] Â Schedule of share-based compensation expenses Schedule of share-based compensation expensesÂ Â Â Â Â Â Â Â June 30, 2024Â Â June 30, 2023Â Vesting of stock options and restricted stock unitsÂ $139,328Â Â $250,114Â Total stock-based compensation expenseÂ $139,328Â Â $250,114Â Â Â Â Â Â Â Â Â Â Â Â Weighted average number of common shares outstanding â€“ basic and dilutedÂ Â 7,457,888Â Â Â 2,431,476Â Â Â Â Â Â Â Â Â Â Basic and diluted loss per common share attributable to stock-based compensation expenseÂ $(0.10)Â $(0.16) Schedule of stock options outstanding Schedule of stock options outstandingÂ Â Â Â Â Â Â Â Â Â Â Number of SharesÂ Â Weighted Average Exercise PriceÂ Â Weighted Average Remaining Contractual Term in YearsÂ VestedÂ Â 61,977Â Â $17.37Â Â Â 6.81Â Expected to vestÂ Â 23,873Â Â $14.60Â Â Â 7.60Â TotalÂ Â 85,850Â Â Â Â Â Â Â Â Â Â Schedule of stock option activity Schedule of stock option activityÂ Â Â Â Â Â Â Â Â Â Â AmountÂ Â Range of Exercise PriceÂ Â Weighted Average Exercise PriceÂ Outstanding at beginning of yearÂ Â 86,466Â Â $6.90 â€“ 25.20Â Â $22.40Â GrantedÂ Â â€“Â Â $â€“Â Â $â€“Â Cancelled/ExpiredÂ Â 616Â Â $14.10-1,425.00Â Â $206.34Â Outstanding June 30, 2024Â Â 85,850Â Â Â $6.90 â€“ 25.20Â Â $16.60Â Exercisable, June 30, 2024Â Â 61,977Â Â $6.90 â€“ 25.20Â Â $17.37Â Schedule of non vested stock options Schedule of non vested stock optionsÂ Â Â Â Â Â Â SharesÂ Â Weighted Average Grant Date Fair ValueÂ Nonvested stock options at April 1, 2024Â Â 28,653Â Â $1.44Â VestedÂ Â (4,780)Â $1.62Â ForfeitedÂ Â â€“Â Â Â Â Â Nonvested stock options at June 30, 2024Â Â 23,873Â Â Â Â Â Schedule of options outstanding and exercisable Schedule of options outstanding and exercisable Â Options Outstanding Â Â Â Options Exercisable Â Â Exercise Prices Â Â Â Number Outstanding Â Â Â Weighted Average Remaining Life (Years) Â Â Â Weighted Average Exercise Price Â Â Â Number Outstanding Â Â Â Weighted Average Exercise Price Â $ 6.90 - 16.80 Â Â Â Â 61,672 Â Â Â 7.23 years Â Â Â $ 13.23 Â Â Â 41,326 Â Â $ 13.46 Â $ 25.20 Â Â Â 24,178 Â Â Â 6.52 years Â Â $ 25.20 Â Â Â 20,651 Â Â $ 25.20 Â Â Â Â Â Â 85,850 Â Â Â Â Â Â Â Â Â 61,977 Â Â Â Â Â Schedule of restricted stock units restricted stock units Schedule of restricted stock units restricted stock unitsÂ Â Â Â SharesÂ Nonvested RSUs at April 1, 2024Â Â 4,885Â GrantedÂ Â 131,576Â VestedÂ Â (27,602) Tax withholding payments or tax equivalent payments for net share settlement of restricted stock unitsÂ Â (10,177) Nonvested RSUs at June 31, 2024Â Â 98,682Â Schedule of stock-based compensation Schedule of stock-based compensationÂ Â Â Â Â Â Â Three Months EndedÂ Â Â June 30, 2024Â Â June 30, 2023Â Vesting of restricted stock unitsÂ $68,750Â Â $37,500Â Vesting of stock optionsÂ Â 70,578Â Â Â 212,614Â Total Stock-Based CompensationÂ $139,328Â Â $250,114Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock units. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 WARRANTS (Tables) 3 Months Ended Jun. 30, 2024 Warrants Â Schedule of warrant activity Schedule of warrant activityÂ Â Â Â Â Â Â Â Â Â Â AmountÂ Â Range of Exercise PriceÂ Â Weighted Average Exercise PriceÂ Warrants outstanding at March 31, 2024Â Â 32,676Â Â $15.00 â€“ 27.50Â Â $20.09Â Â Â Â Â Â Â Â Â Â Â Â GrantedÂ Â 16,524,000Â Â Â 0.58Â Â Â 0.58Â ExercisedÂ Â (3,180,000)Â $0.58Â Â $0.58Â Cancelled/ExpiredÂ Â â€“Â Â $â€“Â Â $â€“Â Warrants outstanding at June 30, 2024Â Â 13,376,676Â Â $0.58 â€“ 27.50Â Â $0.63Â Warrants exercisable at June 30, 2024Â Â 13,376,676Â Â $0.58 â€“ 27.50Â Â $0.63Â X - ReferencesNo definition available. + Details Name: aemd_DisclosureWarrantsAbstract Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative) - USD ($) 3 Months Ended Oct. 04, 2023 Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2024 Variable Interest Entity [Line Items] Â Â Â Â Reverse stock split 1-for-10 Â Â Â Common stock, shares authorized Â 60,000,000 Â 60,000,000 Net cash used in financing activities Â $ 5,379,229 $ 1,077,747 Â Decrease in expenses Â 787,000 Â Â Decrease in cash used in operating and investing activities Â 964,000 Â Â Restricted cash Â 87,506 $ 87,506 $ 87,506 Letter of Credit [Member] Â Â Â Â Variable Interest Entity [Line Items] Â Â Â Â Restricted cash Â $ 87,506 Â Â X - ReferencesNo definition available. + Details Name: aemd_DecreaseInCashUsedInOperatingAndInvestingActivities Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_DecreaseInExpenses Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 860 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 860 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 860 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A + Details Name: us-gaap_VariableInterestEntityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LOSS PER COMMON SHARE (Details Narrative) - shares 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Earnings Per Share [Abstract] Â Â Potential common shares 13,523,429 2,291,234 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Research and Development [Abstract] Â Â Research and development expense $ 414,658 $ 678,922 X - ReferencesNo definition available. + Details Name: us-gaap_ResearchAndDevelopmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 38 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 (Details Narrative) - USD ($) 1 Months Ended 3 Months Ended May 17, 2024 Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023 Mar. 24, 2022 Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â RSU's granted Â Â 131,576 Â Â Terms of awards Â Â The RSUs are subject to vesting in four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2024, September 30, 2024, December 31, 2024, and March 31, 2025, subject in each case to the directorâ€™s Continuous Service (as defined in the 2020 Plan), through such dates. Vesting will automatically terminate upon the directorâ€™s termination of Continuous Service prior to any vesting date. Â Â Conversion of Stock, Shares Converted Â Â 37,779 Â Â Common Stock [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Conversion of Stock, Shares Issued Â Â 27,602 Â Â Director 1 [Member] | Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â RSU's granted Â Â 32,894 Â Â Director 2 [Member] | Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â RSU's granted Â Â 32,894 Â Â Director 3 [Member] | Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â RSU's granted Â Â 32,894 Â Â Director 4 [Member] | Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â RSU's granted Â Â 32,894 Â Â ATM 2022 Agreement [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Aggregate offering price Â Â Â Â $ 15,000,000 Proceeds from sale of equity Â Â $ 0 $ 1,086,119 Â Payment of other stock issuance costs Â Â Â $ 5,846 Â Stock issued new, shares Â Â Â 177,890 Â Average per share sale price Â Â Â $ 6.11 Â ATM 2022 Agreement [Member] | Wainwright [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Payment of offering costs Â Â Â $ 27,999 Â May 2024 Public Offering [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Proceeds from sale of equity $ 3,500,000 Â Â Â Â Gross proceeds from sale of equity $ 4,700,000 Â Â Â Â May 2024 Public Offering [Member] | Common Stock [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Stock issued new, shares 2,450,000 Â Â Â Â May 2024 Public Offering [Member] | Class A Warrants [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Warrants issued 2,450,000 Â Â Â Â Warrants exercise price $ 0.58 Â Â Â Â Warrants maturity date May 17, 2029 Â Â Â Â Warrants exercised Â 300,000 Â Â Â May 2024 Public Offering [Member] | Class B Warrants [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Warrants issued 2,450,000 Â Â Â Â Warrants exercise price $ 0.58 Â Â Â Â Warrants maturity date May 19, 2025 Â Â Â Â Warrants exercised Â 2,880,000 Â Â Â May 2024 Public Offering [Member] | Prefunded Warrants [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Warrants issued 5,650,000 Â Â Â Â May 2024 Public Offering [Member] | Placement Agent Warrants [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Warrants issued 324,000 Â Â Â Â Warrants exercise price $ 0.58 Â Â Â Â Warrants maturity date May 15, 2029 Â Â Â Â May 2024 Public Offering [Member] | Class A And Class B Warrants [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Proceeds from warrant exercises Â $ 1,844,400 Â Â Â May 2024 Public Offering [Member] | Placement Agent [Member] Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Payment of offering costs $ 100,000 Â Â Â Â X - ReferencesNo definition available. + Details Name: aemd_AggregateOfferingPrice Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: aemd_GrossProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_SharesIssuedPricePerShare1 Namespace Prefix: aemd_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_WarrantsExercisedShares Namespace Prefix: aemd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99

-Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms of award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=aemd_Director1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=aemd_Director2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=aemd_Director3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=aemd_Director4Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=aemd_ATM2022AgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=aemd_WainwrightMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=aemd_May2024PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=aemd_ClassAWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=aemd_ClassBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=aemd_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=aemd_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=aemd_ClassAAndClassBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=aemd_PlacementAgentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS (Details) - USD ($) Jun. 30, 2024 Mar. 31, 2024 Related Party Transaction [Line Items] Â Â Due to related parties $ 732,518 $ 546,434 Accrued Board Fees [Member] Â Â Related Party Transaction [Line Items] Â Â Due to related parties 68,250 68,250 Accrued Vacation [Member] Â Â Related Party Transaction [Line Items] Â Â Due to related parties 154,816 167,973 Accrued Separation Expenses [Member] Â Â Related Party Transaction [Line Items] Â Â Due to related parties $ 509,452 $ 310,211 X - ReferencesNo definition available. + Details Name: aemd_DueToRelatedPartiesCurrent1 Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionAxis=aemd_AccruedBoardFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=aemd_AccruedVacationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=aemd_AccruedSeparationExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RELATED PARTY TRANSACTIONS (Details Narrative) 3 Months Ended Jun. 30, 2024 USD ($) Employee [Member] | Separation Agreement [Member] Â Related Party Transaction [Line Items] Â Accrued vacation paid $ 9,688 Accrued salary and related expenses 323,534 Chief Executive Officer [Member] | Separation Agreement [Member] Â Related Party Transaction [Line Items] Â Accrued salary and related expenses 186,000 Non Employee Directors [Member] Â Related Party Transaction [Line Items] Â Accrued director fees $ 68,250 X - ReferencesNo definition available. + Details Name: aemd_AccruedDirectorFees Namespace Prefix: aemd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aemd_EmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=aemd_SeparationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=aemd_NonEmployeeDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 OTHER CURRENT LIABILITIES (Details) - USD ($) Jun. 30, 2024 Mar. 31, 2024 Other Liabilities Disclosure [Abstract] Â Â Accrued professional fees $ 32,203 $ 215,038 Total other current liabilities $ 32,203 $ 215,038 X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION (Details - Stock compensation) - USD ($) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Offsetting Assets [Line Items] Â Â Vesting of stock options and restricted stock units $ 139,328 $ 250,114 Total stock-based compensation expense $ 139,328 $ 250,114 Weighted average number of common shares outstanding - basic 7,457,888 2,431,476 Weighted average number of common shares outstanding - diluted 7,457,888 2,431,476 Basic loss per common share attributable to stock-based compensation expense $ (0.34) $ (1.35) Diluted loss per common share attributable to stock-based compensation expense (0.34) (1.35) Stock Based Compensation [Member] Â Â Offsetting Assets [Line Items] Â Â Basic loss per common share attributable to stock-based compensation expense (0.10) (0.16) Diluted loss per common share attributable to stock-based compensation expense $ (0.10) $ (0.16) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OffsettingAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TransactionTypeAxis=aemd_StockBasedCompensationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION (Details - Options vested and expected to vest) 3 Months Ended Jun. 30, 2024 $ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Number of shares vested 4,780 Equity Option [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Number of shares vested 61,977 Weighted average exercise price vested | $ / shares $ 17.37 Weighted average remaining contractual term in years vested 6 years 9 months 21 days Number of shares expected to vest 23,873 Weighted average exercise price expected to vest | $ / shares $ 14.60 Weighted average remaining contractual term in years expected to vest 7 years 7 months 6 days Number of shares total 85,850 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21:

http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION (Details - Option activity) - $ / shares 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock options, granted 0 0 Options Held [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock options outstanding, beginning balance 86,466 Â Range of exercise prices, beginning balance 6.90 â€“ 25.20 Â Weighted average exercise price outstanding, beginning balacne $ 22.40 Â Stock options, granted 0 Â Range of exercise prices, granted Â Weighted average exercise price, granted $ 0 Â Stock options, cancelled/expired 616 Â Range of exercise prices, cancelled/expired 14.10-1,425.00 Â Weighted average exercise price, cancelled/expired $ 206.34 Â Stock options outstanding, ending balance 85,850 Â Range of exercise prices, ending balance 6.90 â€“ 25.20 Â Weighted average exercise price outstanding, ending balance $ 16.60 Â Stock options, exercisable 61,977 Â Range of exercise prices, exercisable 6.90 â€“ 25.20 Â Weighted average exercise price, exercisable $ 17.37 Â X - DefinitionRange of exercise prices, Option beginning + ReferencesNo definition available. + Details Name: aemd_RangeOfExercisePricesOptionBeginning Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRange of exercise prices, Option cancelled/expired + ReferencesNo definition available. + Details Name: aemd_RangeOfExercisePricesOptionCancelledexpired Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRange of exercise prices, Option ending + ReferencesNo definition available. + Details Name: aemd_RangeOfExercisePricesOptionEnding Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRange of exercise prices, Option exercisable + ReferencesNo definition available. + Details Name: aemd_RangeOfExercisePricesOptionExercisable Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_RangeOfExercisePricesOptionGranted Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_OptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION (Details - Nonvested shares) 3 Months Ended Jun. 30, 2024 $ / shares shares Equity [Abstract] Â Nonvested shares outstanding, beginning balance 28,653 Weighted average grant date fair value nonvested shares outstanding, beginning balance | $ / shares $ 1.44 Options vested (4,780) Weighted average grant date fair value nonvested shares outstanding, vested | $ / shares $ 1.62 Options forfeited 0 Nonvested shares outstanding, ending balance 23,873 X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of non-vested options forfeited. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration XML 46 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION (Details - Options exercisable) - Options Held [Member] - $ / shares 3 Months Ended Jun. 30, 2024 Mar. 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock options outstanding 85,850 86,466 Weighted average exercise price, outstanding $ 16.60 $ 22.40 Stock options exercisable 61,977 Â Weighted average exercise price, exercisable $ 17.37 Â Exercise Price $6.90 - $16.80 [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock options outstanding 61,672 Â Weighted average remaining life (years) 7 years 2 months 23 days Â Weighted average exercise price, outstanding $ 13.23 Â Stock options exercisable 41,326 Â Weighted average exercise price, exercisable $ 13.46 Â Exercise Price $25.20 [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock options outstanding 24,178 Â Weighted average remaining life (years) 6 years 6 months 7 days Â Weighted average exercise price, outstanding $ 25.20 Â Stock options exercisable 20,651 Â Weighted average exercise price, exercisable $ 25.20 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_OptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aemd_ExercisePrice1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aemd_ExercisePrice2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION (Details - RSU activity) - Restricted Stock Units (RSUs) [Member] - shares 3 Months Ended Jun. 30, 2024 Mar. 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â RSUs nonvested 98,682 4,885 RSU's granted 131,576 Â RSU's vested (27,602) Â Tax withholding payments, shares (10,177) Â X - DefinitionNumber, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. + ReferencesNo definition available. + Details Name: us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION (Details - Stockbased compensation) - USD ($) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock based compensation $ 139,328 $ 250,114 Restricted Stock Units (RSUs) [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock based compensation 68,750 37,500 Options Held [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock based compensation $ 70,578 $ 212,614 X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_OptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK COMPENSATION (Details Narrative) - USD ($) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock-based compensation expense $ 139,328 $ 250,114 Change in earnings per share, basic $ (0.02) $ (0.16) Change in earnings per share, diluted $ (0.02) $ (0.16) Options granted 0 0 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 1.52 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Â 0 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value $ 0 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price $ 0.50 Â Intrinsic value per share $ 0.50 Â Unrecognized compensation cost to share based $ 310,674 Â Weighted average period 1 year 5 months 12 days Â Restricted Stock Units (RSUs) [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Stock-based compensation expense $ 68,750 $ 37,500 Options granted Â 0 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 131,576 Â X - ReferencesNo definition available. + Details Name: aemd_ChangeInEarningsPerShareBasic Namespace Prefix: aemd_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ChangeInEarningsPerShareDiluted Namespace Prefix: aemd_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic

718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 WARRANTS (Details) - Warrant [Member] 3 Months Ended Jun. 30, 2024 $ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Warrants outstanding 32,676 Warrants outstanding, range of exercise prices 15.00 â€“ 27.50 Warrants outstanding, weighted average exercise price | $ / shares $ 20.09 Warrants granted 16,524,000 Warrants grantedrange of exercise prices 0.58 Warrants granted, weighted average exercise price 0.58 Warrants exercised (3,180,000) Warrants exercised, range of exercise prices 0.58 Warrants exercised, weighted average exercise price 0.58 Warrants cancelled or expired 0 Warrants cancelled or expired, range of exercise prices Warrants cancelled or expired, weighted average exercise price Class of Warrant or Right, Outstanding 13,376,676 [custom:ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRights1] 0.58 â€“ 27.50 Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.63 Warrants exercisable 13,376,676 Warrants exercisable, range of exercise prices 0.58 â€“ 27.50 Warrants exercisable, weighted average exercise price 0.63 X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightExercisable Namespace Prefix: aemd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRights Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRights1 Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsCancelledExpired Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsExercisable Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsExercised Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsGranted Namespace Prefix: aemd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference

27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-option equity instruments exercised by participants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares under non-option equity instrument agreements for which rights to exercise lapsed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNet number of non-option equity instruments granted to participants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2024 Loss Contingencies [Line Items] Â Â Â Operating lease liabilities $ 869,945 Â Â Right of use lease asset 813,900 Â $ 883,054 Letter of credit 87,506 Â Â Operating lease expense 102,000 $ 105,000 Â Restricted Cash [Member] Â Â Â Loss Contingencies [Line Items] Â Â Â Letter of credit $ 87,506 Â Â Office And Laboratory Space [Member] Â Â Â Loss Contingencies [Line Items] Â Â Â Lease description In December 2020, we entered into an agreement to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory suite located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement carries a term of 63 months and we took possession of the office space effective October 1, 2021. Â Â Lease frequency of periodic payment monthly Â Â Lease periodic payment $ 14,158 Â Â Letter of credit $ 46,726 Â Â Manufacturing Space [Member] Â Â Â Loss Contingencies [Line Items] Â Â Â Lease description In October 2021, we entered into another lease for approximately 2,655 square feet of space to house our manufacturing operations located at 11588 Sorrento Valley Road, San Diego, California 92121. The term is for 55 months and we took possession of the manufacturing space in August 2022. Â Â Lease frequency of periodic payment monthly Â Â Lease periodic payment $ 12,452 Â Â Operating lease liabilities 79,830 Â Â Letter of credit $ 40,780 Â Â Office Lab And Manufacturing Leases [Member] Â Â Â Loss Contingencies [Line Items] Â Â Â Remaining lease term 33 months Â Â Lease weighted average discount rate 4.25% Â Â X - DefinitionDescription of the frequency of periodic payments (monthly, quarterly, annual). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments including both interest and principal payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDescription of lessee's operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe total amount of the contingent obligation under letters of credit outstanding as of the reporting date. + ReferencesNo definition available. + Details Name: us-gaap_LettersOfCreditOutstandingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=aemd_RestrictedCashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_OfficeAndLaboratorySpaceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_ManufacturingSpaceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_OfficeLabAndManufacturingLeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

QZA=S^]/^ERX50!W9U4#IRM'"#;',CF4"Z2F4Z1'[$T3A]S'9;_BH-7PW,T MX)S%]TL>W2<4\4RXRFC*=:B!'O4R2R=9REF6B#./Z#SEE-%'U %3BK#IRR@Z*D/O4)Z?
5.ND^;8=%NA&W7(HYC.,V6HW;+(VP1T_9LVVXV M]15-'6SA9JM .P'%&O(Q7T03>MH1BT1.V1/M])&*$-40#,'T"35?7-R^HK+FS0),IG:)E.*2N" MA,^H6&S8-W%)M
(XOFJDBQVO'K>E*46*UHPH9G]^2<&FE]WSVG?""< @G M5([?P7A+BMMK,NV]JNR7NTL?F49=9+\LT^/U 15Y=KO(6IXEL6>WO;<]U[:(M1R3^VBU%D;4=RW!-"=17-
'6Q*97B0#O^/0A0#,$4%'@]5\V LV; ^1_3Z:4B MJYAQVAZ[KM>3_F:H=6_?^@L)YD."!9!@(1!8(V#<=<"X.P7,9KRL5N7E0FP _MB6X
M*P61V\Y%SW2EI7ZD'=@>Q1D()P#"'"=6C)^K"X*UY]GXDS[K*X;7&XY@]F7*M M]_O6#4@P'Q(L@ 0+@< :\=1;QU-/&T_E'?)1(;M,BWA:T#2/JI HMJDJ$+2(MNR?(L->^%[-C*45?
034G0^$$P#AA*\.OT$H-FKMQ=!2>BFR.\ER90[K3??@ M#@IH5 $URJ0IK@"QO${X4%T&4$##A+KXW2=P0T+"6Q"MQ5SVI0@10W86O==Q"!,TS5=62U1-#W"MKC?=ESBR459T=;I68:0I))H/BA:
HH50:,WHJ!4Q#"B) MJ2.DK8EALV>VZKA"4G)LS[(<8LAYJI+%;!>;'G9:>:K2Q5S3E/,42AA3].>Y MF#C8V9*GM3*&_XLTMEC>)_%$G']@3.2RD@BG182'#4/FH2V4F;:)/<.563A M]E%?ZP !!5!
H7H.>CUCB[J):[4*[R97P>N;N"V[%.P:;8(/T'DTA1@2S0=% M"T#10BBT9N34^A?>30!31\XPB?(<#4J5:[5]AIXCQJ*4Z\7,JM?-HE DNQPS M;0T,>Q8F[=)\@*:C+@I 0 $4*B> \O:2+ FM;44A?5:%
"UVLK0%EP*BA65 MX0"%1U,9(-%\4+0 %"V$0FN^&5+K7D2O> V 1R"51XU;+_D9-5&(1#9NOT<" M)$KY4$!%%"HG %CXV%^D_!:(R-ZC>P'/@LA;:&(N(Y!9.X/$*:V5Q)0-!\4
M+0!%"Z'OFH&U\9*97J[\[Y*&('G(/$9:T%;_B/E&N*R.H#GTHH **'Q)"IK$ MUFH;T:MMNDM-]" 0"&A&%MD;$;TERVL^5)
MC>BA]B$5"&@$!>23]@MR1UY+T('J+GRMNR:9M:Y&]+K:;H]&E((:4;U\U3-= MD\B:FMZ'O9=A2#0?%"T 10NAT%:QT=WXG]#X(.4B8H]QFJ.$/@AXX]@5O;'5 M-QZK'9XMRD\,
[C/.LWFY.:1E+*B@3C_D&7)?:?X:F'I]W4_!0$!+D M" !)B0Y9/.!O+ @& !D' & 'AL+W=OBH*G?&O%VXYT\+;2Z,IJU9;Q\B$\BC$3W/R)$ 81RUBBC0L*?VMVR;+,> (<_U9.
M!YMGFH';QV_>/]G@(9A'JMBER'[P5" _!O$ I6Q.BTS?B^?/K HH-/X2D2G[MBYXK6V^ DD)IL:P& X(ES\M_^E(E8FL ^'$/(-4 TMP2= SPJP&^#;1$9L.Z MHII.3Z5X1M)8@S=S8'-C1T,T/#?3.-
,2[G(8IZ>7MS=7US>SZRL$1[/;KU^N MSA_@9/8 ?]^N;QYFZ/83NCR??4:?OM[^F*%WWW-:I%RS#'T:HN^S*_3N]_>G M(PU0C,-14CWVHGPLZ7BLC[Z)7"\4NLY3ENZ.'T$(FSC(6QP7I-?A7T7^$?
G> M!T0\$OEF?!X^W.^!XV_2ZEM_?E=:J5]@..:P1A0K%4L1S!"M/4LWSI()TN>9, MG;@R5WH.W)[-LCX1*YJPLP&L6\7DF@VF?_R&J)Z?KK'/Y&PG'<$F"4&?]^D- M=*%,*.4*LAPYMB--
JUE/AR2,3C>$.N' ##+NR=H?/T M\A=T)"T0EI 1TI$GO",H;Q";:Z:X\1,Y2]HD,23R2LYT\C3=Y&O=.XA4# MIPFG9=/-4T270FK^G[W@BKQT%VY-6#SVQLUI;5M-/)^$[CF--EBC7JPS+9*?
MMJNG*!%+H#K5"3-J <#^!"]K@;-M1D(/X\ ---X C7N!GB>)9#:C8HZD89JA MF ^AR+8*+&,0!Z)*,>W"'[> #3&LB@;\MA4F?NP&/]F G_3WM@7-GYAJ+ >#
M4]D"R3AJ'%GWTI@<;'^XI0%*;]K>@K?83.UP: -97. M"' !+FD_*!HW0W#8^<$8^QTAD#H$LJ,"=(TGIXLQGUFNQ" MJP4 [J76Z57!2E[)*(@ER+'LS*+?GF!HF7'01-FV&Q(R\:(.J#5-X_T\O9?E
MG,@#1Q.*@BCTFWW(94F"&'I1% J:QW$_D3ND%L_73!W"TOBH-'TL;[N)J(D: M)S/U72&3!35="$AE)[J-F_!5\9J>/,09N*6^NC;3(DON?'70NX)FS< MS]BMTG--G1-UFYA;J-LF_:AK]L;QH24'>5YS>
(5!CZ]HSG,*&O* LNM5![]< M=D?RMIN,6@W@7HX%#A0)8ZE"8]Q!AJ1FY?$%>]92 M4F!-]L)DPI6[<(P#SN, WGN:Y>LP[" E4E,^Z:?\! _"GKE>+$26FCH%YB_?
M@(1$&NZ91K&FF:'^S:TYW#/O06I!)4,@9G3&S!TK76&M2IX8@JMRD_-*!=HA MJII86:5;:21G3MKZ8!AZ45.+\N\QB?TLP[6:E5A&D7T5LFM"^Q>S$WM8.0'\3 M(.8F^K8A]J((Z+(#?RTU2+_4N)
[/66+G@[TD5IPCH&\HW!PEE58WAQ"A,P"' MK, @*YKP76;QN -[K3W(?NW!^%WA-?>TP'.*Q'Y(NA4UJ:4)Z&=_RQ&$1(*K1(WOB>6XJSO WDURD MSL#"=L&%9!)LT5H56-
L07AR(%P1=@=52@_1+C<,#/G'X22.PV8$;4.H MS#@D05!)%?L?<^[4]\OM5T?W^EE5YV-Z&CJ/0:VYT[#4K$8ZVOM/S=7-I()S^X&H&PO=V]R:W-H965T&ULK91M],P
M$,>_BA40&A);TB1K1TDBK2V((8:JE<$+Q LWN3;1_!!LI]F^/7Y(0S=E%4*\ M:7SV_7^^N_HN:;FXDR6 0O>4,)EZI5+UU/=E7@+%\HS7P/3)A@N*E3;%UI>U M %Q8$25^&
1CG^**>5EB]Y8B2WBC2,5@*9!L*,7B80:$MZDW\O8;-]6V5&;# MSY(:;V$%ZK9>"FWY/:6H*#!9<88$;%+OD_ 8'/7N:RQA#DGWZM"E:EW MX:$"-K@AZH:W'Z'+Y]SP^TI<9B9]WX)D#A\^ (W3-
MF2HE>L**![K?1UD'VFXCW06'@5^:M@9BH(W* S">""><^=_+HR/A1'WA(LN+ M_JEP/[[B-8&?0V5SV'@8:YIV*FN<0^KIKI0@=N!EKUZ,QL&[H9S_$^Q1!>*^ M
O$Q>O9%SY@KEG,*Z.0SEW+PD3C$V"+,1-EEI^'Y9!3'0>+O#Z,9<(S"BW T M>=L[NBC]@\=.06SM#) HYPU3[7CUN_V8N;3=]61_IL>/FQ9 ,&YV76.QK9A$ M!#8:&9Q-=/,*-P^)-7\$VUG&
MO\=VTE!0FTF]2?QQWM?/.9%/EHU4C[H$,.B9,Z%C7!I3+8) IR5PHJ]E!<+N MY%)Q8NQ4%8&N%)#,BS@+HC"I>,C1;KN8OW =\H-/IH MC%PF>RD?W623Q3AT0, @-XVESW1
M<"/9=YJ9,L9O,%^RCW1ME=:G4F MV=CR9J#0@R(9%05:*45$;;L1B\#8T]P<4':N:U;M^B,VQC=26%*C3Z(#+)_ M]8$EZ_&B]XZ&C3\7(MK- [?H"B,)@-^XS[=L?<;7Y N^G%KH]'& -<_3^7>
M6D].6[O;L] 522'&}3>O1K/P0#0#XI >?#+DGNYH!&H7[Z=7H&!JM M,EF9_TO=X@X;YH11& ^;]F#309\O4E@ #=L^A+;752U!U#+I$S;,.> M+[':>[;YQ84;YAOV/4_ %0 M2P,$% @
28D.6?YF3_#$%0 /38 !@ !X;"JW;W)K3+S9)\MW;97;XTIE#?DCC- MW^\MBV+UX_Y^'BY-HO.>6YD4=^8N2W2!K]EB/U]E1D?\4A+O'_3[K_83;=.]
M#^_XVG7VX9TKB]BFYCI3>9DD.MN'I$S_,#7ZQ9YZW/BE8R<^Z.OHRC]WM] MLC)BQH!(T_]V9DXI@&@AB_^3'WZBGIQ?;G:O2?>.U8RTSG9N3B7VU4+-_O
MO=E3D9GK,BXF;OW)^/4OA]8+ M;_I/O'#@7SA@N64BEO)%_K#N\RM549/8S3ZP$OEMR&<3GJG3X70I:O7D_/I^>7-\&9\=:FN)A^'E^/ MY2_O]@M,3X/LAWZJ4YGJX(FI#M6%2XMEKL[3R$3;
[^]#[%KV@TKVTX-G!_Q[MF?;48;^C#OH'1\^,=UCKXI#'.WQBO&8NC(M;+I0URZVH36Y^K_A+"\R8.?_M=RU8QC0:/[1[YTX_Y2H?F_1X<)C?9O=G[\+QWELNI.1Q5+HT8N6>ETTPG6ANZ5
M>4?97&F5R&OT3*97IBQLJ$)Y5LT=W,9$"J-'YAY19T4&I=$^F<2MRLS.KHT-)G2::1B.S?= M8HF(6)B4IKJW&42SZ5P"3\Y/S5E\3))B(0N=*H JS5>Q3@M-3_6@ ;4L$]S)
MBS("]#IJ\.I(Y2;/>9"U+9;]\(U:X7&3%GDG>+@DM=:YRO722E+7)(MYU:9-0622L#1/NU2H,;T)ERF]/*FIVZ6A!Q)!21G(Y9>K>#L6FP%^XAM.VH- M))@_%#'1&Q(@P7""
((,$MR(W(;L%]%8"T0"QW$)R^HXY'FF[@DL)#=K<:-;\ M#=1WVYOVU$ _.B2G/LG*AAA$2@64=6_(40.NGLV"JY^P6BN_;9Y D^O\[88^@X"N'*Q5&>,,<[XS>,M0+=8.(D4&N3^"FNASI:(? X2P-
X=O>?R" M5I#0$V[.#]W;J-1Q'C!<=71/NHQ(0]\$]E1QGO72*4T:MN1SJDRALQ4F0)8F MJ. =FQ8NACO*\'@[C706T>>07A17W8A2>4(_MW3KE.:6FQ:^QAY+* 6Q1-8*5H.OF2TV) S?%J.])5F>5-
!#JP?> MQ_ D8@HM"?$'6HL(/<:O"?#,X#.17ZXE8/Q* L?6W)M'5F9 S@PLG9>(BW)"K3"U(1W=8RD"PO (W/P59,C]&(="N2F6^KM.2](_+'7(MEL),"*L1^S9>5WJ1&
<:EA(Q+E^` (70(B5,U!0G#8&J8YPY*+2CM?/X\XH5? M#B^F0\KCT%],/ P!2="":&]3!GU0$,TQ)NXO8C?#;02V;N&ZAO-C[=H!D1O$
M0LIN'$"C5R+4&I.FVC@I5)">.>UKW0Q2Z:P<&T0E8[BO;4=9GE)84V3$2O MU8KH!+PRN< N!59 !.4Y,7P8>C1W;5SO];? /5Z?%J1+-E^#!3; OF8"B0;6* M6>9TU,U7R(A9F3P?
0]42=1=D6<2;T.4;=EV&!U+$S"TW$3$12"K7GP^X/FL! ME#$%G4TK]E8B,*ASA"^P1JB?:2D<$P+,$?_M#++P$2>$!D7NT9LK4G<&8J7K3 MK.!'L'; <[63J2<'54*0P86MHOZT["(;61JO_-/X"\B (=,7-
N^.V,SG,Q?K M'KA#9 F %/HZM:DZZ@JN2MQE\)K+J;X(#5K1Z$ SL8G%6IQB2R+72"G++\=P*;# MR;0[)W,/; Z/8LMBGA$,3US MF>05)*Y%ZL ::=V-])3;00"+POATJ\:C6Z8=/)@.2^]+IE3?
BTI/Z71?L58 M&*^/7,@K'K$4W!UJ9CX6@MX@8@(SJ-=7%-]S;Q!(Q!H237I D2Q4?!2HUB1K M&.(!E(+H+O%JFX64,^OB O.1)J!3_*T#FBN+D-G:B\O1C?
I!]8^.3XY/^H)B@>@"GS1B^P'*V8.^AVJQ*Y!W/@BBE(F"3 MHC.;WY9 ,+'7O>]Z;_5W:MG5+ HF3A@%5@O(.S ,2S!Z_?YBVD4EA'4/%^ M$"/ZJ=E&'_ I'?U55DVN*62'!IK;#*'"#R=0JVS"NJL-
%5ZBG5XUP;BH\P"%#)22:]"-'++^7I-#IRA9*$0'+1$ MQ8NTII[ZY-8$S@Z_BT#1X*S)F,0IM06UH9#CD2/NHZO>7B-;373&>%_[^B!? M,K7W#0PNGQW')Y):5$;0;-8EVL J2I&
45'/$2YUNB"GOF4X3?$N+'[MC7)> M(^LV-Q5;I,3?":K>!R4!M@"99NT>A+%Z'O[VN'WQP/6X6_+ -/7H-9U\&#GI M6K.@;9](H!"67(8@)-V;W;P[UF4:+EO,6SUDWD&;;G8JHM[BISMH]K_)L#FY
M.XQ?ZY6T3TF8'OR55-V&J.UV+MI(=AN)7TMP#AB'.36R.&13:0/.ASE0%X&$RMUZ?=Z0UY8*7:VN,WM/[.63 MRU>VH/X'_$)7878K?7&?Q^6F.R>7 8RWK1GL2)VH4E\?O56/$FB[N BG;V,
M./^N$$D**$WQ,F?S0:E0*0]9E^L3((B 1$ M&IZ]I%FN5N#+KKJ?XG,L]_Y5S 6B1-1@C+J\@IW0Y$-&W>L_1-UUYN; G46V M,+$ZS:C!M!-Y(U'MJ++##8>>@ AD1['-.VKB-FU\[
1G=7<+FE4EYF8% M](#)P-3!@V=.9U(TG4]..T$#(VJ_^H5N-1NH M4K54NV!=:GM9U+R^&%Z,.E50-60WYBP2;:C[\JAQ(GR"PC232\^I*P%A:(PH M%*S%Z?'>X.3XC?1^\[:Q+LTZX%7[%?
L!]%,]G\-3F^SMBPEJ2'CV*=KR8X(4 M2<<<=D*-'Y>:"&ABIE*V_4JV[%M\DML'DK%E2S;@D7=1S/FE,GOE"(T6G6@U_M!V/U>SF(;^">"\-XHN7T4%S6Y+6A?44)""K9"2N5YAU;6 .&W6\\"T;9;IF6T
J=*B[EYD MTK2K!Z!BS._1^/3-3!@/D[C;:GY8?\LVA33O:K!!&]*+"70(6@$-9^K.1JG9 M*%AY7N:ZHM7/-U:>W^5X8A?*MR2WNEK!>FFX)'S,0M=+5E/HLI7+/*HY1"0Z
M7%HR.TO,))LG]/1;"#57A!3?J ?TH&?L.S6=NGG<"2:?0^2)V*"#!OAIG!W MF(,^+O$R?V982@$+Y,0Z281"UN^)]T/=Y!N\-0&QI*_5L$)206L?L7E:{) ' M/$@$1+$!(R0OWQMC_UI17'5ECI$>;8?
Q,B7#4LI*IJFV[0,0R1;4F%521/YDZ:1Y[.L$48E6U(FVR$)>@?0OS M;051(!7-TNH^D;ZR5HJF!LZV(-2,0"Y--[Q#7.6Y5FGYT%W\>@*9?ML]?,=$ M8%3)!RPN5@L:),5;1GPCMP\]CL%
(BPB3GJGYMK&$">O MNQ=KA)@9""8%W F*/E\SW]YEI,;ZL83((RT'J7(.=4GQ\XSXC;4:V#.6689 M3,)%"(34VVV>:G-E!?)6<+ACG&- 1ST:OP7H16/3FJS;7 5&JP:U[^//L50B MGDZJV1F"#<)
W@L^(EE*61=3?Y_44:;>ZLACT"5(3)6S!Q^5D,3YM-8?;H&L MM>S M7"++=$(RA>A_8[3BGFQM?]>! YWF!QX M64B*Q< 5D<,\@\'Q\;&:..M[(<^H+L@C2]<1IT.II29SRH]*.D6 /+/P8E!Z M,'-X=
I7.SD8' R$EA0F-JLE5;IIF5'G!<'LQ:O!R9QZ)HXV)%QXQQ34YH6D-M+OIHG.I59P6FMQ<7P\D_Z+#/=/SQ#2\O%'#T>CJ M]O)F?/E175]]'H_&YU-U)B4?]_.YJDKD-!B=,(BDJJK.9G8EMZ9UAFI98V\3
YHP@.M,'*W=_KHOE MN:4=`2[V1*A H' X$*EZ:G+^Y7PR/5?3FZO1SVIZ_7E\0QLG55?LJ-/:YIS[M+1NM!EW,T!WTU:M^I]_G?^I4^[[^-3F&9U\2P[VE? >'=F/5LFGFVB= MB"MEQ-
L*Y"\FS>43E^`<8FTJ*V/\ M(CN2PG74FZH-,87W90@T/J"=?Q- 2">%N3>+,CU'-3>I6ZUJVOT?$&Y>(35G M-PRK#9WR*.-(J(]F+4![7Q$>FB8O[\=Z)>_4)F^3PXNW$@%2+.%)%*EM%+5V
M1[X#FC9N%X!8(-V7+M/K"I7S[N8CJ,$_GDN085\V:$_W5T>F:1^'1V4?!@! M#BZ^%^5.";M)U:\&%.)X*W8P8+M><0&70KIU9 _L@ARC[3I(UGX?P\&ZY1+ MIW_##BUH
:3Z#E/Q82W2+@II.@5"W%M33HR^0I-BLCK%P4PHA\G7*/2>1*: MWY/.U!"?H*1?;?]@[6 (M&GM]W SV97S"9_JL7P9S&.W]B?6&D%7+A=2]AD< MU=%&%YGH/?A?MBN>]5CCCF)[HR @5Y)1 E-
I0Q1(CQ?*X< N-H@YXVF\K[- MJA, _BK\&$OW)_U(ZU"P^#VJ"%(V"P>#9+R'3E(^[! Q227?G-7;!T&J07** M(5&""HV%'+TB"Q58(K6E/F=!.DJN9PW=&6U.T#Q!!0\V)2G/^#9%X?LZAP
M:./F),Q]O>E835)P44K:Y_19AU5BOQQ4J1"D8[Y,'(,JZ0CXH/)."<0PCXN MOCSRE2L2%][E,6K7IM#]%5!:_ GO+45&[)ZXGI_B()?5;WY0UXR_ZJ5]=N' MK)H*(:C5PF>0/'7+4:06/?
5Y_,OM^&Q\|P\";OWQBGC6Z.IR=#ZYA*'IK% - M86+XYIN5\Q/DUMYQR41!;2)1>E[.Y30)%QCSTA=@X,3]?K-:R:!)Z^.^.^?3AS?S?" QS(1
M8,%,:R/%WI82U)82JCQ*CYAD%4NKL7TLA/QEX0]_@S_%_BAB$YBE[X.+^=P? MM^936V($:^KS LS*I!0M,R&]=?%.>V:(T1P!1J3Q&R>'S38-&(S!?6!@]:Q M&>I#2)7&N)0TP, _PMZJWG^BT)
&E*N%?-Z@7=-COD@ZA#OHO&6"AEAX@U<54 M6-/)4>H#20N=#B3#QK$I^,P/=^6O\V:B@_"6H>EQ]6(?0QJ*4= MFSE>[?=>'^^I3'ZL)%*M^(?",U<4;B$/])I3Y/1 [@_=U")_T(3U+\8^_!/
M4$L#!!0 ($F)#EEPQX$C30, (,' 9 >&PO=V]R:W-H965T,;;[[YDIE,]9]\R5B@-=*&S]+RA#]^S3U M>8F5\ -;HZ$[6^LJ$6CKBM37#H6,095.L^'P?5H)99+Y)-ZMW'QJFZ"5P94# MWU25<-
^7J.U^EHR2P\&++'KL !^E\6NL"UQB^UBM\N_3((E%QBMKP.%VEBQ& M]\L)XR/@3X5[?[(&KF1C[3?> "9GR9 %H<8\,(.@RPX?4&LF(AG_=IS),24' MGJX/[+_&VJF6C?#X8/5?2H9REGQ(0.)6-
#J\V/UG[.JY8[[<:A__8=]BQ\,$ M\L8'6W7!I*!2IKV*U\Z'DX /UP*R+B"+NMM$4>4G$<1\ZNP>'*.)C1>QU!A- MXI3AA[(.CNXJB@OSWY_7:U@]OL#*\]/3\Q^P_KQX>9RF@:@9D.8=S;*ER:[0
MC.')FE!Z>#02Y7E\2I*.NK*#KF5VD_!+8P8P!O8A&V:3&WSC8YWCR#>^PO'0[3.8_O1N] M'_YR0^SD*'QB9&W_/Y2;-)=%9@.X2]+X54.VGH/-7GDHT?*0VZKN@DH8?,= MI-HI23;V#
(V+**7#4"+LX]M/(+#*#4\1'T,IJDVQ&*W'%)1^T4^#S07?!"&24 V MCB\<3QF5E1VICV/V'-Y<% R@#6IYB?08Z;# M@R$836P06G?>DB?\#IC *5]G2%M+\Z/#_&,3O*C(0@:>]+E>R0Y[L13RG'VD
M3,(SCW* VRT-XLZD#64@AK<:%IZ-IJ;'8]/'K+08&P$ $)UQN-^W=T M/LD^0M;//H[ZV7@"E_HN/1F,%;HBCG]^>1H3VAEY/#U^81;M8'V#MY^G)^$* M93QHW%+H&PO=V]R:W-
H965T>8DQ^<#W=01@ MQG13YBCHSEJJC!ERU<;7N4(6NZ0L]8-6J^=GC MO/'1GRL#D7.!<@2ZR MC*F7*:9R-_+:WOY@P3>)L0?^>)BS#2[1?,OGBCR_1HEYAD)S*W=91 N1-VH-I MU\:
[@$>..WU@@^UD)>4OZWR.1U[+$L(4(V,1&%VV>(UI:H&(ON*TZM+VL1# M>X_^R?5.O:R8QFN9/O'8)"*.O[T&,;U:D9B%W-UCUS'-Y;Z+:[M%[W+/EF]J_[%AR" 8POK'VA,AFKCE%33*
IA2KFI3VNQGI0:]3>\5/I;IC9< M:$AQ3:FMYM6E!ZI4S](Q,G>*M9*&],^9"7UP4-D NK^6TNP=6Z#^A(W_ %!+ M P04 " !)B0Y9.)##PCT% ;# &0 'AL+W=OU$(<:V-
+!MC8E!RX:_LHN%"=-9'CPA9E912MP5O&O7\M3A35_ 6\2QK(7A(H-ESD2&&IA(X$PIJ6 IE?*"T?#78JV- M(MW\O2L+WLELMQ/;2X>Z8C&>A-0L&M4]AO.W;R;[XZ-70IAU(0_]?57L5 M<3??
V1!^Y0DN!%$)>RS7J&R!I@,P.<(Y%TS$G!70R_;*4)Z92G1P*ND"[]Z^ M.8BB\='Y8G7J;B=`[X%K76,"B]6=@_LP_@C-MA5F- T,W& EE0-\=RLK'D-T M,'Y_"!=EI2P1VJ+!R&8;6Q<(K>5GKN-
"ZIH";/P%+8>>OY;*\ D)+@R*Q"%S M[XEF4N=!-QZ2S@.M_JBY\GP&@(*D%J.#4;Q\:6-@E6C1>8(@:*;] AAH+!.V MX8:3C#?AP4O)!%=LB4SI88\:%L%EF*5&&SQC[
M(D_V!DVA+5=KU\94T:],&AI],/@5V.P9,TKS&@.6R,J0&A0:)77EN19;N\]* M@A+%R7WKUNF6J"1#^(; *%-Q39Y2IT6$Y-,*JLU+AQJ9;G1Q)24 MG((S_Z4E77#/RK
'VELQGEA0EF4*,YM/6&\AQ005*P8^HZV:Z#,JO%E?$Y^" M9VJMZG5!E-8UE95J^]@%=K$)I)7&?]#?+06SE%0JL76=<<^*FKDIPU,7J=,B MA1?(U"O'M6=3IIYZ>I7WA%L];+JQ$#?-5O6R?X.
(5#@5W+H5C],IH/@<9Y> M"/HFU:[Z'Y8*$V[@#VG5W4[#:,1/%;Y$9CVYV4&$G^6CO1C#!;:0*W=3T2\ M&DKJ/RU13_]$4L%UHD6'#-'QA5!^UA8F? M)4_3;\^2AOXH$7I\75I6;516[,JV2D!ID!LW
M.]P4=JZ(\Q,W0]CUN1_U#FPEJLP=2S6X[O=GM^YM=_)=^ /?XW9_;+YDBK2M M*0DIF8Z"` ="4/XHZA^,K-SQ;RT-'2;=;4ZG=U1V ZVG4IKVP3KH_A^8_PM0 M2P,$% @ 28D.62!:6T'5"0 EQ@ !D
!X;"JW;W)KL&ULK5G;MM($GWG5S0TV8$#T+*NEI38!N3+3#*8.%[+GF"QV(<6 MV9*X(=E,-VE9?[^GJGFS+3L+[#[$XJ6[ZE35J4LS)UMMOMN-4KEX3.+4GG8V
M>9Y].#]RP48ETG9UIE*\66F3R!RW9GUD,Z-DR)N2+&C0ZQT?)3)*.VWT.]6#VVB]R>G!T=E))M=JH?+[[,;@[JB6 M$D:)2FVD4V'4ZK0$[W\X']%Z7O!7I+:V=2W(DJ76W^GFVP92FMNM#QMRC,-
Z>=:4>$:B6+.+_5 MVT^JM&=,\@(=6_XKMF[M<:\C@L+F.BDW T$2I>Y7/I9^:&V8OK9A4&X8,&ZG MB%%>RER>G1B]%8960QI=L*F\&^"BE(*RR W>1MB7GUW]_?[SW3_$W>W\>C&_
MN/O\]7HA/E^+NT]7^'=[=26^?+V^^[005]>75Y?BC_OK*S'L^6+0&XQ.CG(M(#%'0:GLW"D;O*)L*+[H--]8<96&*GRZ_PC :_2#"OWYX$V!?Q1I]Q4\3^0- M:V\,6=[P-
6_**))_XY7]K<@##_VF>C$S':+X*2Z(/-9*!..\@2]\R#ZIS] M^DO_N/?Q#8"C&N#H+>G_[W"]K6S<%?^#/OHS$/-4D*VA+!*_RB3[Z%WHKB_^_/-"2"$U)0+ 1@Q'+ M'OABJP1V*Z-
"$:6Y%C(M57FOJO*%-B('& ?L[DO[U>LP1 6#]S=OL6<3 9.R MN5S&$5(P!!0R%X2.PX11>,H1*C-Z;60BLL+80LJ)G(':[84&LW 4>-U17Q>)P* YNVVL6]9IKW?6&P^'A8#R;]6;O&02R
MZB'2A8UW8A7%@,ZA8SA7%^S"4 6Q)*,4C.6J3\J^!KE>PL9!GSG41Z15*4%2 M@&R&M05<66197+(B!)#0<<]K<:^M,-_(G+8_1"'T^G)VH6#M-Q!
M]4XD*M_H4&3*)%%.QN)Y++>E'R$S)/U+13A__64Z&/0^PEX2Z!A>0^:7_8\4 M(31%5!)*3'%;P ^C_MB#AY(B7K,_]W'-$2A*@[@(R0'D0 L=H1)A9! 9A%L[M:E]+&\H?
XD)F42[CLK0P)ZG+PR:-54:H1S"*1(%6++),R=7S*N +5YT,#R"2#[:\%.UUGG$'@"DU$]>2ZS'=\+T2"VQGGR/GVBUC'RB3 X$((A,4"5(J#93UJUH2I M- ,;2@,B<*80/62U MV3K/^_RTV1 !;TD:K:+
P>>W4&.B9<$/&*V358:%]%1F9M*0*A<]4L4ARU!/ M6J:B:L:8<]B$E6I5JV&W][=*4E/;UBBQ5+UU '$E591$"ZQJY=ZD) "QU2T4 M<&6R1%!5&PLE=9455,AA.=7_1YQ=K,M#6)^6)P%..)X>B#
<\VKS&L,N"US ; M-G@J$C? \@1E2K0E!=]/W>]-CO]V=B,/%GLYD8^/]1L>A/)OYT MUA/'W7X?=6OGYJ2; @$(FH&%IYT=%I=R*:^#6%O7J-SBIE&4]/;:$X75/R:HZ, /5P4;6K((/CK2V<)4]?
S),@.">>E0F MB&SS^DJ&)NH$ERZZED>W5C?"=ZW?&T[:F9 MNYGQS1@WCU$B?C<:I*0A\]'L7_R\[%;O?8\G]) 2EB"K1S0@2Q-#PVV<3?%W
M#X7:+F"F9C(*2[T25=1NJKPX[HY_FA&>D>R\LKU2Q%MEK=+C$KW. 3=)K6KN MUXRG53'4Q 3!5A&1B2[M4R7+,^^1N_N3C]:IX:+#/;HF4(7;9RH)F4$CW.@:YSLQZDYP^(UCQ6%IU-
WU4>BC?P1K@A],WY=N-%K0:.7SQ:\13Z_;'(O$X!6T[N;VL YT^-; MM0],4"5I4!RMZPV<">+=SS;5*B\-BIG.7L$F]MM2XI7QN-FA.ZWYW-Q\!O&
M6AJ>!0 /DVE_.GTO#@A&F01M@5XML,Z*JI3P,/=BF$;'>3:\D9%7C\%&IFO% MKD:=(*AME1B6*_D$O,4T5(-;G**0V=0MG3/NTRA'\K)+41#GR/M8](^KDDCC MTKF6)J387O*
J(WUF#;$)Z<261CD3M]Z*QL^$:*VO^EL^/6,&&EF5H":*D:5F(V*15 M9 -X8Z>D<6VW,(;(V#/:\$[[^QQ9>VG2"?C/4C=KE1M42KX:Y*O;V^+D]N M; 5VNB&V+KCH- ;%JHI'57]Y47.P6U$"5">*4.
[X/ HI[B@7-B<8KC&AZ[W. M)#ZBO.MWQP.:#5T5J.6R);S,]4']><H7STBI[]//^4SU(P* M3!=$0X\.!M%[KD%H.?STJZNE[\BF&AC4& MTP*R*81(M[]*>.BL(
L:LW,,US$X]_3DL!_$TZ.$MP<38DI4T'PFJKQ'RE\. MH8=O#:$8.(][V\X\2>3V;XOCD>MC\6),FO^)(ZS!TT&[KMQ_;3^ZCYW'YN; MY>Z3/>*RIG-+K%;8VNM.QAUWL*ANESN$QOMPHG.D-+<#
[E=9Y=4,* MZO^+./L/4$L#!!0 ($F)#EF?BQ^M,@, /T& 9 >&PO=V]R:W-H M965TF2$VD^Y!X/V;.G#GC&<_V0OY2%:*&QX:W:NY4 M6G?7GJ?R"ANF+D2'+=V0QU,TU;N/-5)9(5U:K@7^G[J-
:QNG<7,GJWD8B9Z MS>L65Q)4WS1,/BV1B_W<"9SCP;K>5=H<>(M9QW:X0?UOMY*T\T:4HFZP5;5H MO6(Y=[+@>AD:>VOPM<:]>K&D\F]$+_,YD,Q=WQ#"#GFVB P>C5?7)N@(C&
M[P.F,X8TCL_71_1W-G?*Y9XIO!'\6UWH:NY,'2BP9#W7:[%_CX=\$H.7"Z[L M/^P'VXB,\UYIT1R.8P]4\XA >'T/(> EF6MTRSQ4R*/4AC M36AF85.UWD2N;DU1-EK2;4U^>K&^^Y1M[VYAE:VWWV&
[SKYLLIOMAW^^;&:> M)GQCY>4'K.6 %9[BN"S:'6EX*XML/C;WR->([GP2&X9G@7\V+<7$/DNA'X8 MG\&+QF0CBQ>=2A8YTUX BDG]!%Q)6L7LRZ'@1W:OM*3=SY?R'F#CEV%-KWUR
MCN4X=Z@Q%,H'=!9O7@6I__8,Z7@D'9]#_Y\5.HOU,M/T D['@-M>UNT.=(7T MDXC0##5&4V.@"N%8(7>R1VJS7/9TT[<=JPLH$16($EY#.G7#Q(=, :-N5M0U MYAQ;C2; I&ZUH)L-
=DPRV[#9CL)1_VO LD3;O12//T$PA*-.T16YF,F$$K#I MN'A"=(%8V-@T@T8Z#RP?4"V7*S>=3B$*(S>)8@BFJ>O[1*T1?:L5%#WE*HCD M\+80(5U3%GN4"+EH.EDK+"8$9$0I!:?!9B2J-
3;]>K*AN5GT'$?D=A9Q,JKW MF5!OE.ZX&(W&I(QTQ(\2* B2V)T&*03II7MU&8T>ZH^\ M^$B#79%MXE^Y<1)2>-\-@V"R%9KQ4R*\ALLH=)-2@JLD3MV8]'OI)?>>C22J
MSLX.7D7RD1[#=!/Q]F>#2/MC_GP82!Q=C6U*,>27/V+R\!0!.0S;8:-%9P?< MO= T+NVRHN\32F-]Z40^K@Q <8OWN(_4$L#!!0 ($F)#EF,73J^A (M +T% 9 >&PO=V]R:W-
H965T*A(2^D,,D*!E*E.[54"WAVD/)KD0JXZ=V4[I_ON='8-IW\3[@&\>M.;#!5;)6ZL4Y\VP41$X0 M"DRM8V#T><5;%,(1D8Q?.\Z@3>F A_:>_ 9.OG6I9,X.W2GSGF2U&P4T &>:L M%G:AMO>XJ^?
2\:5*&/\+VR:V'P60UL:J<@[=[A !S"A#O +'7 MW23R*N^89~J6@2QZ5KRM)JNN6$L^.OJ_O9 F72%XO9EQ4\ MS"?3^<-\-9\MAZ$E>A<4ICNJ:4,5GZ!*X%%)6QB8R0RS?
$AR6JUQ7MMT_@L MX>=:=B&)+B".XOX9OJ2M-?%\R:E:;8$:'CA;<\$M1P-WW*1"F5HC)BLC=7T M)_EYK/*&N'^FT@*1WT?%-]YWO3-4UY2BTBI'X]8!$Y C:7@/27P1 M1PD9<>_IDIN.BMEZ?
9DIB,0.-:C\&"D2M0;OS@,U5M+VTQ7>]KNIDDSDG_# MF\5&)6VX-" P)VC4O;X,0#?+HG&LJOR KI6E&PO=V]R:W-H965T M(-%"ZBR),N2TDT"-GLWMZA3=!D
MVP^'^T!+M,VK)+HDE9?]3=#2K+LRFD6.""(*9$S?&;FF>%09X]2?=4;$@U] MJLI:GT\VQFS?3Z0TS*ZDJ9N!1K:=ZJS@KK%!53J,@2*85$_7D
MXLR^NU479[(QI:CYK:*Z]2JFGB]Y*1 _/)^&D>_%)K#<&7TPOSK$>^X^7-[MJ^!IVFLI1,5K+61-%5^=3Q;A^L8U]L%GP5_U(,Q14N6G[%AS^*\TF @'C)
MEJ@(8'QK=4[Z+5%P..ZT_V9M!UN63/,K67X1A=F<3[()+?B* M-:7Y)!__P5M[YJ@OEZ6V_^FC6QN>3FC>:".K5A@05*)VO^RI]<- (N."$2M
M0&1QNXTLRE^981=G2CY2A:M!&PZLJ58:P(D:@W)G%,P*D#,7=_ #8UH!=GIWFKX]+IB([HF-$/LC8;3: K@A?[\E/ TX.*.E"7 MT8L*_]G4/IT%'HV"*Y'WZPWK_A M="5+2$A1KZEARY+K-
BW%7YSJ#5/\'7*]H+FL(/\UPQ0

MS^()8/L>:/UZ!%&88 2NG[C*A<:\] [$^ZB.B]M0PP$ I'K$?\#S$*K""*I" MZ,\C?(:_P)]#F#'Y;.K;..Q." U+ZI;Y!U52TT$>D#X/\@U&1A^I[:-,\?" M#AO2L1W)G:V%.Y(OVJ)I8T9_Q4+P&Q.*?
F9EP\G'8[@-76R5*&G8>C'*O&1N M:>_'<9=G@M*CIECTKX$#;KCC3>F4PC]A8 MCN*L?D8S_8$-SJSV(;L!9V\(N@[(IKA!6/D_!YKRN]M3(:E]B2=I=X\"(XW]VD T8,F,8R\!&_>;?
OW[M(BO1HZ9J1I=S7G ;]"'+MU MX!6(T6\-4X:K\IE@I^YBW1$FF%>R,N!G6D:\Q9)941 M?[4%1]N2M*XAG8NNJKC[&3U0UAL#,L[.PF': =FM)@[3+@M>57,>&58V+0#. M2N20CSZ]J??
7>'#VJ;WS;[^)V##;\(L:>%3CU>@!NP6J@=#<@LCA?F33%T\] M=+IMY8O^FH'}$EV8PUV-Z[, (-MNE7RRKBB?D9&0L$D:8WLQIV-?$*:#;SH5 M5VO[Y0\B'VN^[S3O^T_CBW<-Z'=D>
<(/^D^'%_P!02P,$% @ 28D.6;,B MG3,+ P - < !D !X;"]W;W)K&ULG57;N,V M$'W75PRTBT4+N!(E^;99VX"336_ %H'3-L^T-+:(E4B7I%;)WW=(25XGM?0#!TGD<,Z9,T-QN&B5_FI*1 O/=27-
,BRM/=S$LR4KKFEJ=[' MYJ"1%QY45W'*V#2NN9#A:N%M#WJU4(VMA,0'#::I:ZY?;K%2[3),PL&P$?O2 M.D.\6ASX'A_1_G5XT#2+CRR%J%$:H21HW"W#=7)S.W;^WN%O@:TY&8/+9*O4 M5S?
YK5B&S G""G/K&#A]ON$=5I4C(AG_]}SA,:0#GHX'I]I][I3+EAN\4]63 M*&RY#.QN8%/U:-)G)!N4QZMIE5!..+MZ6F\V MZS_^?%S$@M$<+>XS*D/]V@_H;AZL.[
M9,H^7=$U/NH:7V._6O*KR/.Z/D8P,,+G1@NY!ULB/1KQI[K;(G1;!%1@/!9X M%+0(PIB&%I+I:$(6QABT?=% 2,B5E/WA:84M/>T7_@+)K*. 0[.M1 YJMT,7 MEX0@%*(
J6Q'#5R^O*)\]RPX44:4603KH3\0[0#MSJZP+U"\23"XG" I %\E M:6EIZ|K/3?!(3:UH*CQ"JQKU=!\P^7>.SSY(XU%,/Q)0%W-6*X+IX%;*H;. M2\B2/F"6CJ:S*;R'9!(Q%GQX-T^3Y!.DLVC"R)JRB'T,?
G%,KVO.HLGAR7F(/JZ_XO:7]JF?1-/M.AIU0OJ52_D\R.'>4XI-.5J/>^WYMZ$^DC>F:VM%ZO!+6 M72?\[M[=)[0Y>R5+@C*(MFDQ!TUZ.[B54'WQ>WRE*7]<.2KC74SH'6=TK9 M8>
("'"_*U;]02P,$% @ 28D.652I*Y$G!0 .0L !D !X;"]W;W)K&ULE59M;^(X$/[.KQAQI_N4A22\=J]%HI3;ZZFT MJ]+;_7"Z#R:9$&N=F+4=*/_^9IQ Z6Z+=!(BL3,OSSPS8_E3IMO-D=T\%RH
MTEZU<<G?5CMJ'C4>YSAUO=">7&{'&);]_-Y\-K;I' M*ZDLL+12EV PNVI/HX_7?9;W E\D[NS).W D*ZV_\>(VO6J'# @5)HXM"'IL
M<89*L2&"\;VQV3ZZ9,73]X/U/WSL%,M*6)QI]56F+K]JC]N08B8JY1[U[D]L MXAFPO40KZ_]A5\L.XC8DE76Z:)0)02'+^BF>&QY.%,;A.PIQHQ![W+4CC_)& M.#&Y-
'H'AJ7)&K_X4+TV@9,E)V7I#'V5I.?YO>SV_GRLNO(!0MVD\;<=6TN?L=<#Q:Z=+F%>9EB^EJ_2]"..^.(#ONOX MK,&_JK(#O3" .(S[9^SUCO'VO+W>>_'JHI".JLI9$&4*,X(KRS66B40+-](F M2MO*
(/PS75EGJ&C^?8N%VDG_;2><2!_M81IXU-9.L6BVV)[\]DLT#'\ $T+_M&$+_G/7_G[*SYMX&&X4=..L'[N;3Y?R5S$.6R00#N!,K3^U"E%5&!%:&"(8E MNX [I ZR<%O"#298K-
!P8BF].P3*"1I,099.DP$0:X/(F6K16K$BB,W&Z&=) MS8AJ#W$PCGO4QY6@?&5\@NF,?HP"?$0>1A2,P]&/4DJLM!%.FWTCJ71"1E,0 M#J)H,!C 4AN#C.2+4 KW*A%&K26E71(D'L!+ GBC<2U#F
FE*3SL90"+N(H MCFJ_T6#TCADXF G/F@GHU+,;].>6VG?@*<<34A)A#->L **MX*"&/2CJ[F/_MQ*BCPQ VVA+E_A E&4SWH=^(!3*VO>&*0CDD\ M'I-T32E1CK:DT^+V27$D4*.63^'<4JW4D
MO]K#*77?&9&=B2U:;A%!,J=*&:\^OQ9]\KZD^0!2Z*@_(1\$@'$) &(QB>H3! M:!P>-A^V%+U2@:>,ZPCPF:8;2U!WN4QR+A%9)]JBNZM%7NA:8 4?@TQ#I*Y^O M!\-LC:(-3DL^?]1& %
_^\FW^:WL%B^O0T?US"5ZZK/:RXE+9:;4DE M,[H 1X,.T^?Y'DKC*02:"5*R,(RDSM+9P:[*],N<9)*NZD<-D7BU!4)PNFQ04AXAZA*ZYI;DQ^B*T'D#=N! MM^[#[LDX4Z!9^Z'-,K[2U9/-
A%O!XJ%)*L)1\DF)%JV!D-VG7- M'Q9.;_QPM-*.1BW_FM-LBX8%Z'NFN2'K!3LX3LN3_P!02P,$% @ 28D. M6:L\..#' P W@< !D !X;"]W;W)K&ULC55=
M;]LV%'WK[A0@6$#;,MVG+1+;0/Y<)$.2.'&3?3E/3SG\)*<;(W]YDIF3]\KI=TT*;VO+]/49257PO5-S1J1PMA* M>'3M.G6U99"I$]EH\'@.]V$U,EL$L<6=C8QC5=2*2:ZI*V-TU*[.=)L/D M,/ @UZ4/
^EL4HLU+]D_U@N+7GI$R67%VDFCR7(Q3:Z&E]?C,#]. ^"IYZYZU M*2A9&?,M=#[FTV00"+'BS <$@=^&;UBI 0:3WO,Y+AD2'S>/]! B-JA924< MWQCUI\Q].4W>)91S(1KE'\SVCO=ZS@-
>9I2+7]JV_)Y0USIMJGPP&E=3M M7WS?^_ LX=W@E831/F$4>;<+19:WPHO9Q)HMV3 ;:*$1I<9LD),Z;,K26T0E M\OQL^7B]G']^G'_Z0O.O^"XGJ0=L"*;9'N*ZA1B] G%&]T;[TM%G02\
(]&]^ELT*718#0^@7=VU'@6\T]BL'#\UK#W-- @Z^NMJ MY;Q%1?S]DMP6;?PR6C@EEZX6&4\3' /'=L/[)NXU/H_V_ M3D*\3' X[-_L.E>:)R*CA3"D=\$:H1GG.THD_NAW/>=+ O?-P7\J4US;K$
MGRE'$AK"QY[(,E/50N^D7E-FM#-*YA&VD%KH3 I%SF.@BHMLV3(B"O&M]"W@ MXMM6)K=W375$+3 QP5-BL[,];7*/(1BGB-BKJVAJX"OLBVD+J7%A!"RLWP;,[XVKI$0]B!3E1 ML-
]UJ6#AY$HJZ7=1=6X<]\ YCXYBPV46,"T$=* S(-]Q9>K&RD*R136^';\/ M8FOA96M5<#9N!/FF,C:89[#I&PX.K!03"(#K&A7C<$\&TT "?V!B44B3O<5M M;TB5T?$31+T#
Q;1[9,%MU<[NO3]5++-3.=>>-/6 M28D%(*Q $?B3SG=)F2P6)^SZW#*>&P6 +DB$*T))T:>7SG7Z[,ZMV*[CR^) M#!+:,Z GK\MH[^\?TJN4#][5$?2LND#KHOSU/R+:O2=OQIHXW^,IXO >Q
M6>(!9ALF(%X8XP^=L,#Q29_]"U!+ P04 " !)B0Y9L0^?CQL("\$P M&0 'AL+W=O/7W=BNPBS9<-FU';"3>ZG[(&8$:*V1.$ECS/WZ>UH:QCB'N6S=AUW/B]3J M?
OKIIYNY6%GWZ!=2!GHNM/&7S44(R_>=CL\6LA"^;9?2X,W,ND($W+IYQR^= M%'G<5.A.K]L][11"F>;517QVYZXN;!FT,O+.D2^+0KCUM=1V==D\;&X>C-5\ M$?A!Y^IB*>9R(L/#\L[AKE-
;R54AC5?6D).SRV;_\WU:.^/"WY3C_+++998>DEEE@"P)_GN1 :LV&X,: *IO-^DC>N'V]L?Y3C!VQ3(67 M ZM_5W87#;/FY3+F2UAD-O5S[**YX3M95;[^+M^MTMK3=TW*2A]L46V&\!X4R
MZ:]XKG#8VG#>?6-#K]K0BWZG@Z*7'T005Q?.KLCQ:ECCBQAJW WGE.&D3(+# M6X5]X>JF?_\P'M+M3W3],!G=#*'<3ZM]\H.O^9#3AIW?CX61X<]^_]W>T.WX
M8_]F]/=T_V=U2I3TO]PT0GPA.UULNK4ZW1J[XU3C^BS-6'A:6ARF;_>WT$$ M=1B]31C7O;T&_U*:-AUU6]3K]H[WV#NJ83F*]H[>L-?/,EN:H,R<-F'2/_I3 M'QQH],]= 2=[Q[OM<6F]]TN1RUM\?
[K%^- MA[\-QY,A3>YO![0Y.[3Z'Z7BWN-['9QAV6Z-72;!3N5CHXCX$8DZ/ :G%PV*73;JO;C?]H3Y@G=9@G>\.\%EYYLC.Z8_],$ =FN34X/7O+S
MH0*A2K]KNCWVMX=_9_D&Y+!X7);+$49LVT*8TH<\5X9!8D-SY=>; IQXZ\ M,5-&F$P)31Z&)80N>%J()TE3*0W!BZ5PV*1,-.QRK)90A["@A :D37-II!-: MK_FU7$;D7UB[=
K&EUXZ%EE'' _O]NQP8A*S 7I%,%U<U:"D>2-8@^"TJ"=(NQ!!5P#WADO*DYR M>%.AN3"V2T=JA4X9,4RTJ3#%GO\K#UO4 DG%QW&^B*UN(5@0@\B] M,J4L+$0@E#*G28"/J#4-4J-
8')\/1TN\-!)>(#'E;9,>D,SH1SG#?S#&.9$ M+&V\P\@!2#/A%XT9QBI<,Q0OCBZM5ZF>(SGBRXKY,*L7I$^?3L?"K=++6:E)8XZ*=F?JF57'>\F(*$"J',<5!GQK" ! M%AH5.#B*U2-7:$J..":V!2AGSA;
P>)@N8EV!RG>H$)%-DKS,M+Z6C7 01\I MV,AQ'O.[.NY%I[[&?$VI1.1H9FJ?.">(BNLJCP*4_-]$#NPKKN"HQB;M8>$D M,IJFKAW)CP2%5M8\5 !+&58%'ILW&K\Y!&2 ,C/ZL>77LEKJ2E3Q %#B 9.
[ML6DZB7P ?,\T<%I/ Z?[AQ39:9 LRD2,=5?3WVOBC9'GCW9I(%TL;/14A!7# MJU6'5; *32TDC:\0DBW9=8+IGP\?[DUD+2JIA"+E-LV M6)R%1IVQ^G =OR2R!{)+
[4*>^$_J^$_VPO_I]&O#Z,/H_N_Q=\+'V]'-Q]I M<'LS&{YO=B5BK['=B=AS @K%X"=C+0$9@3)RD>A8EFLA(\WJ@IGDCKR]F, M!WILY8&@A*(P3H-4_-]<]X[//O1;]509#>*4TOAL0?-
*FNI+J^T=^6,N< MZJI:O/P:)K31(NONRC,%8O%QLD:[S+3U58L-:(]\,[?E+ @E"$V"#"%EK"N MF ,D2AG;4V-N*T7+I#.4XS&6O/0?6/;5R&;D/%5[A#!VEC;]+A-'19XC->Q%
M#&UC$(*W)B>49UO?TDGKZ.Q=]J=[1V?G9W'P?W=Z'/]^=>)]TQ,RBJ8L$ON1 MIA4/R9^A5R#0*Q V$L#7UFE>QM[-QI"/>5"T(O4;,]#1JB6BSB!"Z0'E28C 63 M^GM<$^^ZEOBN$*9DY,K(P>@
?>_1HFXPKZ.K_1"9GXF26<$;IL(\,G&YT'#Z MRC(I3 [R:1G@3/0E QU4B#\S/G4&/)-4;7,^=\QMR4DNTX#R+8&@))JW3G5GH M;'U1*:2;Q^]&<:HP(7UF-@1;Q,L%?O)(QPOP?F8!277#!]0?[*[^ U!+
P04 " !) MB0Y9[26MWF4" !.!0 &0 'AL+W=O;03\DEEB!KV!>-J3#*MRVO/4TF&!54=42(W)VLA"ZJ- M*S>>*B72U($*Y@6^/_*FG,2C=S>7$8C46F6UK*C"&\&^ MYZG.QF1((,4UK9A>B-
TM'NKI6[Y$,.6^L*MCPP&!1%):% >P45#DO%[I_O ? M3@!#_P5 < $3G>=R*F<44VCD10[D#;:L%G#E>K01ES.[:4LM32GN<'I:!$O MX\GBYA8F]S.8Q8_QEZ_SN_C^ >(?_A<2_A[0-
=,53O1IXV^2S*2P[(&[!W>"ZTQ!S%-,_\5[1F%1(99(!Y2G,<&M:M#0-I^'G9*6T-!WSZUS5-6EXGM1.T;4J:8)C8L9$H=PB MB=Z\Z@[\#QV6]UD,F$:&HNP)M5\!K"+MA>] ?&FMP-6R_ #P(X]Y^\
MDQXO4&[<)"M(1,5UW>[-;O-83.H9^1M>OS1W5&YRKH#AVD#]SE6?@*RGMW:T M*-W$K(0V\^?,S#QX*&V .5\+H8^.3= \H=$?4$L#!!0 ($F)#ED'^(@X MI0(,<% 9 >&PO=V]R:W-
H965T>LW,WW@KYH'}$#4\EK]3$RK6N+QU'I3F63)V+&BLZ60M9,DVNW#BJELBR M%E1RQW?=@5.RHK+B<;LWD_%8-)W7%(A?;B>59^XUYL)2M*K%0A*I"XGEB)=SD-37P;\'W
K3JPP52R$N+!.+?9 MQ'*-(.28:L/ :'G$*^3<$)&,WSM.JT]I@(?VGOU#6SO5LF(*KP3_7F0ZGU@C M"S)%+!5?M%[9=;!A8D#9*BW'()@5E474K>]K=PP%@Y+X M\'< O]7=)6I57C/-XK$46Y
FFMB,T9;:HDE<49E'66A)IP7A=#R_^9PL;ZYA MELR7/V Y3^X7R=7R]LO] MXNV8JC>C=V-"4RX4ZZ(YUVI/X+I 'Y53_R3AIZ8ZA\"UP77]\ 1?T%<=M'S!2U4C9QHSF#&IGV$I M6:58^Y
M='B*/5Y00V8-1Q!K8*5H*JT@;Q"TH.[HZJFIG@+5,>4GN8\K__^$9_1 V#0 M'9-I#H%GGR5I*AL*F0HF,U@C*G@-@Y'M1VYQ]$&+&5MEQ(WXQRPK+EX-A@O M"NV1-
P!O,+0OAD&/4$BY.PP^T8A2%!NY%W88^93>M7W/.UL*S?@+DDG#,/#M MR!N1%84#.PQ"./9*SD%SE2@W[0A1D)K[Z/JLW^VG5-(UY]_P;L31Y6P*^L&PO=V]R:W-H965T=.T28B$A'95!Y&
,I6IW2J@\V\.T!Y/<$*N.G=E. MZ?[]; =2)@':"_''/>>>8W,\W$KUI M$ R\E%WI$*F.JZR#0:8$EU3U9H; [MN50E-7:J-H&N%-+,@TH>1&%X&924"9(,_=J#2H:R-IP)?%"@Z[*DZL\$N=R.
M2)_L%Q9L4QBW$"3#BFYPB>:Q>E!V%K0L&2M1:"8%*,Q'9-R_G@Q38BH1.$'%/C&*C]/.,4.7=$5L;O'2=I6SK@X7C/_ME[MU[6 M5.-4\A\L,\6(7!'(,*.J@W3'.6DXHQ.< M,=Q+80H-
,Y%A]B\^L/I:D=%>Y"0Z2_BE%CV(PRY$830XPQ>WIF//%Y\R;0I4 M<,?HFG%F&&JX83KE4M<*X>=XK8VR_Y9?QYPWQ(/CQ"Y!UJB*8Z(C8A&]8PD M>?>F?QE^.B-[T,H>G&-/EC:16?,>64L;)C1P
MS"TT['V\(*":C#<3(RN?J[4T-J5^6-AG$94KL/NYE&8_<0W:AS;Y"U!+ P04 M " !)B0Y9G_!=GTX% Q$ &0 'AL+W=OEP*&"T;D1RM(AP3@<9C3)!Z,S,W8G1F>\4&F2LSN! M6:58^Y
MYX.Q>WKA8BU@5CPF[$FVVD@?9?FESY4A6@(QWB% *@%B]"XW,EK^1A4=G0G^ MA(1>#6BZ88YJ[$&Y)->L3)2 V03DU&CR<'OY%[]\O;Z[NIF,'[[MS)YUF\DNY?_O%7#6V!]9JQ?-
ZQ')E62+XVXXK/OB*^UB$0TGT.,@E&3F0*\ M-B=%2U0G34XS-!XS/! _J1N ML=(R09>O],)V._I>>UDW#24-6W7#N!#T0]<^B2+-<.1X$0J=V+6NP$S&?<"6 M&UB&B&?'D:
<7^4Z(400_E>0$@1T'&/58+VRL%_XGZY7O!=P679;KA7R?Y9I] MK"'&BURA>YHO6=MVUFW+DZE"4[9,\KP*PQ=&!8I#VP]#L%/HG&"K=G82. 3K MR"&.CZW?!O9@U];UB7-9
^LOD0JBH2DLS>_B8P@.@,0&$H>.YV\I MUEP6^JJN^=FAD1MJJ^>F9@E4D>/_9-XXQW=XL9E>KB/&NZCO;G/@8I-Z9M; MCMU%?R_JV_3OVLJ:F)OK-6C&U15GN$/POC/TF28"/=*T8-8-
S[M0M(N,UR)) MD5M9D\1V&)@PW6;+FYZ-WB;FSUVM6XKNMKN7X^UG+IN,^L.GD7@M;P6FQ?LM?'S M1.GWZ%@'"G $T1!&!*X_8DCT]-=WX5T,RZX?6@=5&LY^OWD:T?\^) ?!,T%
MZD*6$$"64,<1B>P0$U*]D/=!G2-[5:L53XQ)K^@+E"^S.!5(PQR#YW- 4AEZG MH*Q"=1>)J% DBF5,CT#9[%VG.70A40(F#OJT+N,RUKO$XC[F/11[.+7,@&_ M[TGLR',Z"X9>V#V?RJXL)6$E&-
NJ-ZSM6ZG=\]J9Z\X\-8SMR#Q:7F0'&.. M=B,,'@ 9HTOLL,EF)T;3"Z/I93O[Z\AB.SD9MJJXC(FEJ54EG!JR@K*@:T:; M>GA<5H&OR\MB^IH*R!$D2MD"1+$3O:HGRQJT["B^-
C7AE"NH,$US!34]$WH! MS"\5W5';]#\2S#Z%U!+ P04 " !)B0Y95*/SZZ8" D!@ &0 'AL M+W=O)#A@JX*/17K+[BMIVOY M4E$H]X1U'1M=>Y"NE!;E%FP4E(S7;[K9?H<]P(<
41;0.1TUXFQM/I^/OS#"Z?Z;Q =34,M*&USB#= MADQJBN@(10R/@NMPZQ/2NC@;1&%X"U'?[Q*S&Q&?7+<^ M6R;,(.RUNU&G30@!XG<'[M&ZWZ!,F3+NR[@=#HAS7QFL"ZE?K3O*4].UF
7W MFXI)$[S+=/[OZJAVS!U$S>[S0@B;5AA:5 MFP-SHZF8 MDW4H5(4^[&_P&A8@'C?W3);T@A*0&!).:((8K ;:R+SQ3$L)TA9?">SYP352 M0UE2^J0*TV"@&:I'$($O% ++GQU,
((H42?;C>P[5BIA*>'C]0O^<#EX.9HDY M3&CT)PE$.-"Z&@I@A;>1F-/][Y /]*UX/HUX^HWV>5M#0_Z6"QKG8MF#F"39 M+W[.C3@0F/8;
BL76,>"]AN"5BYHG1O!S@7VN8)V+DB'KF=C3XUSL<##/]-[MQ%1K25,7J?NI6OI%$C51%H+)NT3JQ' V>GB<>^CN,QH_+J8S;[% HYF+QJ/% M=*%J[^?>PIL]C!ZF=S-T-_]M-)O^E14^N"
PB3B:8<:P2O='=(4>%R[Z\/' MOBYDYU0(W<\[,LDZ8KW1D1:ZI8D(.?*2 (*R7I>#*D9FO8QL;-4"[WQQC0S[M$[(,JU75GWKY']OD&K6,5&Y7R-WSY571O7KY+692;E9%+YG1*M+<2GFM-WA?
M,2-X&0&:)@(8<'%M%D3\0-^^R)9H*B#F?'U=TP \8!R?^Z_X3X)B*B*A/U M$/-*/C2N3*/*]EKEI;8W"?,:@I5L;Q>VMVL=F] XED^JU/5/B(=8AD!X*T+*
MR# ,'*U"6@EK@I7^&#-9.8>IQOAMVC.S3UW>'CC<9U3LC:LG-3N%FI];-F=S3 M^)B':,LA0"1!*Y+@Q"?).ML+$$& 5WE:B[W754B6.1A=N^7T+*MW9.EI.]-P M',=VRNV\ACI70[!2+GI%+GKO/
>Y8,07,@$]%57^U@(N];=WXF_7:1N=(WM[)TM%12OO MO58E0TSC=7-NU%KR!83&ULK53?;],P$/Y7K" AD&!)DW2PD49JNZ(-T:5]!3P@'MSDVECS MCV"[[?CO.3M9Z$8[\Z7O3
5@R;W@T@R"RMKZ,@Q-48&@ MYDS5(/%FK;2@%DV]"4VM@98>)'@81]%Y*"B309YYWUSGF=I:SB3,-3%;(:C^ M-0*N]H.@%SPX%FQ36><(\ZRF&UB"_5+/-5IAQU(R =(P)8F&]2 8]B['J8OW M
5\9[,W!F;A*5DK=.>.F' 221$P0<"NL8*YV, ,.'1'*^-ER!EU*!SPV[!_ M]+5C+2MJ8*SX-U;::A"\#T@):[KE=]'VU]#6TW=\A>+_&_Y))$]O'C,766"5: M,-4,2'R>9+[]L^' "0YS@@;@'Q4T!Z
I"T@,07VBCS95U12_-,JSW1+AK9W,'W MQJ.Q&B;=O[BT&F\9XFS^>;9D#B*TR-ZQO\.3YZ1DW0]3#Q?>?3A6*W_B>Q1Y6E7>?H<>SY7 M%J1EE)-""8%3>?J)-$1]3^16RR(O)?TX2>.+++-P=UO-
W8!Q?]#"RBVNDA@>/ M7H#>^%U@4,A6VN8I==YNW0S]E#WQCW --5OC#TVSPZ94;Y@TA,,:*:.S=ZA* M-WNA,:RJ_6BME,5!]<<*5REH%X#W:X4-:@V7H%O.^6]02P,$% @ 28D. M6:"COM%J
@ MP4 !D !X;"]W;W)K&ULK51M M;],P$/XK5D!HDV!)DZP;(XW4EZ"!:*D:-I 0']SDVD1+[& [[?CWG)?Y[E[KKX+MEP\R Q D<>R8')@94I5-[8MDPQ**B]X!0QO5ER45*$I MUK:L!-
#4@,K"=AVG;Y,"%@-K&'O9NSK>!-PG\-6[IV)5K+D M_$$;']*!Y>B"H(!$:0:*GPV,H2@T$9;QL^6TNI0:N' >L;|WVE'+DDH8\^)K MGJIL8%U;)(45K0NUX-
M;:/5<:KZ$%]+\DFT3>^E;)*FEXF4+Q@K*G#5?^MCV M80^ /($-I4961.J:!@(OB5"1R.;/IC>JR9G^%V,E M\#9'G H741P-%^-;,IQ-R"2ZCSY]GD^CV1<2?9M'LSB*R=D$%,T+>4[>D+MX
M0LY>G@>VPM2:P$[:-*,FCL7LDC4>FG*E,DHBED#[%VUAR5[>[JWODGB3\6+,+ MXCFOB>NX_H%ZQO\.]TZ4XW5M] R?=ZR-((&*)".4I60*&YR."M^Z(M^'2ZD$ M/M8?AYK6D/]'2?4
W\B*)C"P<$(EB U8X:L7O;[S[I#B_T3V1+_?Z?=/L3_5 MG^[IAT?<-Q(.B6\8^X91+YM-Z/?_N5U8&_V9?T=UK^Z?NNZ75A3L+TW R6(MM5D-
DB2\9JIY5IVWVSY#,W3/_"/<2LT2^4/3K+0I%>N<25+ "BF=BRN<:=&L MB<90O#*3MN0*Y]8<,]RL('0 WJ\X5SM@*>AV=?@;4$L#!!0 ($F)#EFF M=@QO8PL &[[9 >&PO=V]R:W-H965T%\)
ND\OS>)G- MPDC<)R1=SN=!\GHE9O'JHF6UW@X\A)-IEA]H7YXO@HD8B.QI<9_(5^V*,@KG M(DK=.*%)&%^T^M9'[GMY@>(3OX1BE6[\3/)3>8[CK_F+F]%%JY.W2,S$,,L1 M@?
SO15R+V2PGR7;\7D);59UYPG@%,6<+8*[&V26Q9PCVV25Q;PCBW@EP7\HN_7G57T- VRX/(\ MB5/-Y_O M!N3FCCQ^8O+O V/D]O/=XZ44?+STQTC3N>$V!W;)>^IR()PEI*[($F" M?(1\(/\D3P-
*WO_MPWD[D\W+*VD/RZ9C.']6O9T&:DGA<+U<6H[E=?WS]LNF5,@Z M.0BF2>574OE&J1Y%,B^NQ& 5)*.T3BPCH*E821@]<&I3\2Z?.DB0")D4/_V M\U22Q>1%3C-A-
"%A1,;Q,B'B]V4PDZ_2+)C-9#ZQ7!,-I_FDYIXIJ2CYY-Q^+K)BWU#%"Q; \9+T="J(1 MD=.I1)3'O).JR6$)\K<.&]_WIY1F,BWXN3'WJVU?TI)=\DDP.E#"2'R/+11S5-^+M,_FW@7C\KJ9-
BR2,D_PD@NBU MZKV\\M.Z@(@<+!P$TZZR;G65=8U#4?;$BTC2=;^L)[T3,IC*@5DH)]_;$RB- MV*;7'A)&NSN!TNEVNV=;<1)9)0?!- 5[E8*] PK.YU*],E\QI*)&3%/%D#"* MA#$DC(-
@FK!GE;!GR%3T#"DO$D:1,(:$<1!,D]?]*.^B\Z=C[TV:+NL#KQG: M5&@HC9:TS=AK=_V.O15[H95R%$U7<<.!LHPJTC+7(%85?I*06D42F-0&D?1]&&@'"RK!XW.4"<+2J-0&H/2.(JFJZSL
M+,MHIQP1G:6%I1&2]K!Z RUIU T??F(\J=LLS]516<7$YW-U375%TJC4!J# MTCB*I@\#97#9%C(ZVU# "DJC4!J#TCB*IJNL"O;Z)PU0 M=(96RE$T73!E1=EF*ZK_>%LL;R/]22)$OCK
''RAQA241J$T!J5Q%$U76?E7 M-G0]F@VUIZ T"J4Q*(VC:+K*RIZRS"R2?.G)0N98HE9B MJ#<%I5$HC4%IO*3YFPOHO$[QIYHF=/F4[V2;?:?[)!X*,4K).(GG) UFN8[Y
MZJTP>ZV5$&I#06FTI&UV4V=[&MW]B-7I^9:UM<:&HUJFRZ+<)=OL+MT'K\6T M*+6(LZE(R@5R89HN@V@HR#!.L]IUA69N8WV@-A*4QDK:II1>S_6W=?P>]I"M M"';O,)I4,DFOW-
&8G5"TF*11*UT4&\(2J-0&BMIVH+@;K=WUMD6[WNX/K9R M?6RSZ]-_$4DP$6217W_38L%K'A_W3V]0$PA*HU :*VF]#0'1]4\O:EN]>$". M\H LIXRJ%RS1754G"ZNXS[YDM_J)\I2 M8ZPVU]?
T*H;2*)3&H#2.HNGC0-E5+M2N9 M$_G=M;@G2JUP9M#;W>CR MJ?JL-H)"'28HC4%I'$73)54.DVMVF'8NQOH@"EUFY.[>O- V5)N%YKF0HTG*(U":0Q* MXRB:KK(RGESSFJ=CTMS=!4!
[TERHCP2E,2B-HVBZ.,I'>;[,AV7YIHA3:?'DJ:%Y%ZO)L^%5LN@-(ZBZ;HI@\DP[0_TRT)FV'5\^LR77-5C46#>DA0&D?1=-$V;J-NJI". M(S67^QM+0_ MR?\]+E1C;\".O0,
[U)R"TCB*IH\'94YY/C140ZTG*(U":0Q*XRB:KK*RGCSS MBJAC0G7-W;=MMR920XTD*(U!:1Q%TS531)WI)%TV),H20<\"7-]C96#NDE0 M&D?1=.64F^0=Z28=]B3,H,*3\
R_>C.7;RPIU&:"TCB*IC_11-E,/FZI4C\: M-?M]CKGNII,JE$:A- :E<11-'Q/*I_*ARY9\J&$%I5$HC4%I'$7355:NEG]@ MEYVV'6"UOIZK.;G^Z490U\K?W<]F]5S7W;$FH=4R*(VC:+J(RI#R_^)NNYIO
MO<:(#76LH#0*I3$HC:-H^C:0CI7O0B,VTOBYAM(HE,:@-(ZBZ2HKB\L_L!&O MR;YHO^;F0G6;M)QU-E8/:DA!:1Q%6ZO7WGA$\%PDD^)ASJG48QEEZR?B5D>K M!T;WB\V?NRBP?
0GT;));),P2LE,C"6R<]J5)Y"L'^R\?I'%B^)! MQ,JQEL7SXL>I"$8BR3\@WQ_'KSVY?\!4$L#!!0 ($F)#EF+ MDS)S%0, /T, 9 >&PO=V]R:W-
H965TP[W')^$F^Z&LGN^!!#H(0ICWM.60B3'NL[])42$']$$8GEE05E$A%RR M.YTG#,@\!46A;AJ&]T]V$W,$$Q'4R8G*E%RSS((*8!S1&#!8]K8^/!]A4@+3B)H -WSI& M2LJ,TGNU.)_W-$-
U!''X0E$0^;6& 82A8!)] ,M)M>(W%7#[^(G]+!4OQQI;0W-84%6H1C3S0_(!3F*SZI-RE:J@EB MM8T3P>350.*$-SZ]Z$]/AVC4'T__H.FX?S7I#Z;GOZXFZ& (@@0A/T3?T/5D MB
X^'W9U(7]3(74_YS_)^,U7^'^NXB-D&5^1:9AV!7Q0#[\D3,)Q%5R72@NY M9B'73/FLU^1"2 3,T8@P\8BFC,2<9'FZO9"EZ%QQ/]6R=;,=\X3X MT-/DW<2!K4'SOGS"KO&]2G1#9"4+K,("JX[=&ZX
"2IOPEL]VD!0V1E2SH M%!9T&DIGYT7NL&.WL;L3SXHRM]5I6=7YQ,;S/[OQKH1.0/:89?3T08Y_(U' M:3WMOEO5%%O9A*WQ!G]08'/BIFQHB*ULP_/8@VM'BCU"FQ.5_LZ-CNV8.ZFM
MJ+.P86*\$UM]:S95+P9RHKL+8HY"6$B@<=22P6?9K)TM!$W2<75&A1Q^T\.E M?#\!I@KD]06EXFFA)N#BC_ M)?21A0 <[9(X90,EY#R[4E7FA9!@=D$R2,5.0&B"N9C2M*)AE! M#!Z7$%C\-
C"".)9(@L>/"E2I=4K!P_$>_6-AO#!FA1F,2/PU\GDX4&P%^1#@ M/.9SLOT$E4%=B>>1F!5?M"W/6ET%>3GC)*F$!8,D2LL_WE6..! PC","1B50
M.$(M%14LQYACIT_)%E%Y6J#)06%J(2W(1:F,RH)3L1L).>[,)S?N^ M_(:6Z<$?+Z[OI IV-@>,H9FB**<72>>=]E0N=4E+U*OQAB6\@4Z.:Q2$*,.?AHABE_0DN*4X;+S'^X$4?1-8>$ M
;+NG(!UMV;=;76[ZWDT%ZPWV"L=G>'(;R)9PE@%C"PU&Z=GV79*W30HMVKE MUHN4,QR+BH1PZHM"4WH1=J+N,6!-5$K0[@$5TS"[9]>9S&5-YK*5S"B,($"3
M'7BYO&OH+@@B#^@_Y6.KQE=&UJ[ML4^4C_8)6/=JUKU3I$3OKY30;4O3M.:4 MT+7GZJRUTID*=]65:1Q1\981REICWH[X2O?!!^^)?]*P5\# F;CQ3-QX4>3] MRLLH@.985SB'IZ?
L58/'N4$Z+IH/1CR2)[R\GVN5^OVQBT?]>?C96]T MB^DZ2AF*(1"BVL6E2#1:MAOEA).L>.)7A(N&H1B&HD4#*@^(8 0OI](!773 MY_P"4$L#!!0 ($F)#EG&%3NN60(+8% 9 >&PO=V]R:W-
H965T MX[/L;DWK+AXD"F 0H\9R^40ITH5-XXC MXQ0R(J% ;G>2;C(B-*AV#NR$$!V%I0QQW=@9,1FN,HM&OW(@IYJ1C-X5X@ M6689$7_&P'@UQ#U%\07VC2?:K,@A.%!=G#"M2FN!
MS20P^3;A.X5*GLR1<;+E_,$$\]T0NT80,(B582!Z., $&#-$6L;OAA.W1QK@ MZ?S(_MEZUUZV1,*$LQJTI](AOL9H!PDIF5KRZA8:/WW#%W,F[1=5=6XPP"@N MI>)9]8*,IK7(WEL[N$$T M> '@-
P'LMP&\ OC5:*[.VID21*!2\0L]D:S8S ML7=CT=H-S+^;K^6R%+J:@"&7R M$GU F]447;R]#'VECS1)V[HQS6]]P+]79E?(=]]CSS7'SK&@_/P+T1H>*\+
M[FBCK5NO=>M9/O\EMRH%@=1:4;"FCBH)$4RICQF4I /T<;:42^K_ZU>6S)@ZZ MB4VMW6ZIAI8*M,0#'O>:X?.H=3.\^SO%[?]:_;M"="@U9H<%;HFBNM MC-LGBTLA(%>
(_7NZ+KG!]^0^S^J4ZYQ4E>EH^F?*%+;0M5[IL[335C16$2=#[">?J&)C:;5MU]!=02P,$% @ 28D.684< M>B"B P F@T !D !X;"]W;W)K&ULQ5=M;]LV
M$/XA%84+;!8KWY+;0&QTZ'IEB:HT_9#L0^T=+:%2*)&4G;[W[$8E M3OG:%@4'&FNG++4]QQG8&4UR*YSHM5L>3E@ITR2'6TY$F664_S6#E.VFEFL] M+GQ*UANI%NQP4M
U+$!^+FXYSNP:)4XRR$7"H4-PQ,&O''3F;,-,R[JDDH83SG:$*VM$4P.=&^V- M:I)7%)7O_\9F)+)*!@[*@*-C/!O"/!?'+-0[SO;R/Q MFKWWR'[F=0)^*/,>\9U?B.=X00N?^MHD]$=B> M]*"6'G2AAU] :-
UL183>-*Q0VT40FL=XW(7D220AKAZ6>2)%6SY,D($.HBK0 M-G3]L>^-)O:VJ?2YF==W7#>HS?8T]&L-_4X-=TS2U# \4Z4AWMOY!![4&-IH M]U]&^[E9%^U!37O02?
NK+E7(EFZ!8^DE>9DM@:M7@?PS9"XV%%\!P2HN)+X/ M]9[.5/%+HC8Q)EJ_P7(8](>CT:&:YW9>X+O!<- N9UC+&?X(.7&2EO*PJ!A! MPQ<*>F[7*6A4"QIU"IJ

H965TK#8@]@Q?;2W24D M__[6:V*#,1/B$C4/P5X\W\PW_CS^V,&*BWLY!U#D,8E3.;3F2BW.;%L&S18L!G<@?IS<2/TF5V@A%$"J8QX2@1,A]8Y M/1N[)L!<\5<$*[EQ3#(J$\[OLY/+<&@Y64400Z R"*8 'F ,<9PAZ3K^78-: M1T^ MP[P#-&\,D/K M(U-L-!!\141VM4;+#DQO3+1F$Z79;;Q30G\;Z3@UNOMV/?Y"QM=7-Y^^WIU_ MN[S^2G[Y"(I%L22GY'I1]CI23[_JI9^)3>2<"9 #6^D",A@[6"> [R).Y>Y)Y MY(JG:B[)IS2$<#O>UH47U;O/U5^X*.#OR[1%/.>$N([;KJEG?'BXAY3C%?YV??[LD3^3"Q; T-+/M 3Q -;H_3OJ.Q_JFG,DL*U6M8M6 MM3'TT9WBP3WA1E_RA,QT? U15$CGE'*=C<+*A]#!R!O;#)@_LBJWB.D5Q';2X M7/:2?(98WY(K2"8@:F\'"O/:VW$DL"W&?L!8_Y^5ZQ^S54<"VVI5MVA5]W#E M$OUTE(JE893.3L@$9E&:ZD/]9HE9&D!=
([H[:NWY;=^O:!JMH2'#7L&PAS*\ MS>XXX5,"CR""2)9B"@ >2!!'-QO]9V?R"O^WK_KN91^(&ZGY3IU8D#S-6Q5 MOVA5'V7SW=@$_3"P!Q#:]E1:ALDC2&N[E^?K;XU$#:\\5Q-
N6S8']I0ZQ@M%+.^9E(GW29 +Y-W2_+N?U$OWH,(."M$\3N\%W.,+'D_8M%&E/7-Q> ;BL'^I7W17X=V65Y4#7L5K6=H; MVW$)B)G9I90DX,M4Y7M;Q6JQ$WIN]O\JZQ?
T;)SO9Y8P^?;J%1/ZMX0D,4PU MI-/J:L&+?,>Y<\XWW#*)^V)$"0]92L7(BJ7,SVQ;A#%F1+18 MCE2=K!C/B%1+OK9%SI%$!I2EMNIX/3LC";6"H=F;\V#("IDF%.<<1)%EA#].
M,&7;D=6V=ALWR3J6>L,,.ACE9XP+EIWS.U MWYG852Q+(G#*TB]))..1Y5L0X8H4J;QAV_=8Q=/5_D*6"O.%;67K6! 60K*L M BL%64++D3Q4>=@#>.X!@%L!7*.[)#
(JSXDDP9"S+7!MK;SIB0G5H)6XA.I+ M64BN3A.%D\'B=C;]"-/9U?SB>C&^O9Q=P^MSE"1)!9S"-:,;%!(C$#'A*-X, M;:E(-=0.*X))2> >(/#@BE$9"[B@$4:_XFTEME;L[A1/W*,./Q2T!9YS J[C M=N
EV)6V:CC"X-4Y\0R#=X#AXKY(Y"-\'2^%Y,JW^=84=>FBT^Q"E]*9R$F(M(TO5BD"^02MX]:+=<]X>$=BI!7:..>0^>7@NH:A:2T"BAZQ-8XCJA5$W5[YH2
M&F*3_)*@:PATX6X"U^]UO:&]:=#5K75UC^KZ8FI R2(;Y*JD8+3?%4HKR]V)IMSJ=YE!Z=2B]HZ','[_:3'8>Z]LAGQM>HF D!54E@]NO5NWJW'Y2O\T+WO= M%>']Q>0XDI!G59?FG6FQ)8,-.6
FH;EI[DK#E-[UX:8/ M B_@6UQD@C)OZ]D&]L81QD(F;X$6]9^VF]7VOVB_I;Q.[$"D.@ACA(QL%92 MKB]L6\Q7$%/18FM(U<%XS&5ZI4O;;'F0(/4*(YLXCB>'=,PL8;]=&S"AWVV
MD5&8P(0CL8ECRA^O(&+;@86MW<#7<+F2>L >]M=T"5.0_ZPG7+W9!4H0QI"(MD"6(PV)@7>*+$4D-TAG_AK 5E6>DJ@5K&F-JP^[]# _3,DK,C,J8,2B[V$@5P.K:Z$ %G03R:]L^PER0AV- M-
V>12/^B;3[7L=!\(R2+F'-#:IM6(3)CJ-4\G5UU#9R>'TV^WH;S2Z'4^N MOTPOO]W4@^K94SNDE['GNR%7F"'G"$1>-62)7 ETG 03[]K8B53 C.V97Q CX
MUR9I(==YCXA#V@W^C,SF8\J5.6XRWW/'+0+MIGCN4X'6V%JEV$JFU"'TXEF]\AEF\R57N$I$D0 M)LLFUAE4)X72->M^V.UT.T[?OJ_2:9CEM3VOF+7G9Z?PLV/T\WM:(U2>Z#UP M5?-
VQP30FH=S>/^S?/#282TVLV.>X7CWA$!KASN)B^]@!Y MN.?[-3>-"YZX7_R"CO^R/#S#T#_,@]]RZPR-/IS(L%LP[!H97N\(330A],9K M]1Q=;]5^Z3I%!6[B9L0]MBB<"6PO!+TB!+U?7#]
[YPS5F<#V0H6=LJD[YZN@ M.=;^"?=\4MO_YB5/I531*?BX0\Y!JU3%"47A M#;1Z!UIQRK MNGO;V"7U-FI>\E1*I:+!9DGSTA:5P]<2USY@:?3B5):E'L)F051O4Z33(N;V M9 8\MNB>"VV??
JFJL/>+6Q0^D\S*P_4:H@V7J@V;9=MQ3VJ!$^F;R9G3B6I%VY M^(J!+]/[0('F;)/([ZL&"WN'"_3FS:[G)Y=6(XI7X8JEQ$LE*G3\E6Z>'8' MF+U(MDZOT69,2A:GCRN@ 7
]07U?,"9W+WJ!XB9V^!-02P,$% @ 28D. M67(/PY3Q @ .P@ !D !X;"]W;W)K&ULK59M M;]HP$/XK5B9MG=0V;Y"P#B(![;1NHT6EW3Y4_6"2(XF:V)EMH/S[V4[(>,VV M:E^(S[GG[GDN]AW=)67//
$0Z"7/".\9B1#%A6GR,($<\W-:)%O9I3E6$B3 MQ28O&.!(@_+,=^S+,W.<$B/HZKTQ"[IT+K*4P)@A/L]SS%8#R.BR9]C&>N,N MC1.A-LR@6^ 8)B >BC&3EEE'B=(<"$\l00QF/:-
O7PQJY:\=OJ>PY!MKI)1, M*7U6QG74,RQ%"#((A8J Y6,!0\@R%4C2^%G%-.J4"KBY7D?_1+5++5/,84BS M'VDDDI[1,5 $,SS/QU!=?H9*3UO%"VG&]2]:5KZ6@<(Y%S2OP))!GI+RB5^J M.FP 9)S# *
<".+N UA& 6P%<+;1DIF5=8H&#+J-+Q)2WC*86NC8:+=6D1'W% MB6#R;2IQ(ICH)-+$#C-.#1#=Y.'LM"I6+U7-G#! MTE! A":"AL_H@:2"HQ/IQ]^CQQ'D4V!/TI$GF 'OFD)25(G,L*(S*.DX1^BX
M:$2)2#BZ(A%$VWA32JOU.6M] ZN=8H5=Y%@?YSYCF,0@[X= TQ7:]!OCE=[N+S&+ MT.,W&1)="\CYTZ'ZEOE;A_.KGG#!"QQ"SY"7G@-;@!&\?6-[UL=#Q?E/P;9*
MU:I+U6J*]@SA0@E"WGF=H]"*;7$MS5>=:M%*'C=9RNN=C4L._5ZG3:M=,6 MMW;-K?TG,N\XBN4G.T*MO9?4=NVV[^UP:\SXROIZM0;O+S0&PO=V]R:W-H965TUVR@(RO:AV@>3'!
UB3/;0/OO9SLA#9!&JQ2I M7Q*.W#WWW..S=+T=H8]L#<#14Q3&K*>M.4^N=)UY:X@PNR0)Q&)G26B$N9C2 ME-O!JKE,:5C<;Q'_Z:2%\DL,(.A M"7\'/E_WM+:&?%CB3>1D*DOVJ6VK8Z&O
WC),J3;[>S?KWM^,[='8-' ; =V"YG[Z8#K&ES)Q:@([D*J12]6H0G=5>:'3^BI+.D5R%))\F[:N:7=L MJ]W5M\5T3LVLIF&:C=SL@&@S)]JL)#H%QFG@<<$SY3R/ \[0V70V9^?H8031 M
FCI657BOO6L:@([D,#))7#>N:R=.J6]">Q JE8N5:NVLDZ1FH5Z==JMIG%4 MU:=6MC RRHNZG=-L5](<Y)Q4OS<0^I4U7 GSUH.I">P@XTZ><>>=:[A3IU0U
M@1U(91HOC8%16Q5G4,5GMV4T6\>/NL%_J9".A*M7E,L-C$/.T+ M\M6\E>RK!NIH?2!;3-4GO<"D_>D(TU4@BC^$I8 T+EOB&ULQ5A1<^(V$/XK&K?3 M2682;-E@2 K, ,E=TVL2)ESN'F[Z(&P%-
+$M*@E(^NM/DAW;&*,2+I>^)+:\ MN_KVDW;UH>Z:LD<^QUB ISA*>,^:"[$XMVT>S'&,>(,N<"*_/% 6(R%?V8'&_&#/Y9N=10A+CA!.: (8?>M8 GH_@F7+0%E\(7O/2,U"I M3"E]5"]78<]R%"
(+X)PMJY7,JQ_+5Z!.0.GF9S1!Q M/*+15Q*#><_J6"#$#V@9EB3K2_@-G";54O(!&7/\%ZX\S6L4"PY(+&F;-$$),D M_8^>,B)*#FYSAX.;.;@5![C+P@.DS*-N-
T;,>'JP1"\&WOV1(<"5PS/^NXS>=OUD_OZKS<[Y >Y9 MLI Y9BML]7_[!?K.[W7DO%&P#:J:.55-4_3^1-#@\72]*0C*5.$G]8SKDD\C M^CJBZDFK/O3./+?3M5?EM+;-
W)8#83,WVP#V#!'68TZ"=$IA3I^&X%)$=!K.^39OCL).L4AZ[P;);=+P05* M0EG;)^ J$8Q(317LWB\9--]0.V;'T!VX76)(@\&>S4Y0,&' I2:O[!XP9">KI
M@5OUY#1:58*,"1Q*D%L0Y!H)*E9YI5/,.WIM0NX^"1DG/#2A0C)!H\SHWR<, M!W26D'^K2B"@7 !!T_2T0*\M^"Q^>5-[T/';S6]>/T/NP$+O0+/@R;L\RKK\ M8F<+^X](S#$+
QVT0)R*:>B"$#WSNOYECG1HSH5D@F;-=(>YW*V!REKK/7"? M$'GV'=U-[ODQ^':-XREFM3K7'/BU;?RMHFW24.@PZ/_//PN@40F^FJXWBK9) M5R$!H5D#'O+3(
M9;@)^1]W:.MVVS3QIM>M0+_0A- O$/62K.<*KEZBSMS(I MM!I\[&VK7(_,LKK>M00;HLLZ,%6VZ^NW1LINY0=NW1$F,VT]="7.ZW92+2 M^X=\-
+^B&NB+FU2#"#S*DTVC+%%EZE92^"+K0 MMS%3*@2-]>,&PO=V]R:W-H965T?<#_O8#/>,?Q5K2B5X3I-,C)RUE)L;UQ7AFJ9$=-B&9NK+DO&4 M2/7(5Z[8<$HB8Y0F+H8P<%,29\YX:-[-
^'C(MC*),SKC0&S3E/"7*4W8?N0@ MY_!B'J_64K]PQ\,-6=$'*O_>S+AZ(C;CUPQS*Y%N!3%M'H>WM742QYX@//*;8Z_+-.L"#5P!#W 4_M Q>(->%4%!<+@E=FPC,
(WA&$!^WH>JHJ'(%;EJJV%\0TSD0G8T55*TJP> 'U M<3/R8EY/]H1'X.D/Y1)\EC05C2G+\;O-^'KZW8@-">G(4?-+4+ZCSOC].Q3 M#Y;HNF5T79OW<5%2
=3,%))D49RMFCCF7GSC1<_HW=C#02#08\NKL&<+\$]UN# M7P&35<"6@#Y3'L"@@V/P]>US&G9_2._ ^%/H,7?^W=]C- '@'L='UK2&Y01 M!A=$N#=K@NH3LJ-CL.CM40UZ4 M";2;U"?
M+S@JZZB2$F37DJ=\AWICR-TO"VKWW!";ZQZY7WXJDCK3.2W'B&*00,V[2SNN MGFL_1.]1I63(+CB6>APB!B;DVAA1#A(GM;^ KXL_[3>D8I5^H;.%+BBU\DB M:6[T0,&"'XPOR-
\%6<")'2I3&&GIWJ"YV?=_$&R MC3E?+IA4:X&Y75,24:X'J.]+QN3A00.4OSB,_P=02P,$% @ 28D.62M/ M88B#!@ XR0 !D !X;"]W;W)K&ULM5I=;]LV
M%'W/KR"\86B!+)8HRQ]98B"ULBU#G!1QVCT4>V"D:YNH)+HD%="_R&*1_T7KXMF^ MTT%A)B1+RF#$(@H2FQ7_R5!*Q%3!*0"7 7@GP.V]$."5 =Y; WIE0"]GIB@E
MYR$@DHS/.%LCKI]6:/I#3F8>KWMS/T,5- M@":W-_=7-W]=WDRN+F?H70"2T%B@&\(YT6_H/?H=?9H%Z-VO[\^Z4C5 PW3# M,MF'(AE^(9F'IBR52X$NTPBB9GQ7-
;QJ/7YN_0=L!/PG2T^0YQPC[.!>2WLF M;P_W6L(#<_B4: Q0E8K1-A(+L'X.IN?)Q_&P/QKU_+/NXS8]QIR' MTF,)K$&/7]'C&^G))W?$YBC3W.0,$2% MG%3(/G;W+C>R'%VN#$F/)0;?_]]
M##W'[U4Y&U7WJZK[QJJO04K@NNR00T1;J^WO5SOPG?Y.L<8\AQ9K":Q!R:"B M9'#0.($G)2<$M#$SV&/&=92VV.T'@[U7YSK^WF.!L5G?6?2P*GIH[OT@)*>A MA A-B%BB+U-
('H"W3J]&I$.G5YM@@26P!H.CBL&1[75J9)-(FV"!); &D:Y3 MJR_GAR>E$J+_RJQDSG0H+;;0FKQLJ5+7/#/-YS0$=)%&Z)H\,#5+,;Y!,YW1 M.&#-L(=V-*MH@2VT]J6XIA3;'K4EHBTV;:
(%MM":;-92W34*6#P5B[9@0@Y M76D'V\]?&>,J10&$>6?6%D+YD+5:@U,U(:BUB::2(:*,\8(#**,MC]1U*=96 M*\Z>]#*]$&\0/AYB3_GEC'! <[U5H&835HR?G &%$B'W>.@,=I^*ZZ%5/!FS
MD.B%D4CDNK[OHQGC"1+/I,XA@VZ8R0Z/IIE5()JLG>,9IJ) 84%.U:K4SG MC*>4H!%VL5OD=?W!"S#H&<8QPAPC]?Y6D.\Q)L3=+^$+5)"94QU5R9(T9;H
MHOH>2@J7J?,K1B5C7]%*]7X0^6Z%>D8JC 9%,)\7&=!M*)E^(86M[)5 MIV0+K=F3:Z_DFLU2T9/G'+YE:EK8:'J4+*0LHB%:D8UFN;5OFU'S5Q!O6MFS M:J1LH379JZV4:_92!7MO(FS?
UK@]UQ_N+N-6K90MM"8[M>5R?]QSE1#;O/3Z M [PG;ZRZ+EMH35YJW^6:C=>4I-F:.L,6,H6?.\B.H5M$W5,+4 \U+-J+5^3]'T ME?38T2K%,JVBERP3<,0RCI+&*&+%9@9+Q8Z,&0Y?
TA\OBXY"9N22@HJ\B:I% M^[+B:%]6-!M5M)JFZ");9$)J0G"[I+!J:FVA-3?E:U>+7W.UWR4I7D$U2 IS MY*LV4)KLE=[7VSVOF^7%"500U+@GH]WEDYSOH/9^1DV%M%-<>U/\FC=]7765$
W5Y0R&>[Q8=3JVT)J\U$X' MO_*S4.'XKLE#OK'4%&'YJ!-&%6:&/U0W6$4+;*$UJ:UM$/9MJS!LT^A,K*(% MMM":;-:V"9MMTQWH$QOU'*=U2"N%9ACO>2>DE3"K?LH66I.PVD]ALY\JELQU M?
LA#Z[Y'M48LE(ZE(F19*I%:,5I_U2IA)69W-0TZ)TX/[_[V:\Y_,%M6+5-W MZ_1' GR1GZ(1**^\.$I1W:U.ZESDYU-V[G]P3R3?%>9L:ICC^,R5\0;6PAKF" M=$X&:GSPXD1-<2'9*C]C\L"D9$G^<0DD JX?
4-_/&9//%SI!=:YI_#]02P,$ M% @ 28D.6:^>X\DC P $A(T !X;"]S='EL97,N>&ULW5AM3]LP M$/XKD1D32!-I&PC-:'IME9 F;1,2?-@WY#9.:\FQ,\=E+;]^OCA)7_ AQH>M M+%6)?
8_ON<=W%QQU5)FU8+<+QDRP*H2L4K(PIOP8AM5LP0I:G:F228OD2A?4 MV*F>AU6I&6<*W.U+EI)^?$X" M1S=1&4O)_BH=W]ZM6_J8%3$GI)+UY >M;KX<0 8N3Q MR\B?
X\:H+W>IV^7'EJOS/:Z=PR:[XU&NY";}7&RTX+%CQ0D9()%7RJ.7CE MM.!B[YMVM?Q!B5_4.;STFY'UG/H-':C6'WZ[/6$Z7PMQU8$HVXV\LX\LBZ5;=0"*:59OQ5]A>
M/^Y>L6PL+C.V8MFDF>KYM!X&=F"C-A5',[^'^1' L#B8 LS'>6%Q M_J?]#-']. S3-O0B0]1GB/HX+Q\RJ3]8'+]/8B__3I,DBN(8R^ADXE4PP?(6 MQ_#ULV':P .+ Y'^+-=XM?
$.>;X/L)H^UR'83O%.Q'.*YQH0?][(TG\U<;B M @=6!:QW(+X_#O24WR>*H*J8-NP)QI$DP1#H17^/QC&2G1@^_OI@3TD4)8D? M *NQS $P(L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5 MN %(MB6/:
(7->=I3W; M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II% MR=.B':5_'L8^K[PAOW.^JAQ(VL9S]HN_#F'I);_GC-!?O!!T6ZJA&\ZQ:> M?
SAP2X5BS4_=E8&LR9T<>Q2Y*XD&67@7&>W,9?1BM\)[]L6$.7O-GW=%"'. K: M&F@@/5UX"7^@PMR/_H&T/=R;TE!6I,0ETP=$VHYX#E'R;(FS"B^1 MWJOR5;J.;]VXBE=QEF!D008
9'!"R+\#"S($(,.30%:UWMS@C*, ,CHA)"3 M2)X#D.>GA PMR L \L(M9$&^HP>)"BK&TX>&HB633I0+ 09[]DY2UJ$;P'"MVX)L[A>EQCE']5NDHS7%4HSDQB5VFE M>RW(=P#D.
[>0JUQC%;C4_\:;FSQ#U75<8KMZSZ'R/7<+5^(*QV5R/<9MB6_Q M*B]TM:D1_E+H'+(Q04'I1FJK['^3!\Z9!K?L6I*O!HK8A&7SVAM0D@SOF// MY#ID.F'696D>^RJ-K])56J=X @@IQG?
LF*K.D\\FHTV6Q"9V-AGD%=^Q6/Z* M2_U ZTFD((GXCBUBJEY:FRP]%&?M9)/ .$N>/4[((]YCD53KJTHG[UCX;O&S MZ$'N\!W+ S3<9, 50!H)3JF1*2:DD<"Y1GY5^-"9GN?9F.!TQ;%&?EG]1LK.
MQH0T$CC6R,\U\,!'Y2L;$?)(X-@CQV+X(ACDC\"Q/^"\MN?MU">2< MT+ES ,SI6QW(.:%CYP#%W*21C0DY)W3LG)>*^3'- T#V>"@$7Y*=P#E/F+F-
M"7DG=.P=$'/ZWX0L%/[OLQ@[FO:4)H0L%#JV$!Q-N[R'D(5"QQ:"HUG:F)"% M0M=S'3":D8T)62AT;"$(,R/\\D<$62AR;*&G$>9__#OU!+ P04 " !)B0Y9OLLS09D! !U&0 &@ 'AL+U]R96QS
M+W=O^/6__9;+]K?XY_#'8_37<*I?+;-N MO9/,I0Y2"-+T009!ECXHAZ \?= 8@L;I@R80-$D?-(6@:?J@&03-T@?-(6B> M/DA&*..(#F'-8'6@EP+@=>"8 N!V()D"X'9@F@+@=J"; N!VX)P"X'<@G0+
M@=V"> N!WHIZ*X'>BGHK@=[:>]DFT%M1;R706U%O)=!;46\ET%M1;R70VU!O(]#;4&\CT-M0;R/0VWH?2PCT-M3;"/0VU-L(]#;4 MVPCT-M3;"/0VU-
L(]#;4VPCTSE'OG$#O'/7."?3.4> \G7J'>*U\>/8\UGC_M=U(=;]?ZY^WOR\=F[[G<<7;PEV7U"U!+ P04 " !)B0Y9(]5N#:@! "X M&0 $P %M#;VYT96YT7U1Y<&&5S72YX;6S-F60U
338D(HDMVU!X^SKA1VI%HR(J=2ZQ$N_.C+W2=\GT;6?(#;9UU;A9 M5'AO'AAS:4&U-Z&SZ[4S2RR5+EH\+@O;+UFD3*F*E/EPS[;--DWE]'!(0Z=78TK2N.& MH2!B9QW:G9\-#GVO&[*VS&BP4-
:_J#I4L6W%G-J5Y.)^B3,9=9Z7*64Z7=>A M)7;&DLI<0>3K*MZ+#ON=?;AAVC_YU?Z=3)]AJ%Q8;5R8F*7+[8XC:;M')@B1 M]67_$4^.0?KJ\U$[[8RR7WJ'Z_W0=M7-P[%NN?Z.O\
[XI']A#@&20X+D2$!R MW(#DF(#DN 7)<0>2XQXD!Q^C!$$A*D=!*D=A*D>!*D>A*D?!*D?A*D&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ($F)#EGF%@^\[P4 +,? 8 M " @0T(
!X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! A0#% @ 28D.6>_JQ#BA @ ,P< !@ M ("!.A0 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ 28D.63S@;R_X!@ 9!P !@ ("!>B, M
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 28D. M6?YF3 .#$%0 /38 !@ ("!HB\ 'AL+W=O&UL4$L! A0#% M @ 28D.69*L$KCQ @ S@8 !D ("!($D 'AL+W=O&PO=V]R:W-H965TQA
!X;"]W;W)K&UL4$L! A0#% @ 28D.6;,BG3,+ P - < !D M ("!E6D 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 28D.6;$/GX\;" O!, !D ("!,W8 M 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% @ M28D.6:X+J%MM @ = 4 !D ("!_8, 'AL+W=O&PO=V]R:W-H965T25 !X;"]W;W)K&UL4$L! A0#% @ 28D.6:9V#&]C"P :GL !D M ("!A9@ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M
A0#% @ 28D.6<85.ZY9 @ M@4 !D ("!LJH 'AL M+W=O&PO=V]R:W-H965TA*G%60, .X* 9 " M@1NQ !X;"]W;W)K&UL4$L! A0#% @ 28D. M63*+L7%?! 0Q8 !D ("!J[0 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ 28D.67(/PY3Q @ .P@ M !D ("!R, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 28D.62_=!0(#! ?1 !D M ("! \P 'AL+W=O&PO=V]R:W-H965T M7!E&UL4$L%!@ R #(
E0T ._B $! end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref)
{e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(e.style.display){}else{var
d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} } XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT
3.24.2.u1 html 93 215 1 false 38 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://aethlonmedical.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet
http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm
00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet
http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm
995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995512 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION Sheet http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION Notes 9 false false R10.htm 995513 - Disclosure - LOSS PER COMMON SHARE Sheet http://aethlonmedical.com/role/LossPerCommonShare LOSS PER COMMON SHARE Notes 10 false false R11.htm 995514 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES Sheet http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses RESEARCH AND DEVELOPMENT EXPENSES Notes 11 false false R12.htm 995515 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet
http://aethlonmedical.com/role/RecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 12 false false R13.htm 995516 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 Sheet http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024 EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 Notes 13 false false R14.htm 995517 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://aethlonmedical.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 14 false false R15.htm 995518 - Disclosure - OTHER CURRENT LIABILITIES Sheet http://aethlonmedical.com/role/OtherCurrentLiabilities OTHER CURRENT LIABILITIES Notes 15 false false R16.htm 995519 - Disclosure - STOCK COMPENSATION Sheet http://aethlonmedical.com/role/StockCompensation STOCK COMPENSATION Notes 16 false false R17.htm 995520 - Disclosure - WARRANTS Sheet http://aethlonmedical.com/role/Warrants WARRANTS Notes 17 false false R18.htm 995521 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://aethlonmedical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 995522 - Disclosure - SUBSEQUENT EVENTS Sheet http://aethlonmedical.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 19 false false R20.htm 995523 - Disclosure - NATURE OF BUSINESS AND

BASIS OF PRESENTATION ORGANIZATION (Policies) Sheet http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies) Policies 20 false false R21.htm 995524 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables) Sheet http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables RESEARCH AND DEVELOPMENT EXPENSES (Tables) Tables http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses 21 false false R22.htm 995525 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://aethlonmedical.com/role/RelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://aethlonmedical.com/role/RelatedPartyTransactions 22 false false R23.htm 995526 - Disclosure - OTHER CURRENT LIABILITIES (Tables) Sheet http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables OTHER CURRENT LIABILITIES (Tables) Tables http://aethlonmedical.com/role/OtherCurrentLiabilities 23 false false R24.htm 995527 - Disclosure - STOCK COMPENSATION (Tables) Sheet http://aethlonmedical.com/role/StockCompensationTables STOCK COMPENSATION (Tables) Tables http://aethlonmedical.com/role/StockCompensation 24 false false R25.htm 995528 - Disclosure - WARRANTS (Tables) Sheet http://aethlonmedical.com/role/WarrantsTables WARRANTS (Tables) Tables http://aethlonmedical.com/role/Warrants 25 false false R26.htm 995529 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative) Sheet http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative) Details http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies 26 false false R27.htm 995530 - Disclosure - LOSS PER COMMON SHARE (Details Narrative) Sheet http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative LOSS PER COMMON SHARE (Details Narrative) Details http://aethlonmedical.com/role/LossPerCommonShare 27 false false R28.htm 995531 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details) Sheet http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails RESEARCH AND DEVELOPMENT EXPENSES (Details) Details http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables 28 false false R29.htm 995532 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 (Details Narrative) Sheet http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 (Details Narrative) Details http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024 29 false false R30.htm 995533 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://aethlonmedical.com/role/RelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://aethlonmedical.com/role/RelatedPartyTransactionsTables 30 false false R31.htm 995534 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://aethlonmedical.com/role/RelatedPartyTransactionsTables 31 false false R32.htm 995535 - Disclosure - OTHER CURRENT LIABILITIES (Details) Sheet http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails OTHER CURRENT LIABILITIES (Details) Details http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables 32 false false R33.htm 995536 - Disclosure - STOCK COMPENSATION (Details - Stock compensation) Sheet http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation STOCK COMPENSATION (Details - Stock compensation) Details http://aethlonmedical.com/role/StockCompensationTables 33 false false R34.htm 995537 - Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest) Sheet http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest STOCK COMPENSATION (Details - Options vested and expected to vest) Details http://aethlonmedical.com/role/StockCompensationTables 34 false false R35.htm 995538 - Disclosure - STOCK COMPENSATION (Details - Option activity) Sheet http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity STOCK COMPENSATION (Details - Option activity) Details http://aethlonmedical.com/role/StockCompensationTables 35 false false R36.htm 995539 - Disclosure - STOCK COMPENSATION (Details - Nonvested shares) Sheet http://aethlonmedical.com/role/StockCompensationDetails-NonvestedShares STOCK COMPENSATION (Details - Nonvested shares) Details http://aethlonmedical.com/role/StockCompensationTables 36 false false R37.htm 995540 - Disclosure - STOCK COMPENSATION (Details - Options exercisable) Sheet http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable STOCK COMPENSATION (Details - Options exercisable) Details http://aethlonmedical.com/role/StockCompensationTables 37 false false R38.htm 995541 - Disclosure - STOCK COMPENSATION (Details - RSU activity) Sheet http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity STOCK COMPENSATION (Details - RSU activity) Details http://aethlonmedical.com/role/StockCompensationTables 38 false false R39.htm 995542 - Disclosure - STOCK COMPENSATION (Details - Stockbased compensation) Sheet http://aethlonmedical.com/role/StockCompensationDetails-StockbasedCompensation STOCK COMPENSATION (Details - Stockbased compensation) Details http://aethlonmedical.com/role/StockCompensationTables 39 false false R40.htm 995543 - Disclosure - STOCK COMPENSATION (Details Narrative) Sheet http://aethlonmedical.com/role/StockCompensationDetailsNarrative STOCK COMPENSATION (Details Narrative) Details http://aethlonmedical.com/role/StockCompensationTables 40 false false R41.htm 995544 - Disclosure - WARRANTS (Details) Sheet http://aethlonmedical.com/role/WarrantsDetails WARRANTS (Details) Details http://aethlonmedical.com/role/WarrantsTables 41 false false R42.htm 995545 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://aethlonmedical.com/role/CommitmentsAndContingencies 42 false false All Reports Book All Reports aemd-20240630.xsd aemd-20240630_cal.xml aemd-20240630_def.xml aemd-20240630_lab.xml aemd-20240630_pre.xml aethlon_i10q-063024.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aethlon_i10q-063024.htm": { "nsprefix": "aemd", "nsuri": "http://aethlonmedical.com/20240630", "dts": { "schema": { "local": ["aemd-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["aemd-20240630_cal.xml"] } }, "definitionLink": { "local": ["aemd-20240630_def.xml"] } }, "labelLink": { "local": ["aemd-20240630_lab.xml"] }, "presentationLink": { "local": ["aemd-20240630_pre.xml"] } }, "inline": { "local": ["aethlon_i10q-063024.htm"] } }, "keyStandard": 181, "keyCustom": 34, "axisStandard": 13, "axisCustom": 0, "memberStandard": 11, "memberCustom": 26, "hidden": { "total": 51, "http://fasb.org/us-gaap/2024": 40, "http://aethlonmedical.com/20240630": 6, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 93, "entityCount": 1, "segmentCount": 38, "elementCount": 429, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 373, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://aethlonmedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R2": { "role": "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "unique": true } }, "R3": { "role": "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R4": { "role": "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ProfessionalFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ProfessionalFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R5": { "role": "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2023-03-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-03-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R6": { "role": "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R9": { "role": "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization", "longName": "995512 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R10": { "role": "http://aethlonmedical.com/role/LossPerCommonShare", "longName": "995513 - Disclosure - LOSS PER COMMON SHARE", "shortName": "LOSS PER COMMON SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R11": { "role": "http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses", "longName": "995514 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES", "shortName": "RESEARCH AND DEVELOPMENT EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R12": { "role": "http://aethlonmedical.com/role/RecentAccountingPronouncements", "longName": "995515 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R13": { "role": "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024", "longName": "995516 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024", "shortName": "EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",

"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R14": { "role": "http://aethlonmedical.com/role/RelatedPartyTransactions", "longName": "995517 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R15": { "role": "http://aethlonmedical.com/role/OtherCurrentLiabilities", "longName": "995518 - Disclosure - OTHER CURRENT LIABILITIES", "shortName": "OTHER CURRENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R16": { "role": "http://aethlonmedical.com/role/StockCompensation", "longName": "995519 - Disclosure - STOCK COMPENSATION", "shortName": "STOCK COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R17": { "role": "http://aethlonmedical.com/role/Warrants", "longName": "995520 - Disclosure - WARRANTS", "shortName": "WARRANTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "aemd:WarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "aemd:WarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R18": { "role": "http://aethlonmedical.com/role/CommitmentsAndContingencies", "longName": "995521 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R19": { "role": "http://aethlonmedical.com/role/SubsequentEvents", "longName": "995522 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R20": { "role": "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies", "longName": "995523 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "aemd:ReverseStockSplitPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "aemd:ReverseStockSplitPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R21": { "role": "http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables", "longName": "995524 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)", "shortName": "RESEARCH AND DEVELOPMENT EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R22": { "role": "http://aethlonmedical.com/role/RelatedPartyTransactionsTables", "longName": "995525 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R23": { "role": "http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables", "longName": "995526 - Disclosure - OTHER CURRENT LIABILITIES (Tables)", "shortName": "OTHER CURRENT LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R24": { "role": "http://aethlonmedical.com/role/StockCompensationTables", "longName": "995527 - Disclosure - STOCK COMPENSATION (Tables)", "shortName": "STOCK COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R25": { "role": "http://aethlonmedical.com/role/WarrantsTables", "longName": "995528 - Disclosure - WARRANTS (Tables)", "shortName": "WARRANTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aemd:WarrantsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aemd:WarrantsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R26": { "role": "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative", "longName": "995529 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2023-10-032023-10-04", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "aemd:ReverseStockSplitPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2023-10-032023-10-04", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "aemd:ReverseStockSplitPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R27": { "role": "http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative", "longName": "995530 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)", "shortName": "LOSS PER COMMON SHARE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R28": { "role": "http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails", "longName": "995531 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)", "shortName": "RESEARCH AND DEVELOPMENT EXPENSES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R29": { "role": "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative", "longName": "995532 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 (Details Narrative)", "shortName": "EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024 (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "unique": true } }, "R30": { "role": "http://aethlonmedical.com/role/RelatedPartyTransactionsDetails", "longName": "995533 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "aemd:DueToRelatedPartiesCurrent1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "aemd:DueToRelatedPartiesCurrent1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R31": { "role": "http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "995534 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2024-04-012024-06-30_custom_EmployeeMember_custom_SeparationAgreementMember", "name": "us-gaap:SeveranceCosts1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_custom_EmployeeMember_custom_SeparationAgreementMember", "name": "us-gaap:SeveranceCosts1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R32": { "role": "http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails", "longName": "995535 - Disclosure - OTHER CURRENT LIABILITIES (Details)", "shortName": "OTHER CURRENT LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R33": { "role": "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation", "longName": "995536 - Disclosure - STOCK COMPENSATION (Details - Stock compensation)", "shortName": "STOCK COMPENSATION (Details - Stock compensation)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":

"Details", "order": "33", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R34": { "role": "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest", "longName": "995537 - Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)", "shortName": "STOCK COMPENSATION (Details - Options vested and expected to vest)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_us-gaap_StockOptionMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "unique": true } }, "R35": { "role": "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "longName": "995538 - Disclosure - STOCK COMPENSATION (Details - Option activity)", "shortName": "STOCK COMPENSATION (Details - Option activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_us-gaap_OptionMember", "name": "aemd:RangeOfExercisePricesOptionBeginning", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "unique": true } }, "R36": { "role": "http://aethlonmedical.com/role/StockCompensationDetails-NonvestedShares", "longName": "995539 - Disclosure - STOCK COMPENSATION (Details - Nonvested shares)", "shortName": "STOCK COMPENSATION (Details - Nonvested shares)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R37": { "role": "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable", "longName": "995540 - Disclosure - STOCK COMPENSATION (Details - Options exercisable)", "shortName": "STOCK COMPENSATION (Details - Options exercisable)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_OptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_OptionMember_custom_ExercisePrice1Member", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "unique": true } }, "R38": { "role": "http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity", "longName": "995541 - Disclosure - STOCK COMPENSATION (Details - RSU activity)", "shortName": "STOCK COMPENSATION (Details - RSU activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R39": { "role": "http://aethlonmedical.com/role/StockCompensationDetails-StockbasedCompensation", "longName": "995542 - Disclosure - STOCK COMPENSATION (Details - Stockbased compensation)", "shortName": "STOCK COMPENSATION (Details - Stockbased compensation)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_us-gaap_OptionMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "unique": true } }, "R40": { "role": "http://aethlonmedical.com/role/StockCompensationDetailsNarrative", "longName": "995543 - Disclosure - STOCK COMPENSATION (Details Narrative)", "shortName": "STOCK COMPENSATION (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-06-30", "name": "aemd:ChangeInEarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "unique": true } }, "R41": { "role": "http://aethlonmedical.com/role/WarrantsDetails", "longName": "995544 - Disclosure - WARRANTS (Details)", "shortName": "WARRANTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "aemd:WarrantsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "aemd:WarrantsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } }, "R42": { "role": "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "995545 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aethlon_i10q-063024.htm", "first": true, "unique": true } } }, "tag": { "aemd_ATM2022AgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ATM2022AgreementMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "ATM 2022 Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r56", "r463"] }, "aemd_AccretionOfRightofuseOperatingLeaseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "AccretionOfRightofuseOperatingLeaseAsset", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Accretion of right-of-use operating lease asset", "label": "AccretionOfRightofuseOperatingLeaseAsset" } } }, "auth_ref": [] }, "aemd_AccruedBoardFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "AccruedBoardFeesMember", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Accrued Board Fees [Member]" } } }, "auth_ref": [] }, "aemd_AccruedDirectorFees": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "AccruedDirectorFees", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accrued director fees" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r58"] }, "aemd_AccruedSeparationExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "AccruedSeparationExpensesMember", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Accrued Separation Expenses [Member]" } } }, "auth_ref": [] }, "aemd_AccruedVacationMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "AccruedVacationMember", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Accrued Vacation [Member]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r16", "r17", "r73", "r120", "r338", "r351", "r354"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r8", "r17", "r280", "r283", "r309", "r347", "r348", "r570", "r571", "r572", "r578", "r579", "r580", "r581"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r523"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r66", "r463", "r616"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r365", "r578", "r579", "r580", "r581", "r601", "r619"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r529"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r529"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r529"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r529"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r42", "r43", "r226"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "aemd_AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "AggregateOfferingPrice", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Aggregate offering price" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r494", "r505", "r515", "r540"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r497", "r508", "r518", "r543"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r529"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r536"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r498", "r509", "r519", "r536", "r544", "r548", "r556"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r501"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Potential common shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r168"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r271"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r98", "r102", "r116", "r136", "r172", "r176", "r178", "r179", "r182", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r273", "r277", "r291", "r335", "r396", "r455", "r456", "r463", "r475", "r598", "r599", "r608"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "ASSETS" } } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r113", "r121", "r136", "r182", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r273", "r277", "r291", "r463", "r598", "r599", "r608"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current assets" } } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r501"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": ["r551"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": ["r552"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": ["r547"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r547"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": ["r547"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": ["r547"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r547"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": ["r547"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative", "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest", "http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity", "http://aethlonmedical.com/role/StockCompensationDetails-StockbasedCompensation", "http://aethlonmedical.com/role/StockCompensationDetailsNarrative", "http://aethlonmedical.com/role/WarrantsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": ["r550"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r549"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r548"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r548"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r188", "r613", "r614"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r51", "r52", "r188", "r613", "r614"] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization"], "lang": { "en-us": { "role": { "label": "NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r80"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets", "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r20", "r115", "r448"] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies"], "lang": { "en-us": { "role": { "label": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r21", "r97"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r20", "r77", "r134"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r77"] }, "aemd_ChangeInEarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ChangeInEarningsPerShareBasic", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Change in earnings per share, basic" } } } }, "auth_ref": [] }, "aemd_ChangeInEarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname":

"ChangeInEarningsPerShareDiluted", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Change in earnings per share, diluted" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r527"] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": ["r588"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "aemd_ClassAAndClassBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassAAndClassBWarrantsMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class A And Class B Warrants [Member]" } } }, "auth_ref": [] }, "aemd_ClassAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassAWarrantsMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class A Warrants [Member]" } } }, "auth_ref": [] }, "aemd_ClassBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassBWarrantsMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class B Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r109", "r117", "r118", "r119", "r136", "r162", "r163", "r165", "r167", "r174", "r175", "r182", "r195", "r197", "r198", "r199", "r202", "r203", "r207", "r208", "r211", "r214", "r221", "r291", "r356", "r357", "r358", "r359", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r384", "r405", "r427", "r438", "r439", "r440", "r441", "r442", "r564", "r576", "r582"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r117", "r118", "r119", "r174", "r207", "r208", "r209", "r211", "r214", "r219", "r221", "r356", "r357", "r358", "r359", "r458", "r564", "r576"] }, "aemd_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightExercisable", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants exercisable" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative", "http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants exercise price", "periodStartLabel": "Warrants outstanding, weighted average exercise price", "periodEndLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r222"] }, "aemd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants cancelled or expired, weighted average exercise price" } } }, "auth_ref": [] }, "aemd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants exercisable, weighted average exercise price" } } }, "auth_ref": [] }, "aemd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants exercised, weighted average exercise price" } } }, "auth_ref": [] }, "aemd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsgranted": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsgranted", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants granted, weighted average exercise price" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r222"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding", "periodEndLabel": "Class of Warrant or Right, Outstanding", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRights": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRights", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants outstanding, range of exercise prices" } } }, "auth_ref": [] }, "aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRights1": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRights1", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "[custom:ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRights1]" } } }, "auth_ref": [] }, "aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsCancelledExpired": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsCancelledExpired", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants cancelled or expired, range of exercise prices" } } }, "auth_ref": [] }, "aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsExercisable": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsExercisable", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants exercisable, range of exercise prices" } } }, "auth_ref": [] }, "aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsExercised": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsExercised", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants exercised, range of exercise prices" } } }, "auth_ref": [] }, "aemd_ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsGranted": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ClassOfWarrantOrRightRangeOfExercisePriceOfWarrantsOrRightsGranted", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants grantedrange of exercise prices" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r528"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": ["r528"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r82", "r189", "r190", "r444", "r594", "r595"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r465", "r466", "r467", "r469", "r470", "r471", "r472", "r578", "r579", "r581", "r601", "r615", "r619"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r65"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r65", "r384"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r65"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r65", "r384", "r402", "r619", "r620"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001 per share; 60,000,000 shares authorized as of June 30, 2024 and March 31, 2024; 13,937,327 and 2,629,725 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r65", "r337", "r463"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r533"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r532"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r534"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r531"] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r22", "r23", "r24"] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r22", "r23", "r24"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative", "http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r137", "r138", "r204", "r209", "r317", "r324", "r334", "r449", "r451"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Lease frequency of periodic payment", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)." } } }, "auth_ref": ["r15", "r55"] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Lease periodic payment", "documentation": "Amount

of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r15", "r55"] }, "aemd_DecreaseInCashUsedInOperatingAndInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "DecreaseInCashUsedInOperatingAndInvestingActivities", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Decrease in cash used in operating and investing activities" } } }, "auth_ref": [] }, "aemd_DecreaseInExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "DecreaseInExpenses", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Decrease in expenses" } } }, "auth_ref": [] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredOfferingCosts", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Offering Cost", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": ["r590"] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deposits", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r568"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r6", "r172", "r177", "r179", "r455", "r456"] }, "aemd_Director1Member": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "Director1Member", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Director 1 [Member]" } } } }, "auth_ref": [] }, "aemd_Director2Member": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "Director2Member", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Director 2 [Member]" } } }, "auth_ref": [] }, "aemd_Director3Member": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "Director3Member", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Director 3 [Member]" } } }, "auth_ref": [] }, "aemd_Director4Member": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "Director4Member", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Director 4 [Member]" } } }, "auth_ref": [] }, "aemd_DisclosureWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "DisclosureWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Warrants" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r489"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r487", "r489", "r501"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r488"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r476"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r489"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r489"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r522"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r479"] }, "aemd_DueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "DueToRelatedParties", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Due to related parties" } } }, "auth_ref": [] }, "aemd_DueToRelatedPartiesCurrent1": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "DueToRelatedPartiesCurrent1", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Due to related parties", "label": "Due to related parties current 1" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations", "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "label": "Basic net loss per share attributable to common stockholders", "verboseLabel": "Basic loss per common share attributable to stock-based compensation expense", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r130", "r148", "r149", "r150", "r151", "r152", "r153", "r160", "r162", "r165", "r166", "r167", "r171", "r267", "r270", "r289", "r290", "r331", "r346", "r452"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations", "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "label": "Diluted net loss per share attributable to common stockholders", "verboseLabel": "Diluted loss per common share attributable to stock-based compensation expense", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r130", "r148", "r149", "r150", "r151", "r152", "r153", "r162", "r165", "r166", "r167", "r171", "r267", "r270", "r289", "r290", "r331", "r346", "r452"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://aethlonmedical.com/role/LossPerCommonShare"], "lang": { "en-us": { "role": { "label": "LOSS PER COMMON SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r159", "r168", "r169", "r170"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of exchange rate on changes on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r292"] }, "aemd_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "EmployeeMember", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Employee [Member]" } } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accrued salary and related expenses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r58"] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r482"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r478"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate

'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r478"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r563"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r478"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r560"] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r501"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r478"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r478"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r478"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r478"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r561"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r110", "r126", "r127", "r128", "r139", "r140", "r141", "r145", "r152", "r154", "r156", "r173", "r183", "r186", "r187", "r223", "r258", "r259", "r262", "r263", "r264", "r268", "r269", "r270", "r279", "r280", "r281", "r282", "r283", "r285", "r288", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r309", "r345", "r347", "r348", "r349", "r365", "r427"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r530"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r494", "r505", "r515", "r540"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r491", "r502", "r512", "r537"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": ["r536"] }, "aemd_ExercisePrice1Member": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ExercisePrice1Member", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable"], "lang": { "en-us": { "role": { "label": "Exercise Price $6.90 - $16.80 [Member]" } } }, "auth_ref": [] }, "aemd_ExercisePrice2Member": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ExercisePrice2Member", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable"], "lang": { "en-us": { "role": { "label": "Exercise Price $25.20 [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Patents, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r326", "r592"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r498", "r509", "r519", "r544"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r498", "r509", "r519", "r544"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r498", "r509", "r519", "r544"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r498", "r509", "r519", "r544"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r498", "r509", "r519", "r544"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r75", "r407"] }, "aemd_GrossProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "GrossProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Gross proceeds from sale of equity" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Accounts payable and other current liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Due to related parties", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r447"] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r5"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": ["r498", "r509", "r519", "r536", "r544", "r548", "r556"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r554"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r490", "r559"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r490", "r559"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r490", "r559"] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "aemd_IssuancesOfCommonStockForPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "IssuancesOfCommonStockForPublicOffering", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuances of common stock for public offering" } } }, "auth_ref": [] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Payroll and related expenses", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": ["r573"] }, "us-gaap_LesseeOperatingLeaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescription", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Lease description", "documentation": "Description of lessee's operating lease." } } }, "auth_ref": ["r304"] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Letter of credit", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r15", "r57", "r58", "r59", "r60", "r61", "r62", "r63", "r136", "r182", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r274", "r277", "r278", "r291", "r383", "r453", "r475", "r598", "r608", "r609"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r70", "r99", "r340", "r463", "r577", "r589", "r605"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r59", "r114", "r136", "r182", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r274", "r277", "r278", "r291", "r463", "r598", "r608", "r609"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "aemd_LiquidityAndGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "LiquidityAndGoingConcernPolicyTextBlock", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies"], "lang": { "en-us": { "role": { "label": "LIQUIDITY AND GOING CONCERN" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r191", "r192", "r193", "r194", "r254", "r457", "r596", "r597"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r191", "r192", "r193", "r194", "r254", "r457", "r596", "r597"] }, "aemd_ManufacturingSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ManufacturingSpaceMember", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Manufacturing Space [Member]" } } }, "auth_ref": [] }, "aemd_May2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "May2024PublicOfferingMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "May 2024 Public Offering [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": ["r528"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": ["r528"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r547"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r555"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r529"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r133"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows provided by financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r133"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows used in investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r77", "r78", "r79"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": -1.0, "order": 1.0 }, "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r74", "r79", "r100", "r112", "r122", "r124", "r128", "r136", "r144", "r148", "r149", "r150", "r151", "r152", "r155", "r156", "r164", "r182", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r267", "r270", "r290", "r291", "r344", "r404", "r425", "r426", "r473", "r598"] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": ["http://aethlonmedical.com/role/RecentAccountingPronouncements"], "lang": { "en-us": { "role": { "label": "RECENT ACCOUNTING PRONOUNCEMENTS", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": ["r108", "r111", "r142", "r143", "r146", "r147", "r157", "r158", "r180", "r184", "r185", "r265", "r266", "r268", "r270", "r284", "r287", "r308", "r310", "r311", "r327", "r328", "r329", "r350", "r351", "r352", "r353", "r354"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "aemd_NonEmployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "NonEmployeeDirectorsMember", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Non Employee Directors [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": ["r528"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r526"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r525"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r555"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r555"] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r45", "r223", "r578", "r579", "r580", "r581", "r619"] }, "us-gaap_NoninterestIncomeOtherAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoninterestIncomeOtherAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "OTHER INCOME" } } }, "auth_ref": [] }, "aemd_OfficeAndLaboratorySpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "OfficeAndLaboratorySpaceMember", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Office And Laboratory Space [Member]" } } }, "auth_ref": [] }, "aemd_OfficeLabAndManufacturingLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "OfficeLabAndManufacturingLeasesMember", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Office Lab And Manufacturing Leases [Member]" } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OffsettingAssetsLineItems", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": []

}, "us-gaap_OffsettingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OffsettingAssetsTable", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Table]", "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements." } } }, "auth_ref": ["r71", "r72"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "OPERATING LOSS", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r101", "r454", "r583", "r584", "r585", "r586", "r587"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Operating lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r606"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r303"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease liability, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r303"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease liability, less current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r303"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset", "verboseLabel": "Right of use lease asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r302"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Lease weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r306", "r462"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r305", "r462"] }, "us-gaap_OptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionMember", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable", "http://aethlonmedical.com/role/StockCompensationDetails-StockbasedCompensation", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Options Held [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)." } } }, "auth_ref": ["r95", "r392", "r397", "r415", "r421", "r435", "r436", "r437", "r465", "r466"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "negatedLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r9", "r14", "r123", "r125", "r129", "r152", "r293", "r294", "r299", "r330", "r345", "r570", "r571"] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "negatedTotalLabel": "COMPREHENSIVE LOSS", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": ["r2", "r126", "r129", "r257", "r260", "r261", "r293", "r297", "r299", "r330", "r345"] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "negatedLabel": "OTHER COMPREHENSIVE LOSS", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r4", "r8", "r94"] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": ["http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of other current liabilities", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets", "http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other current liabilities", "totalLabel": "Total other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r58", "r463"] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": ["http://aethlonmedical.com/role/OtherCurrentLiabilities"], "lang": { "en-us": { "role": { "label": "OTHER CURRENT LIABILITIES", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": ["r58", "r61", "r593"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r528"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r489"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r496", "r507", "r517", "r542"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": ["r499", "r510", "r520", "r545"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r499", "r510", "r520", "r545"] }, "aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Par value of shares issued for vested restricted stock units and net stock option exercise" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": ["r524"] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payment of other stock issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r19"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payment of offering costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r18"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r131"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r76"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r527"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r527"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r526"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": ["r529"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r525"] }, "aemd_PlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "PlacementAgentMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Placement Agent [Member]" } } }, "auth_ref": [] }, "aemd_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "PlacementAgentWarrantsMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_PledgingPurposeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgingPurposeAxis", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Pledging Purpose [Axis]", "documentation": "Information by pledging purpose of pledged asset owned." } } }, "auth_ref": ["r322", "r459", "r464", "r565"] }, "us-gaap_PledgingPurposeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgingPurposeDomain", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Pledging purpose of pledged asset owned." } } }, "auth_ref": ["r322", "r459", "r464", "r565"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r526"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the

Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r483"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } } }, "auth_ref": ["r485"] }, "aemd_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "PrefundedWarrantsMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Prefunded Warrants [Member]" } } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r569"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies"], "lang": { "en-us": { "role": { "label": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r566"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from the issuance of common stock, net", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r3"] }, "aemd_ProceedsFromIssuanceOfCommonStockUponClassAndClassBWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockUponClassAndClassBWarrantExercises", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from the issuance of common stock upon Class A and Class B warrant exercises" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from sale of equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r3", "r356"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from warrant exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r574"] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Professional fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": ["r455", "r473", "r617", "r618"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r112", "r122", "r124", "r132", "r136", "r144", "r152", "r155", "r156", "r182", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r267", "r270", "r272", "r275", "r276", "r290", "r291", "r332", "r343", "r364", "r404", "r425", "r426", "r460", "r461", "r474", "r572", "r598"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r7", "r307", "r333", "r342", "r463"] }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Property Subject to or Available for Operating Lease [Axis]", "documentation": "Information by property that could be leased or is available for lease." } } }, "auth_ref": ["r103"] }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "A descriptive title of whether the property is subject to or available for operating lease." } } }, "auth_ref": ["r103"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } } }, "auth_ref": ["r524"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r524"] }, "aemd_RangeOfExercisePricesOptionBeginning": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "RangeOfExercisePricesOptionBeginning", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Range of exercise prices, beginning balance", "documentation": "Range of exercise prices, Option beginning" } } }, "auth_ref": [] }, "aemd_RangeOfExercisePricesOptionCancelledexpired": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "RangeOfExercisePricesOptionCancelledexpired", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Range of exercise prices, cancelled/expired", "documentation": "Range of exercise prices, Option cancelled/expired" } } }, "auth_ref": [] }, "aemd_RangeOfExercisePricesOptionEnding": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "RangeOfExercisePricesOptionEnding", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Range of exercise prices, ending balance", "documentation": "Range of exercise prices, Option ending" } } }, "auth_ref": [] }, "aemd_RangeOfExercisePricesOptionExercisable": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "RangeOfExercisePricesOptionExercisable", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Range of exercise prices, exercisable", "documentation": "Range of exercise prices, Option exercisable" } } }, "auth_ref": [] }, "aemd_RangeOfExercisePricesOptionGranted": { "xbrltype": "stringItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "RangeOfExercisePricesOptionGranted", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Range of exercise prices, granted" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": ["r491", "r502", "r512", "r537"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r181", "r224", "r315", "r316", "r336", "r341", "r378", "r379", "r380", "r381", "r382", "r401", "r403", "r434"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r315", "r316", "r607"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetails", "http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r181", "r408", "r409", "r412"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r181", "r224", "r315", "r316", "r336", "r341", "r378", "r379", "r380", "r381", "r382", "r401", "r403", "r434", "r607"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r312", "r313", "r314", "r316", "r318", "r361", "r362", "r363", "r410", "r411", "r412", "r431", "r433"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative", "http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "auth_ref": ["r137", "r138", "r204", "r209", "r317", "r324", "r334", "r450", "r451"] }, "us-gaap_ResearchAndDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentAbstract", "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails"], "lang": { "en-us": { "role": { "label": "Research and development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r255", "r446", "r455", "r610"] }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "presentation": ["http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses"], "lang": { "en-us": { "role": { "label": "RESEARCH AND DEVELOPMENT EXPENSES", "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period." } } }, "auth_ref": ["r256", "r445"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r492", "r503", "r513", "r538"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": ["r493", "r504", "r514", "r539"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": ["r500", "r511", "r521", "r546"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets", "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Restricted cash", "periodEndLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r567", "r575", "r611", "r612"] }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:" } } }, "auth_ref": [] }, "aemd_RestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "RestrictedCashMember", "presentation": ["http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Restricted Cash [Member]" } } } }, "auth_ref": [] }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity"], "lang": { "en-us": { "role": {

"negatedLabel": "Tax withholding payments, shares", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative", "http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity", "http://aethlonmedical.com/role/StockCompensationDetails-StockbasedCompensation", "http://aethlonmedical.com/role/StockCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] } }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r67", "r87", "r339", "r350", "r354", "r360", "r385", "r463"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r110", "r139", "r140", "r141", "r145", "r152", "r154", "r156", "r183", "r186", "r187", "r258", "r259", "r262", "r263", "r264", "r268", "r269", "r270", "r279", "r281", "r282", "r285", "r288", "r300", "r301", "r347", "r349", "r365", "r619"] }, "aemd_ReverseStockSplitPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "ReverseStockSplitPolicyTextBlock", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies"], "lang": { "en-us": { "role": { "label": "REVERSE STOCK SPLIT" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r555"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r555"] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": ["http://aethlonmedical.com/role/StockCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of share-based compensation expenses", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": ["r41"] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://aethlonmedical.com/role/StockCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of restricted stock units restricted stock units", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": ["r92"] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": ["http://aethlonmedical.com/role/StockCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of non vested stock options", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": ["r92"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetails", "http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r53", "r54", "r408", "r409", "r412"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsTables"], "lang": { "en-us": { "role": { "label": "Schedule of amounts due to related parties", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock", "presentation": ["http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of research and development expenses", "documentation": "Tabular disclosure of capitalized cost and amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } }, "auth_ref": ["r591"] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": ["http://aethlonmedical.com/role/StockCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of stock-based compensation", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r92"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "presentation": ["http://aethlonmedical.com/role/StockCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of stock options outstanding", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r93"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest", "http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity", "http://aethlonmedical.com/role/StockCompensationDetails-StockbasedCompensation", "http://aethlonmedical.com/role/StockCompensationDetailsNarrative", "http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": ["http://aethlonmedical.com/role/StockCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of options outstanding and exercisable", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": ["r36"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://aethlonmedical.com/role/StockCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r90"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r28", "r29", "r30", "r31", "r32", "r33", "r83", "r85", "r86", "r87", "r117", "r118", "r119", "r174", "r207", "r208", "r209", "r211", "r214", "r219", "r221", "r356", "r357", "r358", "r359", "r458", "r564", "r576"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://aethlonmedical.com/role/WarrantsTables"], "lang": { "en-us": { "role": { "label": "Schedule of warrant activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Variable Interest Entity [Table]", "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements." } } }, "auth_ref": ["r46", "r47", "r48", "r49", "r50", "r273", "r274", "r277", "r278", "r321", "r322", "r323"] }, "us-gaap_SecuritiesFinancingTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionAxis", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Securities Financing Transaction [Axis]", "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost." } } }, "auth_ref": ["r96"] }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionTypeDomain", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Measurement of financing transaction securities held." } } }, "auth_ref": ["r96"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r477"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r481"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r480"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r486"] }, "aemd_SeparationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "SeparationAgreementMember", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Separation Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accrued vacation paid", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation", "http://aethlonmedical.com/role/StockCompensationDetails-StockbasedCompensation", "http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock based compensation", "verboseLabel": "Total stock-based compensation expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative", "http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity"], "lang": { "en-us": { "role": { "label": "RSU's granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r242"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity"], "lang": { "en-us": { "role": { "label": "RSUs nonvested", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r239", "r240"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity"], "lang": { "en-us": { "role": { "negatedLabel": "RSU's vested", "label": "Share-Based Compensation Arrangement by

Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r243"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest", "http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity", "http://aethlonmedical.com/role/StockCompensationDetails-StockbasedCompensation", "http://aethlonmedical.com/role/StockCompensationDetailsNarrative", "http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Warrants exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": ["r11"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants cancelled or expired", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": ["r91"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": ["r10"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable"], "lang": { "en-us": { "role": { "label": "Stock options, exercisable", "verboseLabel": "Stock options exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r233"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r233"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Stock options, cancelled/expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r238"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Intrinsic value per share", "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed." } } }, "auth_ref": ["r38"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock options, granted", "verboseLabel": "Options granted", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r600"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r235"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r245"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r36"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"], "lang": { "en-us": { "role": { "label": "Number of shares total", "periodStartLabel": "Stock options outstanding, beginning balance", "periodEndLabel": "Stock options outstanding, ending balance", "verboseLabel": "Stock options outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r231", "r232"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price vested", "periodStartLabel": "Weighted average exercise price outstanding, beginning balacne", "periodEndLabel": "Weighted average exercise price outstanding, ending balance", "verboseLabel": "Weighted average exercise price, outstanding", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r231", "r232"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price expected to vest", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r248"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"], "lang": { "en-us": { "role": { "label": "Number of shares expected to vest", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r247"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Terms of awards", "documentation": "Description of terms of award under share-based payment arrangement." } } }, "auth_ref": ["r37"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative", "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest", "http://aethlonmedical.com/role/StockCompensationDetails-RsuActivity", "http://aethlonmedical.com/role/StockCompensationDetails-StockbasedCompensation", "http://aethlonmedical.com/role/StockCompensationDetailsNarrative", "http://aethlonmedical.com/role/WarrantsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, cancelled/expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r238"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r235"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r39"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable"], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": ["r40"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual term in years vested", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r36"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-NonvestedShares"], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested shares outstanding, beginning balance", "periodEndLabel": "Nonvested shares outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-NonvestedShares"], "lang": { "en-us": { "role": { "negatedLabel": "Options forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-NonvestedShares"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value nonvested shares outstanding, beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsExercisable"], "lang": { "en-us": { "role": { "label": "Weighted average remaining life (years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r93"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual term in years expected to vest", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r248"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average period", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r247"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "label": "Vesting of stock options and restricted stock units", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r246"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-NonvestedShares", "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"], "lang": { "en-us": { "role": { "label": "Number of shares vested", "negatedLabel": "Options vested", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-NonvestedShares"], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value nonvested shares outstanding, vested", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": ["http://aethlonmedical.com/role/StockCompensation"], "lang": { "en-us": { "role": { "label": "STOCK COMPENSATION", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": ["r84", "r89"] }, "aemd_SharesIssuedPricePerShare1": { "xbrltype": "perShareItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "SharesIssuedPricePerShare1", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Average per share sale price" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r484"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r109", "r117", "r118", "r119", "r136", "r162", "r163", "r165", "r167", "r174", "r175", "r182", "r195", "r197", "r198", "r199", "r202", "r203", "r207", "r208", "r211", "r214", "r221", "r291", "r356", "r357", "r358", "r359", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r384", "r405", "r427", "r438", "r439", "r440", "r441", "r442", "r564", "r576", "r582"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r9", "r65", "r68", "r69", "r110", "r126", "r127", "r128", "r139", "r140", "r141", "r145", "r152", "r154", "r156", "r173", "r183", "r186", "r187", "r223", "r258", "r259", "r262", "r263", "r264", "r268", "r269", "r270", "r279", "r280", "r281", "r282", "r283", "r285", "r288", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r309", "r345", "r347", "r348", "r349", "r365", "r427"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r139", "r140", "r141", "r173", "r301", "r325", "r355", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r399", "r400", "r401", "r403", "r406", "r407", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r427", "r468"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r139", "r140", "r141", "r173", "r181", "r301", "r325", "r355", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r384", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r399", "r400", "r401", "r403", "r406", "r407", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r427", "r468"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r495", "r506", "r516", "r541"] }, "aemd_StockBasedCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "StockBasedCompensationMember", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "label": "Stock Based Compensation [Member]" } } }, "auth_ref": [] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common shares upon vesting of restricted stock units and net stock option exercises", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r34", "r44"] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuances of common stock for Class A and Class B warrant exercises, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r9", "r30", "r65", "r68", "r87", "r205"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuances of common stock for cash under at the market program, shares", "verboseLabel": "Stock issued new, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r9", "r64", "r65", "r87", "r356", "r427", "r439"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common shares upon vesting of restricted stock units and net stock option exercises, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r9", "r64", "r65", "r87"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r9", "r64", "r65", "r87", "r236"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuances of common stock for Class A and Class B warrant exercises", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r9", "r65", "r68", "r69", "r87"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuances of common stock for cash under at the market program", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r9", "r64", "r65", "r87", "r365", "r427", "r439", "r474"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Unrecognized compensation cost to share based", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r38", "r64", "r65", "r87"] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r467"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets", "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "BALANCE \u2013 MARCH 31, 2023", "periodEndLabel": "BALANCE \u2013 JUNE 30, 2023", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r65", "r68", "r69", "r81", "r386", "r402", "r428", "r429", "r463", "r475", "r577", "r589", "r605", "r619"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024"], "lang": { "en-us": { "role": { "label": "EQUITY TRANSACTIONS IN THE THREE

MONTHS ENDED JUNE 30, 2024", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r84", "r135", "r206", "r208", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r220", "r223", "r286", "r430", "r432", "r443"] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r88"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://aethlonmedical.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r319", "r320"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": ["r535"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r527"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r534"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionDomain", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": ["r451"] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionTypeAxis", "presentation": ["http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": ["r451"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Adoption Date" } } } }, "auth_ref": ["r557"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } } }, "auth_ref": ["r558"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Expiration Date" } } } }, "auth_ref": ["r558"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } } }, "auth_ref": ["r556"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Title" } } } }, "auth_ref": ["r556"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Termination Date" } } } }, "auth_ref": ["r557"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r271"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } } }, "auth_ref": ["r553"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r25", "r26", "r27", "r104", "r105", "r106", "r107"] }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityLineItems", "presentation": ["http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r273", "r274", "r277", "r278", "r321", "r322", "r323"] }, "aemd_WainwrightMember": { "xbrltype": "domainItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "WainwrightMember", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Wainwright [Member]" } } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://aethlonmedical.com/role/WarrantsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r465", "r466", "r469", "r470", "r471", "r472"] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants maturity date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": ["r602", "r603", "r604"] }, "aemd_WarrantsExercisedShares": { "xbrltype": "sharesItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "WarrantsExercisedShares", "presentation": ["http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302024DetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } } }, "auth_ref": [] }, "aemd_WarrantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aethlonmedical.com/20240630", "localname": "WarrantsTextBlock", "presentation": ["http://aethlonmedical.com/role/Warrants"], "lang": { "en-us": { "role": { "label": "WARRANTS" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations", "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding, diluted", "verboseLabel": "Weighted average number of common shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r161", "r167"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations", "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding, basic", "verboseLabel": "Weighted average number of common shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r160", "r167"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://aethlonmedical.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r562"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480843/718-30-35-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-4" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r114": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

"Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",

"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r456": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r506": { "role":

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r564": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 59 0001683168-24-005708-xbrl.zip IDEA: XBRL DOCUMENT - filename begin 644 0001683168-24-005708-xbrl.zip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{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

M=RXPXDFUGP#-)+<@8D4=*97M6?/BFKOQGP#]8C(!=:0.OT8U MRM%I17%A@.H0\V34'YB.I?1H>,&VIF\M242]@05EZ09R>=+SGB>#U@?3Z^O1 MXGI(XM;
[DTO\]V0QFGP93@:CX5R=3+UCVW7WF$W!G]YXT^K(<4&D*&($E$/E ME8D.9\,2V-W3):I\"/>-8S\AQWN=^_>_(]U;V%.G_XP'"&'BRG:F^$>-\#9& M>+JBAWD7:$I:*#@#-
;LL8\I%Z^3B@1646Z@Q.9';Q;$KH0/]!F_+5@.50Z\E MJDHUT=> M3Y=K;"YB&VML79O.Z3:Z_Q)TQ89UJT2M)"KDN,RCM/+R)GLX! M9*XURU^1ZZ3D,C8;$ZAX!8.L3CBH;-7EK@QU
BL$5HL]@+B78ZQPJ[ES6L MFP,2/X_@M";-%KK03.("GZ\1\L:D!R)OJFD+UVB&!D^B10:X&G[P78PCU/+?(W1 M5$V__>7OOAL&1E7?WP@/DV=CZ6MFM93UMW[]!< 7D<0K:0DXZMVJV;C%
<\#G M$ \.#H #X,__[^DA08^8Y'&6_N6K-]^^_@KA-,RB.+W[RU1:>SM-U]B=T%3S@ M']%[GK(2%!GY$_H4)%OV2W81)YB@:?:P27"!Z8/RQ3^B/WS[JEV 3D\MROV$ MTR@C'Z_G3;GW1;')?
WSUZO/GS]^FV6/P.2._Y=^&V8-=@3=%4&SSIK373Z^K M_RO5_YS$Z6_LO]W&^08T>^5YC\^Y?%?OF+OK5[[^=VW&;E[]?;UZS>O_N/# MY4UXCQ^"TSAEWRW$7]5:Kl!29WIL??
OCA%7]:BPJ23{?QCSN%=9F%0\&HWO@8I)=B_3FNQ4_;3Z9NWI^_>?/N41U_5'Y]_09(E M^!JO$3?SQ^)Y0ZF4QXP7U6_W1.\EH-)"'G%]%^E^"XH<,1>] -[T9OOV8O^ MJ?KY,KC%R5>
(25)^*.WZH5-6I?3*-=@E)G$6S=)QJ/O:GN#3MD.*%QC0UG=N MPBHK@F04^+:F<]A7>-P7W^FY_]+4S^-Q7[JE>1#8A0AY\.>5?]>$_7A)_^I MQ$\%[49$VUG/R,MX-7BA&$3UDZ4V1A;]]P
^WF"B,ELBYI)(29IL^@A 8RJB0]6E2 MRB$NB'XI1?US9!)%,0M5@V09Q-$\G0:;F/; 6KX8=%QRQPI^FT=:!3"$P:!*&VX=MP@+817&/">MU";[':1X_XGD:9@]8[[OL]9WZL:%F=7R: MK3(8-
@Y%+/BZQ72.)D5!XMMM$=PF&!49]7J$1E]PJ'I%JSU+"_HQ:*EW\[3 M]#,66G;J55P2T@9\FX,Z>3"TLP#99UI7!=4Z<%BV3'1T1Z$MMV23Y5@S>I1* MNN24!FJ;2A(0,
Q28^L3IY9$E2B40>$E+BB%%^LIP31>U'HCN:A+QNC MBDC MDP/#&0VX/FE*492M42D,Q\WA&S,H9NSLE!T M.G%E;4AG]LJH!89NUE#[Y-LIHD83M53WY,$"_!!Q?KW^_MUKSC'VRZ^3U0?Z
MX]O)'<%\ D[JF;22+EAD 9711B/FG2=F;$*TO?J F#1JQ_VP2D>&8+S1+OHQ9SP(132$81E8QW?AB B=.:.U&^[']8-_%S M$*>?
27QWKW$0HHPSUZ""USB%OH#WZM:AZM?U3FQO#D!1S1^"9_;C*.ZM\"] -#S2R,"AA!MAG!]5@W<1WJ-1!M1*@(+9>W9LF09XO
MUGPMQF:]593WLM:J@BU=9^T+>Z>5+4*AAV%B;$Q4+9T=LGOA[YK\'! :]A;R MY0F-G#-/HX/9N!B9D'<2F)#)*W^":N%#==SS\?6>6!!#DW!) ;-+@#.P!) C MDQ/@S!D!EO3AEJ41F3F@%'5&
P/8A@D*.1ADT(,3YE5K:7>,2(*0]U>3.^\V MA%S.'1$Q],#D(C#)$?=]ZBQQ.G M,<1DDD:#@@FU@N.PT@"\%U\]I&&0Q@:B*N*D6LAU\'$>$QQ2X3=JK@@BSMBA M -?PH?<L=3
8Q(2B+]M3*34*8+AD M@U),K:QUJNDLKH6^IGKY-ZZZE[?F[N6MM^[EK:%[>0N$!1I0RN[EK:L:?F>N MX7?>:OB=H8;?0:SA=W8U_,Y5#7]GKN'OO-7P=X8:_@YB#7]G5V?';J&K[)T
M]K!)LF>,ZY=JQHXZ:6?U;H;<4$ M"H,-1GR2#&%4:Z!&!K"_AS'O)H34>J_O8.QO4F(2-R;57 N.+V)AZL9ZPR;2[/>%PRWBZ6* C M$!,I>XS2SK*(S9";9&*UJ'<"V>$3?!'30(T*JG3@=&>*@&QX+
TF>!X8+8/J MYLP85?$P5W&XU24,R19'9UE H@N,-8-[E:2[K2Y;J+NM+E(Q[\PP8Q.6?DIA MQ*4!$S_T;$_UQD]!>62@D0M0]=+4D /M,Z$K!8H(4F@J'M3"CEBPBYEF3QN<
MYA:^0:WBFADF\'V.J.1!L<4 4L6;5O!;Z\$)6UH=G2&_0"KI= 2NAMH9?XMB MWEEDQM8G3SL V6/V@6HDS9:?SX(<1^ST%4I10_^CEWUE> X&(YPL5'R22/G=E^5 F9W/U5/R#MO3,@4VU.6DG!
(8L$/ M?]0PL0(D(2RX4(KDZ"><1'"H<',?$"PX0?YK/MD6]QF)_X&CCVF$28OT2VI9 M?O8\>\(DC'.\)'&(K]GTM&Y'YR'>Y-1G'>Y3=;S>_E\#IIDT?OGV[/Q:\N!^NMKEH8[*>C,N^
M3PJOW6MU!+R50X=*/%F%R\"API)D&TR^YYOM[=]Q6*RR!9D\!G'"#EN]R,AB MPVX@BM.[2QSH#Y7<7H[3(RG'FMDYL')H(6"H.1:YN"F[+ =5!;'C>#.*FK+0 MFOZK*0WQX@X;")5KQ1-
^BT_&+\MZOMD$H2;]S*3AK#*NT@]YTC'IQ[U2SQRB, M5;D2WX>Y4T-<[_#'3Z7;=1 66W9^D8$W:EF'!T_IX;9.G9(+PF") 9UXWE1+ MW TO2DI2-E2]=E[//9IFLY\NCPK6]>$$ M:F=!PJX?
O+G'N*CO'=3$8VIQEV&7"70[NE+)>N>9)4!Q^:8Z_HP=:58=M,ON M;,ER?GT+JHLX057!APV4=AM2IT%^K_9@>5+@$IU'U+!A8%1&!J)K1D/3GV:WP7LZZ%KW+6P:?&C2GD7;M^ M+>Q^7R
5!D$:&X3*WJ*MA!HM3SR:I.DV2*[Q)B,Z^G3%7+-&!K)/EK8,*(Q" M="FI4$K.< U4J<"AS>R11>],1 ,4:.3?\DF:61%44:.3\$ MZ<&4TZ,2 DB.+C(3:-BT3V)UNL=1 MBSI;E#6 ;=9G%7(@B&(
)ZS:EN(=HGCJ@69I$1?/%W&"K[:2] YSPB"MNJ,#5 MG.@_!\$%!2AA.P<70TP.E8)>:KY>)4@+=O^NTIR^F%L&R$%V6=" <0$*3 % M&W:R_#ID+XR84L]$@F2>1OCIK_A9:9<@YY83"IA=4O2$
+%"CDQ!BTH8<6E$ MQ;T08TGBAX \W\2AH:L0!=U20P6TRXV^%"!R** IV%%)HYOYU&=/L@J>YA$E M:KR.RR14 TN4\F()8H#=Y8Q"&!!U] @5#*)*J*OEDTCS-,S()FNE.TRS+76
MS],L4D!V.241!,0D-3H%?RK)D_H/Q'30(H5"FK<#3'WKGS1O M;4GS%C1IWHXAS>IS!H0T[P:8^LX :=[9DN8=:-*\&T4:6O%>?F%,B)4*6%V8O+H(F SD84IL'B&J?BD"0^L%F1)LLV3
M$LLL+X+DO^*-=B N% 9"#RE@*4DZDO"H(H-G(DRI@ZB2CX%U15>VH""=2M9[M[FX+L 36;@MPZR$($L@0B5N R]F34LAU-3..$APH/$+WL;-*EH!JZKCU#$85
MBX"$&N;MFLKX:,CL2(ED>9^EZ@0!4<153:O U;7=?PZBQA6@^K7.Q1"7\S0; M_U3@-)>[[]8S9SU['T[3D=6 M-ZB0) YE5,B%7 MA% #K-D@2H"@@A*6<*A3(XAJ2<\:.
M%WSS]NO;;U"MY;CZKL(5"2)VE.OSPVV6*$Z?DDJY(H$&8LT#B0@(*JAQ]=EP ME:%*%)6R/DZGZH"5R--[[HH 4EAUU7<>@JAT&2+)+B*48$3 V=M0NO;D\F=/X3V[[4:Q M(4$NYMKURT#VW7];!@0%-
,"$04DEBFI9'QL2=EW6G3D(N/,6!-P9@H [B$' MG6T0<.DT$#N\T,B"HHJ:GQ*G]&HH)V. MZQ,M^1%G\W2=D0?^_@OZA\1*A9RS,RUU,)M#+65"(#BB0R8<:UD>.M<21DS: M-2^V45S@J
33G*#>'(\HFQ$WJSACBR7XACQ&>1@'M$$6=IB66!V M7T3\B,^#(JBP*>U5B;O>5?D#W=]-*9,%1"$M0.7^R4:''143U)SR=F0,F=)0 MZR[39(GWI-P?"- %,^.:40 T4.&2W."#$&UK!,4Y^J.J"?E
ME@M2B%TN=$0 <4&&2\$%+HIJ62][M_S*FU32+OEAA9R MER-244!%3<*960:5.?:2N' (\[0X4+T]95%LJ$75,&R78'F<$.4B$48$3 MV))@?J_<55:@588^YA@5]QCQ=-:(_MXZ";XLQ]=-(V'(-
D2447D:!41&(9VP M\UM'E("%NT<$21!$,L)3WT/2:*!:Q3%K%I3#I#V.XR#F!7Y0[G8PJ[ABD"WX MFD1!LL@0IW+O+U+J#:ZZ(F*;/TXS:A]NK0[R.D./(6 *P%QBW)$!P1 E+
M%1:W[PKP]C:)PXLD"]2S+!T9QR?FB?!ZA^7M! Q0$2E.B*/"R(NZ:7^ MSX+T-[+=%.'SDF0AQBS+*F^\E6G^S5:+;+6<&F=1EDY4J()0-X*U"KC MI-
5C^9S,8TGC[#2W+/SMYCZ@'W"Q+7+6@U)2EEPK9+CY04+ WJ+#!H-0-2S M@*E:<.":B*N>H%(9M;0]C< _RW2F .#I[OL9K3-B^@Q5^*L[HBW[3C# L=%V/ MWJS-Z0_FC(H@2#@4K6JHEZ-
V >B6Y8A51:!?6"&(E[+?^\O707[+[=SFIW=! ML"F9B9,BKW_94;3ZX=V2Q;E)*EEDYL:&XT7Z8J@N"CC&&\7.(GG=ZC@ K M)"S6JBS5=9=!5&NC7VI]_[RN,)\4T(.29!H&?@F3;WU8Q4-
,XB/H(COIV8C9NS7,BW-LBZY)H6;IM;4D$P7-*A$Z+U2A;5PHA)>R?. MDN!-$$>SIPU.EQ1J06G/ M>NX-&UQ>8;5[TJFX]4MF\%V']8'Y(F,($475*IPUX-K^.14D- -*DX0R&7!T,8 4)PF*,6],Z?
$JQU(^!AX MJ4=<$(=:VC$6D+'591SW259AAK5 MII.M+A@7,Q"PKQ?2O/RTNSV?7-__WG_[U[9L_M_@G- O9QOOI/2%RU6ZC3*7CBH\62G5H:(N>&++XE.T7O=*KV2.3+X#F@@;YA
MSE$A[+0/U +N](E223#TT<(3$@0J8;0II5 *FP _1)P,K[]_JYH3@OWRZ_D6 MK[)KG+ LJF5 &$-[Z-5B+DA@ LFJ7R7CO>(-P(0P>(M1D2%2RM**)R <1G=" MJO:!SWK'85+R-U&H,D]4]C7\,ZK03!-
L@=DLE%X;!+BT^ ^7RX$&/!8$\@W=^QHXYDQODD :\9T%UTA M,4;A5XTSB19Z /H]_=RB40F.?[}$.J #3-C5W-!ZP5:#,CF32Z)]??_OZ]1M$*R44LRV7?T+?OSYY_9K_ ME_PE1\&VN,|(__I$?
GOR_=L?3O[X]@]UD3${IC8J$R9W6SPMBS]!M(@-Y@<+)OXY M/HDBOOTJ2)9!',W3:,")"^%>0J.TTSE//>3.I*=<% S_]?B$:<]&&K'4W=,X M16&IX)]&8;A]V/*Y.3[89<= _$'S/+E]]Q&PWZ@.^S'*6,
[-8KX(G]23PL%(< M3[6/,;$W!S^D"#@T'85;,FM?EU(GF7+04FVYU,4QZ5+%4&B6 5D0 M?NA#Q,=V2TSXN3CFH:!:T]/ VF2*8JRM4@/3A=ICM1R10^)?>0C3I!G^F[^!
MJ.&);RKH"I[UQ2'R2X%1SRMA"@<>O_B51=;C:>2]Y'BH8$MS._K"8/AD M0BCDMM([4U5223*4 MT<(3][8_TP(3/@5)^/71PAYY]![G%(7F5!;)M%#G,;,/;)U=CV9C%HN665I
M0IM>!A4P/+/#V2=RI>C)./8P,7L>AM 5@]4LR:'TZ7,U6 MO"]"D]7J>G[V<34YNYRAU0)-9JN?+A=7Z,/L?#Z=7)XPO_*M=[;HL@)7P=.R MW"TT*0H2WVX+MF5_E2T#MI/HC:KS?
DF)SC>UOLQT8>/KN.+7U[.?9EGF!-VR$J&RNFJKMD?#@TL!P&R3B1;<5A4!G=T&W/OA=U2^Q#O# MFU2E%>M=%!^J+^3E1LX.0.G=*FK+0 M#,4>N,24-R781IW&!+^-
'',W3@H*/;Y/2IESMSTQ*+NEF9T";;WH-,(2S M@BGXM:!@8T 8CNP:YP6)638A&ZPJS.P+N>2.'&";*UT),-R0PNIS82?$YPB\ MT^$<;]B$>UYQF%:/-JY6B[N='=*#[

AB\BE(MM)MBN[>#L"K>33Z8)SN4+K&@RI O:/"CYWAU;_I M>&6-8[?.6/_J+Y';EA8[<=;U3ZA! \M]C[GH3+C?C*_BK^Z#ZOZS_!,W?9Z6 M6AE3_0AME=3Y&ZX[%E
2+@BTT0CYQJ9C]YB=7R48[*0NM$O>K'=4;Z MZTV^/-]!+]V",\JQAKK_NZH@=E<0[Y^'XQ6&UL[7W_<]LXLN?O5W7_@VZNZFI?U642 M.\G,9';W7LF2G-&.(VDE.7G[?IFB* 1J.[\;?_?%ZYG2VA@>-
[?__NZOLWWW6(9_L+QWO\^W?WLU?= M66\X_*X3A):WL%S?(W__SO._^__]S__1X?]W]_^UZM7G5N'N(N?.WW??C7T MEOY?.R-K17[N?"0>H5;HT[]V/EONAO_&OW5<0CL]?
[5V24C8'^(/_]QY__WU M6ZOSZA5@W,_$6_CT?ZKOUW2^KWG/ZVO/OT]^-[V5[!9Z$5 M;H+H];&^>WR3_%W?_F^MXO__,_^?!"DB'X>4%/S\'SM^_/-OOU[?<^?7Q] M_>;-
U>O_^G0WLY_(RGKE>!PWFWRWZ\5'*>IW]>'#A]?17W=-M,!*[\C,=80O^KU>[9J_XKUY=7;]Z>_7] M<[#X;@=^A"#U?3(ERP[_+Y/>_JL6"9^88JW(PK$MEXOM=6_RNN.$3"7G'ZDP4#M
MCM=\G6&*7$XD\J%:Y606^O;O3[Z[8,OBX(^-$[Y4YD@\9*N<]:S@Z=;UOU87 M46ZD.OD8L9V DO'R9A,X'@F"KL>4/7#89R>4!(R 2#G&]-'RG#^CGU7\E!^Q
M3K[N_"'8$,HVWI7OS9[8E%71+>Y1)UU3!H%%[2>&2I]LB>NON90'SVNN DI= M@?6NEUZ;?:%KV_[&"YF)-*&^QWZT8^54TPOI72>]\8R?4\L++#M:UX;>G)%' M/OELS0X&;*XM_K'QR-LWG%
5_>5&JQ=_EZ\;,\YID.-O+Q?G32.V69(>QO* MM\4[QWIP7"=TU,JLZ%8GA=&>P(UP-D] BYBP0YU4?;$HDXQZ%F7;U;N/K59. M&$U'MJBP+8A/4W8> L@/T+56&6X> O+'AJ]W6\C:(VJ/NWM.V X/
;?ZR.WM M6G/KP:VZ=QV/T<8*]4:TKN%U11&+JASHRLKC$Y%MR9661AAQ:UQUXP^"2W' M#4:UA7(O6,WL9J#Y83J'N+ M%(-EH3M."WL6$'18[T9WK>1;KZH?%)0CM<+'>!W)_C,)F$JP18>O-
#;[<>[S M7Y5F"C9LBQQVF8YO 5Y#S6%:X6#D>]L(R&@KTS>9%..TJ6>#9T)M>^ V4U7= M*ABJ%4ZFP::R,A6,T=ZJQ:^C%O4M7<+AVN (O.F!!VCB1 'P73_89!WVNROO7$=./?\A8B-BH7'4
M^H@<4'X$J8-0X4CU$=O]:M'%W%DQ(=9 L'2T^H@>>H&S()19L3PJH\NGSV/1 MA8,&Y>HAFR)_YY>;4-^NB?RB(67DKU/_COVBZ,NY#DD_)RV&XBSH!>]$#HA M[Y+$D%QU7O&
DPT'E_T8MTS(V1'D^O81#2X/S/ I)X%<6)XV \'>-@_?HL^ MU'T(0LH./KN17.N!N<$[$VF2:O6Z!QA\2< MAEO7>BRK,&VB>]2J^12< MAEO7>BRK,&VB>'1YUUVM(3 'O4$HCO-Z2-];RU#/-]NDS)
MH\IY:3L8SSDZX*@"Q#XMY@KA91;) ET/6]CN5.R]JD"^..60+S?8>)=Q!L2 MS/_<6#0DU'V!()UK# 3[/2;8 @Z1\(X\O@['!P)XOC40\1]0#0\!CTB0SYZ(MZ_+SF^6!M+RH/1#V'S%A%_-I
/!1;$>?;2UP[%-=@/#_9 K\.6Z1)# AU/%Y MD"H%8)]K#$3] R;J @Y1\1YX"RC:^Z,@\P\^V!GVD*"^=0+;#X_08ZWPK*,8HATX14RC8[CP-7L@S'&7X9EM",48Y M:\]80\&YQ_BAECOT%N3Y5_(B
SK7%(HTRAE3RAX*Ū!/JK"SZ,G-L]:*1;PL/% M&^5D*6<0!>VY]3Q<,*ZN9*(H; Z^(\(3Q@(1-0V"__MUH/]&@X[RCE4R:8AL+_5@_7G_3Y3[/QW;#? MG;-
_W'3ONJ/>H#/[93*8SZI72UU:P4,DOTWPZM&RUDE%63<,=K\YZ&?RB]_V M9(Z7>S__Q(^/$)*RJDEW6. _JW9W]AS_AL[51'^*(/[%T0)W1RL^6D)4&&NB2 \JHG#3J/Y^6D(8*=T9[
M/+7N8JZ%%$;DA7YHN5%+O+GFKPD-7R;,^ [Y&U1LN8Y>TQL1Z223]4*K?JMC M4D 81Y]/8T:BQ5T@=\0*R-1Y?&+FZSU;!3B'8O$HNJ&5R=61#XAU= &QHX03
MDCMG2Q9#AJ#WZ#RX,8F!= *I^J&5TM41$8QY=!E-">/"X0_K<7M4+)-L.[3" MNCHR*&8.'?,^6?.S=9!H@^_9*IM W .OZ*Z.(%0+<@*H^N$5*2X[$6!(X N,^P#SS$DD M)>J
5]JXM(CDO*/+1D4:IMP9S+4RQ]X:#KH-%&NN?M]@:-M*B90%=N0:XE7'T!F.KZ_@ MP1 Q=!>+2*&8:EG.8NCUK+43%M9;VYWR1!WP2CZ7%8]"=WS9V/9FM8D.>Y&] MRN/Y*7GB51"WA
=LKLB='_![DO%R/C#U+?0QZ ^'5D"XMRW)8H^XY_PHM>!MF=2"SE^.1OZ/2ZI!8^<, M!O281K0N(B-\0FB4C@0Z>H@[GVY2@@8VZ'MM+H>LNPF??.K\>9CI4OGE.V%G
M+=0C.!$8Y@DLJHVE(ZQ=!^RLA3H%=0R">4*2IZ2+N"J3D-]Q'Z ^<<$250VR M60YU ,?+Q-N>KN- 9*^\@]DKLSG[SZ?!B-DJX]O.>#*8=N=#UJ$WSOWD1
M(EDM\;E^SX+:4!%V0+X>2A(S !F1DB[(=HA"&**;(!'KZ$OCA/I+$@21?_"6 MR*Z!\BVQ30LUNKE$AD)>T87 #H<^98?/).8E84=R(!>TQS8A= 4BYQM=+!^) MQ_AQ&8'=Q6%"I7R4';&-!UU! 9%
EUB.+XTM!C_745^=G#9/TI MK2,&9(36J@aU"7N.OF+LPCYV%U W5N##8CD+FJ,GH.I)5\HT^L:,I:[ON)M0 M=I,C[(">/%I-+!G&T07SA?"2%F31W;*#TF/RRO1XF;NZ4,PAS6'0DTCUA%@* M)%-
%FVB@QEV=]D#HB:>UB%<%U.G]7W\9W_4'T]G_ML=9^\-?.X) WP_F_\" W4M>XY5([0-VQ D<3XN;<9 LLB=Z)K/9EQ'3SLR"FB(6PT#[B$L[P-LWNY02A#@ MWSM1 7+=C+-
%^AO^OD+\:&B4G#4B7Z._2$_'H.[&F"^@[0J%X\17T-^N#3)+ M]-=03GXMDW#@50H^$%2,Y*K"TWJ#\3)UG+SU:?RFX^XYDP*!\>[@WL98)T(! M:K%CTL3*+P/Q-
E!^65&6(6:>LNW$U+S+J#H<=ZUC.SY5BAR[F[M^/'P G9(D6WCDUBIJ?$]A^]:!1%A3PK6 MH+:D@*YN/&?9">6Y(.DVZ+&G8!'F.4,'NUK]R5J+3C875PH64,D*DZ>7?E'% MBZSAQ6HNEK2\
((E!+Y:A@:;\\;=_U_\]J!;S0YGXTEYW]DOG]F[\Q8!],:FP MQ3VK6G&D!;W0,B$Y+6R?V#I,#6Y>[@/^?.(^7[IKA\XVKMNH3BLN,98Y%>^$ M@LSG599$#'WK;33MM3%[M0+@36;$;@E]\
."NJD>6>CR22#$>HKOB><-_*EPML-[8-\B-"C#W M/"L83G39:SO6JOG.&K/@6Y1OL_XUP75TU[9II$CC9?1 N;_+:+'_V#B4,":87H.;!FC>1Q()HC($>BE!!5GYIKL_@+ +'K8[UP(
A]H411^Y\]L^DN>" M:MD^I&-!U:,Y[*#*VP< ,SM@_HV(8O@EL&PRW@Z2GB21A"JND*%V;:K$R*9 M7. A#*>&[D*4W[]?^U[/M0)N'$?_O?EB41X5/W@FU':*G[7@0]9,M 153/ MT80L0+$.FP"N-
LTG(35A"YR!L3A8+HG-P!D\VT^6]TBF#*ZQQ_GG_/3UO+ MC:<+ \VQF0+S/T2O=Z5_D6HIUIQ&/@:.UC)(Q1I$'7W7JL1%G):3]R':[F81
MO:UTP"O&4*QL;=,!U<,VGER&ZB&.K$YXN6QH86QI"33)85OW8G>:A9!,U">- MW*;K-MZY;D6C3*GK4STT=K->NQ%REKM#;N@M?;JRBMX(+XB5A0X U9'F\]_@
M.J*)#KHQQ4LJ,C(/CFIOL3^'1!E_H*<5H4-)6J4YU87H:;<>Q:-4LAWCZ_$ M=0YN??J9T452"T_LA?*%)0=&Z<1MM6.HH+,:+N/&O*H5955,JXF5(H@("8C]:_.?4WL14S+9+ON
M.X'M^L&&'M0TKC7PX%Z74R#(3R=Z$SI;TF&'^Z-,7P;-%K*V@]0&89[0C!:R YEH?)5*# MW'7=+"$.$3_:P;K(>^!#+E6;%/YR/@Z5-MJ0PM!;.%MGL;%U4!6.U35'=;O*^HE8W-81J^I1
WQ$)8IZ1&FJ3D2; M]NZ<'5!NW.(0SQ3UJ6;P8(G:CXZ5K=\>0NL!W M6Y\+_IP')456UZKH8B92GDPC,-KU7[1JZ7PA;^TCW+5#=KYR7WB9;Q70A6W! M>-=_UZF'MX33EF&/#@J,
(DZ%+68.SKOPD$&ILJ3A&!CRA)3480_H6=P&*H_[*NA!@D?&,L0'O2X,N0N L\ M0+L)24!1]J'LH$@E?@21W\"L#%K>!7%TO0=_IH>88=ZI9ATQP#+K9%3L[[<
MRF'4NC/CF)7/0;0"1\%4\8.7TU!YHM < RS(1H[=^H(LAQ&Z(/=51[7%5]03 M++1&SN=U"$V,![JHMBX%KUS@A!RTR5I M#I9+(RZ(§G-Q3G^BB<\#(O:@F70B"NBEO4,TP&Z6T89BU
X!8I;@I%N\O&H A0E5 !X2T]D$?!X M#176A0W!4#?YD)(4:@E_&-Y.J:/_N 48VR:+>$JQ+>*H_:M#<8C. H]@*)LL M1@J@AQ O/=^GJ\>UO\W9OK[4&-E#=0RFY@<31R'BTW0X%WXRW#
M@&TVZB@T46.P1)JY*"\7$ROGO$.&,F0 QH))"Y-B'R72XCDSZ=M"7WI^,L. M&\'WB+\)W)=.]ZO%)+'H'!5E;$'+=O2,ESE^O[PB29$L6 MM\0/Q=>10OHRMI"=MM,H><)S4MFDS_XKSG\H;
(@/ODQ]4F 74MJR,N5IIOS! M ;ZD]'T+*7WI:41"0E>.%S_+RWZI7C;R/7"3?DHNW! 0VCX4/#Z&"0]B-TVF M#6[*#PA$7T@\"LH[MAIXR5P E4PF; U;I*/ ,J<82)DLV749^'O$VJ/Z3R@
M@R!TXG)XGTCXY"\4$H#UQ$WS44I#A_VVG?";D$UBCY?4A2Q DN:X23Y*&2@9 MQ5ON1W[X+[)?0HEJ2L!ZXF8!*<6APW[+DKEE[/H>V5D6S& 3>Z=%;7%S@I3H MRUDL72JK[B?
JB;AJ0$Y(1NI@!GH&2_7'C?)JCGIXIX% MTYN)3P)V()J2Z,7AO<=>OL[]),?-N*I)@OJ &7)G'=TRSQUF+3S*[ZW?9N^M MHYZ=N&O+)7QCHE<1Q7?R.VE!TU8<*OS308_!PG3JD[=V.
V2JVA9>_RK]"GF M:3^*A(NV[Z%/W)4K3?J*](6:_E>KD@Q$B_BZ<@^(-#LI%VF&3[<<.4NYJ#6 M$(!2#TX5OI;;Y6\J/T;[?W#S,F_D: MLAH42[90^LWPWW+)XF3GW&N[XC9%W!PWLD'+
I#QV_;%ÜHX>R/6NL#%N9(,V M]D;ZHF5"R".G*6]RZUJ,<]TQ3Y*@&3=0+^<32=C;[>EZPH #0LVV1HQ=* MK#-Y3I%@_\7_>J 'N-:(^B ',&B*0"M -R MZ)0$ ">,29%H;$/F1FJCL@A#97](=ASI)
RZ36+O =R,$(5>9SN74K$SKVW MH.[+XXS8&^$]&'A'?;$N:XX8D:(E/QB_&)!H\4WM"'%W5>L<5)M< ,%M)#.<88! M[T=VVH\R;&XMAX]>=U17-08]_Y>"W QKRTC?SS'7C[]'D9ZT'OR'B>%3_*R
M3JH^N%?Q4#G .#?D_F[H!0X#;4ZM*) XY1@KNL1[G[W$2[IWDOZ=HP%:N:') MD)\33/:V1MR^E7-%2-TYH:M@O)S3!?N^PI"5M0?.AB:F@AKV]+E"R7/;-=HB M*J26:J8)$.I&EATMK
M9.R%S=$__G*\Z"MDD;<#FD#'".6*N[="B..O!*+31&3B O.G*Z\$+C>I-L"46_$45=ZN5$VJ5B.8HN!4+2\4A73 M-?+#A#2%3TZCNSE^HVHRDV#3^A)HD?
#)];T563BVY7YO^ZMX$1Q9LNEQLN; M3<#X"X*NM[BQ B<8+R>I;XWIH^4Y?QZXOOO%)W5=79Q''7G]]-!9WS;N;F? M#4>#V:S3'?4[-]W9<,9 .YD.9H/1O#L?CD>=\)?1C=S3\[^@?U9?
+4G'=MLU3 MJ5,2[SX$(4_.+%#F72"MI].D'2!X)@X9\ZC%R55>6&>9-FD38:M-BK6\@L0 MTO$LKH5;PR8W+_4]{3PD:>5[43-Y9C=C=ETG0RFG=[XTR_=*<# MG(DYL*C'H.9<1/2KIZ6X!\ZDS-
(#F'&2+LC3226.S&12\F[,3)FR 1D93VRN M]\F6N/Z:7\8F55,*+G7?7[W+511F.UIWVOLEVNCZ@\^#N_'D$]OC.H/_F@Q& ML\$,9P851ZI^.+-I1U6:)"_*4MF$3,G\9?B5Z1FLE'J&T1)#(L]&F&@$S
M<[(R@@;-69L<[6.H]\;@0;I3S&N5L(Z>4V!Q!+?L4,@K60U9?1?+C2AG3/?32;1S/ M=M8NR'*M9W1C+%BX,N2>U*H/96-F?_P -CNG>X$5HS#TYDPMR2??"Y^" 1_P M'QN/O'W#M:YH-?
@ANQH,_GD_G/^K,YJV1[-NCY]&9YWAJ#/_9<#^?SH8=)@Q M//]EUAF,^H-^YQ_WHT'G[9O_VXG&Q[$M(PP -G&F'5(.;\CT*Y/+X@I&OFA MWEZM,02V15PHFFR>K2XBQLR^*7&MD*?
^TN,Y6#3/"N.V??0J5,%%*Y"=:+/YN//6BJ' MEY<3NXC[X+,%1R!'0/V13L)N+(F/,9IB\4S7@J=--*?,1"SIC+!(M*K[']?O/#VS>1DO'? ';XP(X4R=S@/60=2DT2 6&[T66ZS1L6M,/27!4\QRHL
M(-XP!>579DZX=Y'XD5N$>':Q@?5]E=59?G,VG$<^Q.@^H#>.W(N#40_-R)*P MI&-O:0Z#LX& B 1L'[KC(&\>I42WS]+NWHRBGL@&6X9>B 6FK@+\FQ2B2-KE*EX-V:.Z,=\
M[4]=BF93+GRD=.Q7YR^[[_P']L4;8AB8P#"%?#)/X?[J+:6BXW MBOB+#=2Q0[(H_GO,C>1 5FE4M.3OLA.S#A"-,3OE,991<;Y" U_TK+SEW@T M)#/RO$(N9_8366Q- MA#Z12X6IYQ&(I 7M!
%'7WDPY%@:)CS!S, M!:.(9U\N^C(?DH(\4XL-F6_?J?Q[_E!>.O3 *,XJ73>BB+OE6L4O[/!1 M@IL7_G"._K;9*CDG$26#*2CT1E_\N!>^5K3J+'G,:1LR_X3)FIO"T$W94YUZ'
MN<]_E7H^55]9VZ<)V[&NJ;)80C->;Z.M+V&RRPSF+<\"JDG_(&-C. =KT2,X MB ;IP\CWMI%6QZGGI64/&P?[=D!3SCK@&"13@7KRWP;=3?CD4^=/PFO#$YK2 M6;
[MLMUW\$RH[00D*A0_Y0MC'6M #=_&OF>H9XVH30@&Z=M^FASN4"*6[CW^ MR'CU)45G6+2BN!57&'WH#%(@5U5LR%14>3U5^2MU0C5E35NCH'8-9)+B]ME
M&E1SB!B;HSJ=A\TH_>K1/0LMQ@Q%G MD2T=147(KG.9B%A(DZ' Z]\YRR!17 M#&#(^FZ03I@_M)UF7%D64C@RVD2'#24]G1#-EIZFI&D$HF#R^]HX6UNF3Q
MR%5S0]=^0+K/CD1HA8W/05"%C*4]BBS7\)/9/5 J%@6Q:VQW3A2AQ$9+ '.!QV(>KPGW#3 Q>^Q?W+&MFAC!E&N,A&U&5!*1 M-F+HJ]]Q=HQXA*%7-KC+,P(!P!GX-E<"J/!%
G,P_AK=D04EA#TG'0V>FMDKOK"QOU(>L2I=JO+-T"Y%]%#++TXB MCAO:%B:N%3_5UGU4;<7%38% ?S .:!GG35T4.OQ%/9]>27'.M8+:.O5OME4Q M%C#
<,+S7('BO=>&M/VNF+GBO6X7W+0C>M[KP_F@LO&];A?<=-YWNO#^9"R\ M[XR+)K3"F)64ITKA_A%W.3FC7,U2*N8'WX&JB2.RFQE+X@(Z^YRJ]0;0G%3[$1@-;)BVIM']@:.;*XI$-GZ MK1E]9
5L-G629' <\,MB$+C"UD!\ZS=GM/!5,-O*81V&L[0+V(N.C#: [T97 M8EX#77/A$/>[!@MY8P*[XJS@'-U8CVJ2<7> W$#/-#/$ -0VRC-LI)R8B ^I MRJK(!:(R<@=./#Z]/:EW?
8=7(U\S0Q<*];CH6=;:^<<^0A25^YG.[E7'"44W M/)]IH\(JU L0@@WMC]W'1TH>V4%V=X\:U>D27>8+&F,_:RF+QSJZN).CW, @VEF>3,9U9?(>)X^;$TPG2%SOF B0G#7Y,$5ORG';"V8[: MJ
2P1M@IDUJB O!OD)#ZY"'4EE%!)^S,RG(B$G*/+J&]\I!%?Q,MSM&# M'#^F.G6^K(30^3E @94VR'HV1Q%^,D)#VB>TOH@Q^0J&V] MYD5,:N!":&K(-)
[F:IG:'F&GVV);PD7H&DJMQHPRU.QN$^.*]G MN2[/?<^6GU/>UY0?V"37MVI^UH2BF=IP5+EW_\<]\44S6 :+>CB37/.E)]% M#%W>^Z*4WB(F+57W_Q.OW\CLZSX[)XE%#!_!I
L!E51U<6GH4/Z1\K3X,J=! MWAW<&RWT3W<_U<2C(:GLE&,WRY-M7B %86NC[FRDL"L81E_%TAJ1T+HC57:H MD_:"2L[>+4U>)OD8:>?0BP]%%>X=:J,
MJCU&^&W:%LSI:N*OP)"QK$[[H=2OC% M!WG9>4?1SZB(>7)!@2"J;*:*?QV6$5>Z*_KU8PT2RT-A3,T2T=/&DO) ;W\5 M\<:N" 3M/>-]W+T%VB=$]WAS(CT:.Q=[T*>\:N="C-
+4I@;;XSMP9*">W. MQ7*H>,8OE"*@41Z!)^WTS42QJC!V1]*CHP@J*==-Q:C%'_ULQ6]N0Y#.ML4.UB@+=#'/S>(\ M(XREZ*N[JIT0Q,6]L*_MRV*OPJ&I/.(-F?LIFOG]\89R/D4Q$](>Z 4X8=;C
M46*Q&H&:0UV,/ 5+:W2^*W$<1B_!>3D87P[&EX/QY6#SFW$;.'5VO5?"-E5?Y$?#F0=T Z_50O?J%% OQV#K0*E M/'Z%8YS1*EB"^V;*7984MXX3T) 5L 3D2IDUNQ@#NYK]T\G4K
M9@VGH.Z30Y:#9V)';^2,ETO')E0(.=]'91VP$W_4*LX,&1SX;G-XV4JR$>^ MCPB:F['FU+EE"!A%+[>63EKO>MQ\LO2_;.JRMG7'L@,&4OU-5NA0Y?%9O:7 M@^\95F9?TAY[URFI?4?
Y="HTFKT0V1GY_,)+?@ERW/($7>\2CM&WG1E__']? MMRR)[\LU-/2:52@)$1^&\G)(29LW3G6@^,ZJ6L:L60 7;'7JY+" H-B3!!F M%+6?$) \(?7;V?3OF[C'?#[LWP;C@?XC_-&/&69FI/M?JN M"=
(7R9"+5<~)]90D[8&]D MI26E@*#T=7[HAY9KQ&5^%'B?3H))%L!7N3\4K:P_9%?6V7S<^Y4_9\V?NNWR M>_S#-3[[*Q^S8Z<&O3RJ"9F(RV5 PNA=^H#]H'I.4]#T6-
3T\@A6R@QWEKQ'8;&\\MT2:Q M#)]O8G+]6:S5N4.-FD7(/!B4%@KA&MT6SE*77Q0)Q0_9!.*D]3SSR1@I^]= MZOFMY=#/EKLI+#>V\[(T]D7L8Y5JCRW*Y6X0>C-T*SBO'")[CM@YZI5E6F&\[-
(DQ)Z5H_LSJZWX&EZ_!6%N<]_5>1F_5'/S9I\ MH+.-OM!A*V"')-_HA'[TZXO?52M+JORK&N#,J$IMKJB#F M@J;8#KT6WQH3 F6&=[:R^_G8M)6TUS_[-62/?WT65"-7 \6R,4/QRJ"6,)?R MCF6<:4?
O031@G.H28/PZ5TD_VQ.A&2I;83XF7'$C, M TG3)DMYVZ2Q)SB-7;EUC! C+\N[=NALTT_EQ1[?'RIS.=ZQDA$O%^&'7B_#+ M1?2CE(OQLKDDO%^'G+N'+1?CE(OS<+L)A=^#?[/6WN3??
YWY8O)P5*P=EKZ/$ MNEEHT;!*N+T@*7;*^1HOCWR-0WTIQ' MJ),,)W@^CA#J@+%;H*M_X(/5GI+_]NZ'FWE<7G]3C.@H3#)3; O[CN=W00KE M_%2V0^'!HU
7&]H2ZR3BO.\@VQ6E^>JK8'GPO';BLLHM[&^%'[M<-.J+IOV= MKL=K$+LN61!.59DM+S\"4/(_GH[DM2$XE55$M7(6Z"K23JA-"5 +?SH=+42# M\E2TV6!?ZF_78(W\<'X:60:M6GP4
V_1KCMU(*NT^A'=OW CM3341(@Y^>W MR!CM1M58D*Y.R&W?/H@FK%/H6I^*YVUZ:RWX%%2/O[T; :%]$G/EM0RC46<,BZ4>^%Q>$B@N?"CI@UXH M_7[$3A ->8FE;R'];
]Z6R5#A!]$CJ"'!=@WB_9YA!G4@4]FC8RNI?I62/;U MU%M04 -V,%<[2HM6"C?O!Z?4!6FQDYZK>@FL*024 L_Q%KHDN4TY42D M<>W06* :YJ&HP1L#PUPI>1=1@3?EW9MR5?O)8=2+0^52G
!QF;@4)[@4)[@4 M)[@4)]"1*4XP:4X0=W\7XH37(H3U#/OXX-*=Q,^^=3YDRSNV9F IMX6X/PR M8(YN>*/8!?E*W\C'S)CU.!9!1>A2GO*3T[X\3^4VG8H?,T3[FIO%]>FA&,1F
MGH$_^MZ5]/GWXJ9F[DVUS(YTT)D,IX9B!(\^>0T7S;6F:%H._VM6--E2.L?%\]=TY+L-&9 M2OA!/Z>7C=:\,F85?S<4Y1.*&6EQ0RE;UI9SR,YYI(;<_*Y,=-@(WEBXMV5
M7B3'='9_>5_B$L)Q">$P9./)+8>7$(Y+",I M28@GG;J8L8+BN)AA&S8CD+"72+;JCOZ0"PLH\EI?ZWFM#P-W[-3(%P?VQ8%]<6!?'-AGX]Z\-+#/7<(7
M! ;%@7ÜQ8%\0YS,"%TQX%C%TB5=U+T,=X-5NK1+1!0 M#15"$7V[[[B;/@4M[+7^47A@-@V>B&%IPTV'HM8+>+P]")EFA'(-YV=? S) M1^H'33@(9!^[9!WKB^;,EL:JK\"T20CVBP_L!-
+P0B;Y)%## M?CP]#6M:3*>KB/MUMLLFX.IXGC55;P;P3:]_O3MJ")84*>KB\=O>FUX:55O M,7A>.S0:060SM+5R5J4+J-,?OAV=KE7@^'I?;,=$1&K[VDN.!?;6GIZ*6486 M7RDX>;FT)-WW-N-I0?
B-TMSGO](O8GJE6!@-H1&JQ"=TYV @RH:%&'[A 8!> M&"0!@44!A>^R 85?NM-I=S2?[<,(RP4/"NYI#I_:T28)#^0]9!TN<8+&QPFJ M1'@)&+P$#%X"!B\!@Y> P4O X"5@,*M#R7ZI"A#,-
#,^NJB^@,!"@-#/ICW7 M"H+Q,B%N3*?\^) Z3X@EJ>YYKD&!4,Q*!XO$3[W/0HN&300)%\I$_Y:",ET?> MY'V;(&E4M()'05I51C1^"2@7MU8=9#/7!@7Q$A=3R>'.+ZZQ&AYFK"UX9\V1
MGQ11RQ59BP)'I"$7#7[S$DA96E!-Q5F77X+%FE1Q;==5EQ.*9*P+F9U0D'9 MH[XR0$<5EP#!RI 88OLTL.I!8@(;_>KY1@^V("S,VJSU;W R7:RXD.LKW D%
M$]:'C7';7"F5J%T73BB:KP90SGFSVT=PM;S=I;Y[B;;K)###SSF4]R[.)ZY(X M0+")W2O_A3,,J:L=(^,VLSV)-6YFJ3'/,$*M!E0.VX MK\7Y//
,.PT575I47",UPEA/R"5<'123UXB6K[9T5I,3\@-7A>34EIC4@]\E MC U8Y.M.#<[($7P4`F?<0:.D4$L,#A7]"7EEZX3'N)-%M>E>JTJ<@]^T%EW MR5AAV*R<,'*>=+T%3[!A1C+Q;
(<$D/+8[]/9++WQIT_#^.S."DTM)+F/6B3C$ M3U[)499;C #RNC,MV42N@2KAW)F4$3*A/C/.PY?9YN'?Q [G_IAVMVQ)XPS= M^G3, FAQTN\(VU;D62,EACI!<9;@$CV51(MF5:9(J<',$'1I9:^B S7E@@BL MY?%RR6RT;G2R]BGO]C);6S81IGSP7JI.V-'?%?0U;=O"L&GH&//)\C9+GMO- MRR*H12)NCAUJ79,P5'@7)(98!Y@",#4X(B$B-P!,$V5?[*C16F<+$"ET7_&- MY?
([KMD3(>$=_P('6VJ>B'N8L3EI62%B9E++@3F24=D4LCYF2$>E;P#Y-&L(M')XVZ%G!DW1=*VZ*'1>HUIOT:B5C%WUQNB-!0$AFX26!39VUO+J4LB-RJ];Z M.\]_,*00)=8GSR$A[BK6TK^V#
&7\;+N*"58R<.5;'HX"-@6]?:0M0%QS!! MEA1A6;DU9HA7E)NIPCI>'.X?:U2ME"5B&23D.(US> M![QJ,0&+--<-.WNMHOP$,)ST@SW).0OF8V7/4:UDXX5[:ZXV&?$ M$N2=0+)'?:@N;8>5P5IV.&
[=:#2B+. V)_^AO7Q-[$4_JR79] MN(E/D7+YF-;'!I3RP*7V/A@7 W-63+NP/VIF N$)%A!L!SF<=W;;<62W6%Q/ M@0=V<<34"T8JR18T_>:D68 !?GP93'S2N.0*A888<]9,5=*$$UN&_[WW\@VN
M.3ST H=1,J=6=(Q*<=ZT;:7Z#,Q,#$N;'1M[5I;;]I(%'Y'XC^, MD+I*9) FCYLPB(9,!MW4*"NVH?!WN V=@>ZK&A[* ?[\R82Q)RTQ)U(RX/ M@.TSY_J=RTSBOX7O^I=ML'-MO/#*TN'C=:5YUO;.A_
MNW1_JXQ5DIVQ>FV6,5_&0K.>6+"!BGE2M3>J;"A2..Y(@;VG[ONG,4GSS[4C^J-XQ;TZ_]WSNV -0<%NEH=LV:GZHG;"K+O,O7#9T!BVGYPX/K[Y>NM^8
MT_;+)3PZJ=5.7GMT]BB@TO2J[!,GXM81ZZ;\FJ@"D69ROx39E&=G>Y+S8E[Y M.]>D;*59/[(RMC\)-N5SP5(EV(A0E@D-?LSYRD<&2W+I8&8J31C*F%=E<90
MX_!/IL;,$=DTPLW/(I0!CZK,2X*C?7G\Y3UQLL,3+:YA/VR*E^PZ48M(A!-1 MM0Y)C1?*I5!!:J(R%D 5+A/&DR7+DRS!=*,9ST0,!)) _%2 !R6/V(@'N)4R M%&K<"Z$-1,*4*52!$*
((9!KD,>@2K(V(UQ/H#\\)M&!CF<"1"$JYM/%<%5$&/9ZG&P)$8HR$X)D$(YD$41Z" M*<*SY:8J0BN116P&YQ(P"#!1M(E\X7-J4S:!*Y3$& T#')D$"H1;(29&GC8*
M!5Q/V3A2"_.0.*1B(G66@VP4^*,):X/]'OC'H_Q5)A(P+%R% ER&!,(_RB2>DKY060QLITR MGJY#J8-(Z1SKJ ZD*K(1F:4J$"%N:W: (0"(;5>=G\$4YY,!'.088,\$KI< M,@/"QP-AU3!# EW92TF-++%8(
&,\G +(C9BI,RCDE@A:'Q#'T!B"8&BY=!LX M(*&.\$)=S7=:F(W:[N7EL. ^TO=[OOU5]%7/==SJ=U?6S!2YDF$V)M/;NG(U4 MBBIX&*@HXC,M,!84ORIF0&[X@Y6 .<$"[6L%L$S-*L40W?
[*ZJ"^X71:\N2PS&/9;0\>P60ZOE/*:7FEB*Z?OH2:SD@ QH4DV\94GH(!JM9<:BJ&1"42PX?FKDT9 MW2[%J8BXR8NBCVV@72W*-#V4J*C01:M(ACPSBHZT#"5/)1D@;;LUW2$A3KFF
M#FAJB3;MTE1.I044RE"J:=&,$YCRB%/%AUE&B4TGQ0K;E[7*?O9,73*_R3DP,)-9-Y$/S4/'#G/,I-[220B/$8@ZR<([QZQSRZ'L>>T OLY>X1U< >"U''M1V$ M1RK/[M?@*=*V*KZD%C?
GCQ[<_;+3:09A,%M83T.>:+Z=D\V8G@9]1M&E)4$.0I06AK(MC!-58ZPWTZP (OC="[P_80AAW1KO=Y;K:9R)=CLU-HOH+-Z,>];D;:-5RX0FAU4VJH\FVC9%-U*,[/F§/N M#,8K]JWYS SSC6&:9$
\4]I'"=$'/0PD%#9,#@ EU5%.=QC?- MZ*L,$-]S"?T-VO,D,(<:[]^VG&];3BO>B3!=@KE$8J$6ZRIX7*LIFLL04(M'U4[=6C8K?,8>(7!QIBB^^P\GR;*%)[#QM&^[WQ[
MMN_*9*ZBN:#FF_!)\=^"M.@+(IY%:BGP=#%5MA'PàVD V.YE,CEZ-2T7PQH< M>,:VO.W44[G?600VXOL)[9 MI_'/L?DQ]?=6<-?
Y8K/@$(O,8%MVQTPI]=9.Z>_>H6%%/X9REHENU[/Z;4]YW*EY):"[?1_V%;[\\ MV-&'(1N-Z&7E>@E)?O6$KW<]"]02P,$% M @ 28D.6=M7=XCS57E-[W83[]3?
C%7)(MHEXO::^]* IA=[WSS#//[CS0NW"N)OUJI7=AZ"-\!?KI.:8S,?J]5OZ*LZUB MNC>8C6[=FXFQON:TEU!IWV1H$C0I[E-^"%85,:OF !C:/A5_#_'1^;<^ M=PXABU="GD&[UN\-
^L;UA3DP'>@>-SNJU@#QS5^^\SDH?J<:+! K?.MRJ7A< MZ_\FE\GF_%<.@'P-#<&5B+B0&=+FMT3HZ6=9B- MP;DPJA7;&"XLTS$-&XSKX84^_6" /G1HOO.N>Z*!;H-^94Q'QN@[\X_H]>D(
M$%"&O=,;]:1,*Q#1W# O>=C/,I$[H_+[#OYB:CH%/.;]#*0QG(P..<'K1M)O# MYH/-ZMH/2 #)&LWFA&B?^Q+&N_;; CC8NC70IX;=F%U(C)MJI>#\N-T^_E5U
M_F>:*.%OBT$A/4X;MING0M;ZI@0WDI*[2D02;H5:@UIS^)BR&%$%VVK%XILH M5A#YH'.U#G#5%?>$RP(-3.DV-8CB[!&+KT2B8B85#DD81W&(J!L?P2\6;!!E MY % '!Y>NF5SQ:F48A:%(
M$D*+O[348XK#FL<\\A&2!I>,6!HT81RS3T2/202+$(9KP7W<"K=6X@N'F>\+ ME\=9@'QN+"23KF#!;@[3/DP.AXE/K5K9I'&2XABH"/;$79!)XM8H->9%&X7)
M[2\O%Y'TBA@VBY=,\]0QNPOX%G0W(YV4I^$\4V>OJ8T#&?PWXNLTP=D7&Y1: MR^53K9!^-*K+BU<$H9(8)C1CP+,^,,!IA1SU\@O4FWJ:2@F)+(N9+62I%B=Y\I8W),T-0FY@G1KN%S
MP((\=#AQ!.'$QNL0Z)EI/N[DXB1/)'%I'.*J](@KU[$%TH&)BDJ17=5>4R; M/ZX(CC[WCS_71Z/R_3>#N!6>6M/2]IMS6$:QQ^.& M&P4!VR0.!MW-9V&6D5!36"C_9'3&;6R&[/_XL^AK]@,OW]GK?

"G,ZD(NZ4!6U76E(=N>>1MRKO=1 M+B(L'6&]84T_&[3BU*=)+)*$'3)[+9#+[UA(1KZ+<7AX. Q91)+=O7 IR_%I/@;E<8,R:*U) M-KVNUB0V;V_#>5K2$>'[MV6X9#;,I9(OY7-[IG\@R@]V$"
[PFOUB=.2&L"-! M\"Q}_?3[<[Y&:U4I1&<+H,>K:,V%SE,[AK"2F2IF'] 7#[??2W__O=SP,-U-\U. MN .)HE-'&V?#* L"AC M^\5! O3&5W[#407Q}!_"]&^1\,F%3B3R7#*?X0H! Y\8$ M'&KFUS>MBSN[
MV;7MX&/.[L#9M7WA8\Z^HGE84OQ;[}U:5?Q9CN>#1,3[B5\+NYZ@^^739'RE MI63C1__U"QDBB%B7]8]GN)Z$((X#VE3>SA@ Y)H]9?VS_] OKR?-@_\@-V7 MCV>W.
(PW=%"3#YJC\PYNLYQ06\ -(39>H3"QAV/XPB<\@K9J63%9R,12B6-2 + M% O;1+V[M[_/TSQ6^MXBEH-%&?FV__%A*=^!LG'N(BK-QI[N%(+,N2-M?[EE[G0C-C-1KV@SOX#KUHD< /SR-
*X6'D9Z2LV]HY=AU1C"C;=_YP6]97CU. M.(C5V@X&8^T)93%GMXU*7^6(R+V$+?G0X6P]D^1X/AT'M5'):"&6T6@X6XA# MO*@X&X=X;]"N+%J,0NB6KU%:#.\PI.QSR#J)G]3O?_\;[+PIE,N:M1D-
"T? MG?:6!2B.#/:KP=.Q!H^(LVL;BL:TGEUR8NS'5%Q=NT)6#%G(]=I2TIK]S7H@U!:WLY\VN11R2-QX*71-S1,G1>):B M,&)",E#2*I[8XYO80&41\<0>W\0&VA$23^S!3&Q4Y[&N60(-
U;E%(;>PE(H M!$ML;XF@*!JWQ."-1BL%20#%6@O;%M-*2C@E]P-`IZQC/D#*UB\-4!*Y_GI MUS#;5*Y_?T_GJ6D^%_"XI1>/VRVEZ!;L/G%[;+7JRS@;,11/TARR '34>RK^Y[-M)
<]GAM__?!WVWW6XI+YP4NDPZV[2E:.!^0D$31#.VP ML1FX2=HVX$R&KUL$7.YF1F_,J&8#%Y7*R3#]T/*Y+E<)HWK,#%*WSA*]L;U M=MOZ!H'?HDF3;_?D#)=-)[F<$)$Z?
8G<1XSGP\=SR%P>OT7C>=^CO'EAN],@ M,;C?++B#Y@'YG9:=8K-]!$C8HY9;TEE,[A>LL8"QR?S7#Y@QYG] N7C\H'C MAW;>.(PHRH/+/\H7{2$E8@_+,D1UBDDD53/AJ:
(.7ZM$ANL&NJB0L:B;)UH? M&PD;%&$AX39>/#Q.91EO-'*D+ZNBVI/A=1O>B/#\'C3 M_R02Y$]FBG1.&N( ]%"+ _IY0M0>8HR6A\T:_DOP0= '$HB&A:F X F:B[2^< M&{),7)G8 6&*8@LTTQ#X-
PAIS_E[\94]^^3[<^)\FIV&QR>3?RVH/>08OL,W M]&"@;S63CGCH' HBYVY=X'4@-5 M;+&^IB&_L^Z;WCMWX2}^;Q>\CQ1PDXS:SE%U'] #9'I,JT[%^T27@C(`>L8,
M"L&FTNH$94#M3O-E_ID;=:QPJ5XK5VJM2AD/-V_5ZIE M=@9\JPW_W9JJ[1:I7Y%2L75-KF[JWUJ1$GFEZ:RC??NH4TINFZ=%##@U3)$GD MWXE*C?6G-&L9:"U$14C-WW>J.)%D,
(#O[/<$TVK.@I*0S'1X/M5Y_M3+W7}^ M,H5G/"[2F(S@W5-V":.@-QYZ2!-ER)HB+OM/M&1!,Z9XZ:ZAK5SV#'=*^]&3= M?\[N=A]9.UNU+.1QM2T]6W=+LW6W9^F.?
N[^*%$ME_7L#;GYM=M14>YXK/X] M__C\Y3K]}5=^&O7"4N%;J0{(91][Y;F\OFF (>H>G#%98CJRQ/1C5W]_80NK M]7E!9!+>E]3B&)6P]K)TG.^C{-[@,+_1XV:)=$8-G3M008>7T[O
M(/JHJO4QU47L&UN$D/%!-F5J%+N&B1%D1{[L/_>9#[SXZ_?6I;=XY??J!1)*:HCT:9(<QD:P2S:&1B#,BS]>RT_?!WL#*?RJ@#*SP0=%9NBP= S,\:,C)HVY%8>AX,P8Y^OM7EQ}1-JOIO.L2L?
UN_<<8JI$'+.3. MV?Q?7C$$4&AO8/%TV_F_O+73\E5>C_Z/WS-]@H -^>T%7GJ6AJ6MTC!3LSZO M)H!2NZ_+I+A,CN?2Z.1'(LB'@UZ\>?<6^+VA%"^U^Q+!N@USVW/,4UQ+?LWT
ML)V'VI,5NL"(MK:UAD_RH..5;\.'9DJZ_#D6(E'R7I*_R@C7 (FI$=T9(FM9 MCFH O\7/UL%27:V173Y]8$,":T6P_CW+C@JJ\HA)G2V"$ M-.5:.%OZJK#9XL2(S8(7OKQ+*
!6O(Z\,P+!)V^70C44&"J$/B?/O(K:SL!4[MM ?.AS8"/ZO7TYE>]?>;R!FM#Z[&S(>ZH<"#HF%0]}U2K,W R+ EL,E?!SJ M8WO4$E .:!,Z(9J > (-D)K0\ PEW^D8*B$Q%ICQA*/LZ[2$?2>5#VAI..(72+
M.IY+\5X+Z)N@]>Y5Q')W5FZ2TMT;E/-H2*(05G=4!,&/C@,M4^M?"'>P4&P> M\R ##'`1,F2Q*RLL/("8:2D JOU[}_SX8S 5FOE7M)VEH:@.J+$4U; !,+=6
MF0\ACG!V=:E6@=-/0Z5B4I3+M4UVG4L7JLP[088BR@+2J]!JCU?"I^=OP^^1 MQ3TI'[S8!#L=X2V0:$@LZ4U@"*IIH^=5/8=PC ZI_K?8&^)WK$*!RWN>JW 0 MHO!BK-YD'G;O-
\6GLUPZN3EY%D+<9+98Z*#_*VOE',PFB*!I_0IKC)C^ B&=$+=)F(Q MM)I\::JY6E(RA##@/6YK'OS$W:&;C"W"/<3=92$.#(A!F!Y.YM-;9'*7$K@I M@(.LIT/U(*0YK*\$(6(Y}>*N+/OFO2!JA/*I%E*NG(E[;MZ
M]2IY5_@=V?J6GQ0[I!'=HNW 0+3$N9 BN=1+Y9GJFB0:P[5@F17.OPU!#,+(M38*7>34V[FY6FY1MVVF(^JH]O1{\]%8?KTJC5AB?>3_V=[88:&'!#RAUN(3 MHYX5;;N,Z=:%,B&*8};A,DS/E-VLR.
(TAE0'H,/K/"Y6>.[9WC@?P9EZ1).Y M855\[.Y22?M'F&E4EPAN3G5%G!.URV?7X8J?T)=U>Z,3$M9IH=+*/GX"I=75 MC$GE^BG-
#_;G,P342K4@JXL84LTETOGN(RR/Q=t'T[FMALKL M7MF#C4(2)G"/4$GMT>LYW"3L01'C:2$RFRU$57V@QIH"V;OLEZ>RU7>]K/2B MLPN>9,&R0UE<^K0C#-QUTN J.
<=N]7Y/9)T"($ SF=.&(JIF495P9^\8+\%M(UP,2++5@/+ME\YSM]M^&$Y^3S*O5X/AXT(T)GIO*.{@=8G8WM(+(5(G?$< ML<79<+9"X"D-Z3]D P7J/M8F:,0>!SG[F,Q-WD/H6#4E),%EV)SLW$-
<$\YJ MH;IJLS2H.6FK66A3?+IZOFY]%T?7P];&JS6;BR^HOX!C/&S:!4SDQ_\YF!J.GYOL:.@-,SR7S&IC*BS@C=')OG\NDTETX> MVF^>\KX68$S4R%& M\?Y}J.7S]9=1*KH.$/O3)C!.\C@?
*!9+6ENVX+,1 (;9S@=1@:\8(;.?82+9 MYF)V^ ,QJ&DJ5KL@W% #@9PN|[@.A.DA-J56N36[A7VGC1D5L[6+LMQONAD56 M.(66"UW=F>&2O,11'=DJV($ M-
>8LK5KX7L[_^_7N2;K>8Y7IMFG53?'U$0,[5%K.8_)"+J;0!P9F ,L%+I7: M'%#*1G62&=RDTX*69#8)C+8=U/%/,8IU4_L\T;\I8;8;!4[*6F- M_Y;.HR Z#(. _/7LG:CX$:B,>
(8V."@1\#JDQM]B;=A_3W0A3(0=]2[S YF" M3.IZ]^)C/A]FOU>\Y/7ZQ&Q,>>P$QP;594U.+.#O*1.TW&[@6* 'O]XG!Q, MY11.,^=_J-?)N_%U[KL4I=Y&UUZV"25_2S.I[[!V I4U9_G]\SR'E:APY3!>
M0*6O5RV1>?C=;=A:& M8M^9H+,,%?L.V*LC_2#]KDE;ZB8<\&/#ES8N'$[M%.0*?#BIP:*, Y?.,6}%Z M3E!X Q/{\.C'?/,Y W],$*R=*0A. GOVS_4!,=6YM"LC/NHCM9D+/,*4400% M87BE.
(!5U<(4=L!VEW# .S#V96EK^<7L5II=EX"R4FR0BR49/T8R);FTO[#GE MW42>$QD7<@=`02R"!R&"" OL.!5A/=_5HTJS!>BJ24>+^RC$\:1@_LO5GY& MNH]BG1""B4@P071MJ%.E>
(_%WM"1=I5NB_I749G0>I_52AE8A$JE*TW_"IRG M+A_"JD,%ZD' 3XV:[.\ZJQQT2E%9#??SE]NNU)2_3QZ+T;3(VG<-MZB3!^0 M(H^54!JLBAN/_,@)\8&5RS!R
E02VFQY"WZH%;A\AYQ$VZ9HQ"Z^B7 209Q MJ/%"T[QAE.00>N]++=0<3:.Y&'&TO6\7"MQD$1L['8=27R78IWEUKF-S.#VJ7\ M6VN&VED4YF!(YJPS^Z G.X(EK9B3S4*.R]#1K]=@5%;;G
MR!A2:L8N45B7:"SZHBLR3]^A04!M.(V&NOTGGN7K.O;NFS]GB_[\]) ,;DX M;,\R0FL9;^$F9\?JA,I>;61PX'QD8.AEZIT6!2^926 APF4.K\E"+SN;3H8_ M?
2;%Y0LY+B=$W!KHXEQM(NNW\$T(7FB5\[V)W= O3DX^CIWG]375;D=# MVO*(&J1&'TE3&XDJ9WW!D1;5Y?X',A+U@0R/QTN3BV.L:.H/G_G.+I7?]0O MVA#,BCT\9554TL5EJF;R$6
Z'@U$9+ANH(L*.\/@!*)EB'T-W^C77A: RPT3 MOAA9@8U\<1;I(%Z"3T=._\(K_B>1(%Q](#=2IQ?J:AOS.N6]Z[]R%O_B]72C+ M4V\O*RE'0WU\#Y/I,.TZ%>\370I:%N@9,R@$FI\H92%W0A T%5FY'_S
MG62R@./%KRY]]7:E1=IU4JK7RI5:JU+&3ZWZ3;5<;,,?5]5:L5:J%F](JPU? MW%9J[=,)WW>UXEVY"K^_BY3J?RUR0AN[P5>^*.& M3QQCR*1C5LOMLO'PZZ*O>"D:,OAX#0AZL+R
E1FI4@M(DON@FE73/EH&M\"# M;$E/ID8;,+A4L#\;ZD4CGD,POG!NURV,[S]=?6FI!*W[_I/"G.S(9G,TS,#P+$OO!E&8>DAW%8B9!_30Q3[D8]!5!SJ$ D<4LE MM,B@>M3>&8?=E.Q?.+:H4K*4.
[DD>)O$WBU#*XH&5FWX34Z8&]B,KBR:\$# MZ+&FS_!TB3Y011NC$XM/NZ8C;3P!RF6J<_"4GB*KS!\YQ3LD#P:353_4BX M7P;#*U'(MD
>S;,KH1G,GRT,BCZ)!#+%/E2D!\A5P@B3V;@DN4G&9#5URO&L,'CT(S(0 M#R4,:0_45B2S!FZWA(958Y8'G#N@R-45]>J(@TP&!V%<(MH_<;JGCS](RTAX@<*WY%.N=DB>,QJ
31FBNVW17GEB,/@ 2ZD<21.$4"1O X M"T&4&),Q,(S-VPG>.0+2 &*@HCCV%'C"K<=N$P,K+'C/8T&TDS)W5GKC%QI MFC6597TR(5!!%/!>"RCI "TKL!%SF8_8G7&?{=2?TG(@H.M@I++I7\
<(F^'A"@_M309#4F8X9[_P'QA4S4>_8/9K3%D*##\[++#J/1OW,HP&W][\<'6S]RH7@P#>(_M.-U0-@ -;;C5%:#\ZE1X_K\.YS,)C/41V*,)+NY0"=X,:HXKOMWZ4Q]BI-M!!Z#{:.AS5F0
,\J>'';R,7MVC6>\B=#]GKWC&R)1 MD>D#7='7S+1T*>AL8})%>4!K=6*+\VSH)YSS5F>N"\8'HMX,,M\%8$_I/7PWF,!E&CS: AZZ!%B0H8U& M6!PGHB.%M(F^.#EN,LY.8!H1S/.)Z4#+HZ,?
HUUGLX W8S2%6>+9#982*# _/ MC7BI6>?0;04 =4MAX3YG-:XYAXK3+G,?,PY#?#'R>+WM8+1+(M$&?!JHSMW<^\?QB /#0-4SQ8F4WO,#ZT8@F7?NB<@90^U=4)P@@7&!@4&,A
M,#L>AH&=B .=,L$Z8?RK:3K_R(+AN'7%D2-F(8K&H8&J#"1@)N;$INY6O&V M5<20 J9=@9 .(RV/3 MJ66;,8{82.SOF Z =B/L=(Z,FP#N?+N&3IMM845J7!["U<&+/=Z#F8V 0^B MSAQBR\
(S1\#26I,Z.Y0@M,0:<]2&!B^*M1DJI\E"^ 20\R2",NES"-C!84 M0Z^IU3M8H0_,57(F%**? 34ML-C=.1?# HI?(8#A HQ0-UL&BU58FM_G 46 MF2H,&Q8XQZ@2 ";UB'@=X5G8;()SV0>?3NY"
<&F?8=I!DWT+>[/@'XR!I[?6?#7PLP+9MZG884[M*!6ZF-F#!XL/,IR321+^[$F(9@:CN,YV:^D02 M ,Y] =\:GT,'KIF_4;0EDJ2'.9-*AK&+B?:,K>@J M\"">@6DF=A7;9]+4IO#(H@2^
\K0M6:,97/9V-IA/$L%8RZ4<0IE64:_U?$C M3IC*$(;!)!D%QX6TNMHSKLS,*5@ABO_B09+%JP>VP5>L86]<;#*&8W3O>1UK,Z]I3;@&0OH>0,*.G-U#VI$> MH(_M3!7
6)02QICV0.Q'ZZ,N,I0'0T#&0)GV-&/*'&*F6R&J[FK#J<2Z<_8T MZ_OUX9GE%Z&GI* K/W5%:@X)3-F IE:4! MTSD)P40<"W*IU*=&Y,F,,9+$ MW3F^CX$:O%,0W!/V+G<.PDZ>.>&C]7
KFRO1OLS\MJDU-#;RZ^1?#KQ@U-.F M,"1*#+X5"%M?%++RTSE]0[^UT:W]^-9 [[H@L9$25A+C M$+*&++|S+(K=7U,ZTG\5=EXGV1M9A\)SO.D6_M<[/ (C6{\)BZ_#?UXI(?
D2XNSEP=9=SS>B87[B3J8 MJ-/9<\L4_J;.7]_P2,U69E]P2SW6'MR4F@'4ZV*DN9O1/F!X" M[63MS&.VW6Q*X/IFEF&3@3#9G)CT+20+ZG:XP>=8Y4G2@=XS5;2>GJ0#G'9
M&:DXF1I[5IQPV6*G*_ZWDQTG5DJ8=5! H<-?)C>[4NG_QK MIJU6J&"."$E#!6$#M.(,1P(Y4RWTP7""ULU"V,"@0A.'Y-YG\6?HO&Y?5>4X@ M98V[+^N@8^UG6GB,Y3&0 NNU@K-
R3P)N$+1/,BS<@BVI $K3 T4Y1DI3V9I M#>8TNM"XDGH%*,[25ZZ@GF4Q $TCF540G+A(A1MQ3&?D6GM$A'+L7E 9<[#-_M4\]8#VA-
!^3+E8\'DB&,'7LL7SBC;,:4P9(&]O(NF!"6QZ28!*>LU,7NWH$' M2S"66<>P.>/J._F'B<-NP4569R<>=09T%+4SM M2YD[KF*R M5 ^KCM2G5LF1BYQ'65%
<*ZRLM@Z7*)GJL7/HB[G,QB#MK[3=5&._+8H-CL!WGBTL@ ;(%(I*P#;_^3/?, MZ"XA0&#LG5-GO\L!-)I+=T]?GS;49W#&V2YG$*W2:K$)>@B9$#V,!0=V&*#(M?
XW+X\/@/P/#W)D/^H,@M5*L*<["HH I:J\4,HH_9, MHD]2X8%$VG,,#^16/C8.A4MR)GKFDK %M5?H=28-!@)SM$;M?)9<[C2^1;,K MQXP8>R8A=CG[T0C/%;]
*!3D0PN=&_>*L]26>$;@984IC)1&]9WSW1UC,V4[EW#++!9YR(G! 1D?L\ M5<8]HK2H"[+#O2_^")WP>4+^UNAWZS)-AFXB!.J ,4S.]1H+"#;5):RS96A M#PCCJ$1C4C3AR(#\N%#6:=*MM6-
P713^&;"DL@*>>38J;N7A+O[MQ^(M'MK1 M>Q91A,E*&<4;Q/ FX_9TR:!1F;,U43;C\ %$^S"URI:.XM>6[/P,2M"7B@QI MY#29'KC%6VA)&,\T0,P,M*?0)6NC%%
<\\5K21*K0:UUD6[\W0&R=*2\.C)-\' MCP^2UK>YB>Q#7H.?.RRIDYT)QDO)E2=DQW7)80G>LP+GX&7]LI'E=S5XPVAX M7.#!WV#2%K5TX/9'VY>9_'S7"?N1$:EQZ'(YD.?$6JE*0\^FFX7(8C-
XE.P8 MV0"0[SX8(+(55\N9KP-RB9AQ3$F C4G,>K,)((?DJ_=#QK'-2\[R#,^4*O M ;"[W/2?;P*6JE,V1D6R'VWDI$7U\(@GUA23S,A=RE1)3?Z@@Y\,9'0KM MB>UP;=Y'T*OQP\+A,#'&5&
(GC\H>Q/C%\6]>=QY:A7.+K(;7LSK>+#8B06 M!H_ME]M>KK! #==.5:CUB!SSP!K/5$,)5I0_H=?=A%YK;Q=Z+3TL)M5?P^OJ M9:5YH;ZCT"L12+KR:_'KU[!Y+^^>\W<1>A5HJ1Y->
[=5)4S[@YLVXV2&/GJR M1)E#@YC!S)2XNSH^>2J^TB^B$I EU7G2J3,O(P7C+4'GZ,L(\.^;DQU@^ED MJ+6/!2X(XKUTQNB\QA=I'-7+?JQ/;4E/X, M5NLM$)=H"13Z0P:!%_9?
&$@(>47BE0U.J:>=2 M]O69QD)EBI]F:.#&)BVBCZEC3$B&4+4A#2QA,)OT:.051W"^,)1'A7T#ZA68 MBQA(-5Q#4+)Y5B7F#9D:*NBDNG\62S+L>F=;+W],MCVR6P,[FBR:G:$[.4, M3MT9;,MZ?
A"$[86"L&U?V8]Y> 6?6AW,&ON.Q37"CTFQ"YMI&EPG+V22;]YNH M$(ZUY';!0S1&96U+R/U,#A6V6($4> ^]QXP'U)A?]"> =%E<83XI%$Y9#ID6)ULH5@2G%I2)*:}3,A6!WF6NI
!@,L/E*X*XNG"%!DCQ8@ M\U>XXGQ^&<+#]'BC;%.,"TC6"D)U$TK^ MX8=$9$')&9;H#C2)"QS8,4+XDR=A(*D:MO+@ ?$7"3V9 [P8;TJT M:518J70G ^H0]F?UP&QJ2)M$,W8^)4S&ZX%9&V=2
+!5<;RB] '8N\?S4U"\Q,?T)>H:4]9 MU-D_+,^GBYC;IS.;@$(*&3B2"0 .GK.AL[4(76CV93V8(95+*(%8*AG\ =W M+769OR*[D>]HC7/" \[H$Z2O N8&72Z5O M]Y=_X17D4N5XH)+&$BFD
.P"6[.KXLU++[!G-G4XFS?A.4RT!(,0B?I)/QL[M>9VEOMN'_P&D ZIH'E63C/E MA^Y15E4 /WMY>3F4:*("*YD\)/=O6]>5\L%\'MJF94U$!@NTL0RX8U4LE6&A M\99DRM0)OLE%4:%S2>YTF-
%3FEC%S[$X(.!SR-W]C7-C9O+R-KU/< 3=%IZI3R8S M0A[7"JU+G @GNC$F:SOX;D=@$!RH8+AC1HY/*4"8OB'16.W:;I@H/EK?AP;"? MS;6"-<[8G:9#E$H+H;KF$?A?Q8+3*&O9DP\+L]48&-:D-
:UORT_IQ?PJUQX6 M4O \N&-GW_=2)^^7C=OF]>=IM#IMAO?A<[5Q7DW732OM\U,YJE.Q:RKO'[MJK(D'R):S=/K&$]MI&M$-IH #&S-\?YT(=!Q5RN\/# _BH^+&[O3\A4U5]W M\]
(GHD]9L#*V*)+)CQLPQ?$&[A@#!=kF#_5?01:MZ/8Y=@TI^^B@>$B\EX M"6838"#'$(P&!{)N"9K)V6"3XF8H0B#@[6QM(L9V).NF^=0 &!5&;!E:9I(M>/V[?NP>PG-
EX0N(Y<6#1W02;$4\%W_G; MJ0X)+[:K6PU^.KA4? D:#.0=F)F-5L2$G VFQ['WD?%GUHC8.@M%]JZ!!J2H M%N.GL+P;9!X?HB>#BVI2JNF:35,/URBQ?G&2/ ML!0=._KER1'-
\TE;+YRW3ESHU_2%G[Z6VL9D,A3+T&F2,#JPGE6:*$[^' 'Z M&\VQ,8*,#E>L2BQ?*P,EZWH?JZ)1):M/#543Z(U9(/2DV42*Q@J16Y2RI3%< MV][)T-=+#INEIY,^IV>+Y][7):%)(N]:SU?
E7J]^G5_JYO#5 ;>,O4(PLEJ^ MKER>E4HOQ8VC?AM,I,"P.+(N1,[KO'+^K93"1 :/:!*1&Q%],#PLAD=/M449Y MM#@[6QM(L9V).NF^=0 &!5&;!E:9I(M>/V[?NP>PG-
P+-EX0N(Y<6#1W02;$4\%W_G; MJ0X)+[:K6PU^.KA4? D:#.0=F)F-5L2$G VFQ['WD?%GUHC8.@M%]JZ!!J2H M%N.GL+P;9!X?HB>#BVI2JNF:35,/URBQ?G&2/ ML!0=._KER1'-
\TE;+YRW3ESHU_2%G[Z6VL9D,A3+T&F2,#JPGE6:*$[^' 'Z M&\VQ,8*,#E>L2BQ?*P,EZWH?JZ)1):M/#543Z(U9(/2DV42*Q@J16Y2RI3%< MV][)T-=+#INEIY,^IV>+Y][7):%)(N]:SU?
E7J]^G5_JYO#5 ;>,O4(PLEJ^ MKER>E4HOQ8VC?AM,I,"P.+(N1,[KO'+^K93"1 :/:!*1&Q%],#PLAD=/M449Y MM#@[6QM(L9V).NF^=0 &!5&;!E:9I(M>/V[?NP>PG-

C2L^/(VX;MBR^A_M+ M077HZ!!*2A>WOYZNGKHM<5B.N*]X@B*GJ^71F)@=VI+(B5B>E]#R:Y? BMEJ ML9@MQ@1F4C$-]M/\<%SYM')(0"++9I,%S+,,+BF84PF_CG63.I%PBKO$'W!U M5K5GE7'/BNJ/J&5B)JX#*B0)$9!]#JR?Z,8,%#Z?[$1/ W!P\/2K5,5]J8LG-M@.$>,&,/Z(?1?\(?@#@CW4U=\& P2*;KWWLNX);3:OE/:_L-!MVVPZ=5?1Q MC/IW4G]IXYM>.RUOZ=G=$)X33BD%?!C,TOK44#4!0/"I?@LU;[07"V&H8\1W MTPV3FCO/ %7I1*B40=FB?$'$+6=&%"4F*]T(A[GE_^&**MY$@/M(${]20{BY3.A>,PA/7 5YDL:)[!P47F+/ MSH.GI."/(3/ 4@=#@H2W,$)B6C4$Q/V0$@<1,$NL_P 7!(B#/XE'I;RPE6#9 M'Q=7@C^CB4N4X&G*NZ?9@,>[K$-="F$:%5P]M9G:.MK6"T?.,3 $85 DR M8#BQB 'J#:7@SO?LRN+_IJT@W+O\<-*Z2V8;.S^OAU=EN_&27=L*/WN&'% MM#;LI'MT-[\%F]W?*9$;%@\'L*,M6PUTSB^Z.(A [&[XS*[-:@;?\Z[E-]BU MS?*SWO.N%3;8MD=]'M[1A?#)+05 /X.F:\YD M7&XL2C&G&ICE%$M8:%%0(=IY)8^/0 44/'K&WG*RY9X4B MG!.C@AH14!F-^-^2IK$&H&@SY9V4?L.Q.% ##2C9M(96C3A MSO[,Z1%8$ TY>+1%"?NLE+6GK++!L>J 6?;9/C/!R? ,N8"? M)3/C I7W4.X7!V$/JT7 9B/\2U;#U9!23. .\8<%DAE]*!GAT_""Z>=*9D3 M[0&*$I80S ?@Y8<1Z6;OWY'CQ[0]B,,\C@,{)M2L)m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ŞV M<*@F# BO. I*P7%^D<8?:G+W33D#V0^F\VMCR/%'\P:R15 #CB)XZ6R^0'0 MQ5(V5UCNG]OLA$,%F1AC@=@2K&N+,,L68>?!:OVO34J/3^N(<+2\5{'Z%)O M[)G<@}\PRLI<7235=B:2WIM#>7^.+2AH*BEX>),*FO?AX=ŸVAZ<2\!@/3T# MSJ%NF H MS0<]."#T(=F@JG;I&$:.\%F= :5..! .1RKE.,NTOA<0<**Z{;0<0C MI^[-K).SI6E?[4$X>A+6 !_- ?MG8[=9(;3F9H=S?EA(';UX7OA1^?79;BG7# M!;G=]K_!MTC!,1+?8Z=<_F$Q/KX? 3R9'C\=3M221.N:5\O;YSKOD04DJ_J)H3 MXUO_Y]GM<"=>NCJ\NF!/HD G,1D\M=NF^/*$L_8LWJWGRI:2[{}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{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

(*.CF\-PNQ0?2;*EKPKICO!N]/D1% @BSSH2& MK&%][:=[:)[3933YV MXF9_SF;) 2EE8F]CP?[(;F32F)C_.@0I0?9Z&B1J82:Q3<]\/%T]J5*4)RI! M)RC^#DBV^)PI*2FU$*.!D"0L!MZ $M@$^\>4-
Y7($2SHXXM@B\0HK:.Y[H# M?$:.O*&4CKV!+"!8],(<,06(J.V#H>U.3)-9PP[88QH$.C^KJI).YR4LOB<6 M-\;$PY8;Y"T%)5>(OV0J[L}^3/M!!+%GA(!TS[0-OMFSO.4#'/&^HX% HOJ M)K#X#H!%%=1-87*N+U$80,D'<"TJ"#$J"J$5(8RTFE320 GDE6U3C7)$U*=*3I(V)UHAM2A"^P?)] M4YP4K\5PS#&5MH6"4DJG8J^G34EPM2D!X*%U0TD4.KU Y(\XIE),T9,^JWDE ME<_,4*0%JX6X!$UKEXSG&:TL[}$/$KKI1GB%&33V6G5PEVBOHXIDN***("%X;G@)XW_E)TI\7S%#!>XU(4B&B[4U=C1*#3T *B(M A>.(WTNEA0UEYZGLL?,)P]6K4648K$$ ML3T,"$JL\6WV#<_2OWS+?(0!J)I@ -TY6D9)Z![!AV;W.X0$Y*FC$@0KH%, M]$ S4C#%N1A8NX:%*62MW!WN]_E+]97.:UDB9X'KA&_C_O!,E!B<3^N\(4-_MR"K0TE!_<=RT0Y6,4TMCT1, M$7:F4MNY(G @.M#LI#@1B+],%H>L#FCKK%=[_)W$&-CJ!LC&$FG/*?D8U5+2 M[!=>4K84TX,^>TFEQ<9Y8DGEV)*2.P]K.KL@\Q=8D<(26Q,*8R.79)}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}.GVL1/J6CJ,?]3#O M'(*+KO<=N//(7+H_8.Y{7O\ ,SR3Q^+)Z4T\^1WBR>E-/"F5+U0BH]NG]0U< M/(EYP[)8"A$,B7@:8%= 6M B=IGA$ A4+P4[/&++F7/.:%1R*6+H'W_^&J#8 M=N_(#B\J /2%"3PO*.?"SPP3.9!@V(0X@-,6AJ,V!*L8^E!? /GI_,"3++! MUD,!SLK$=%NS!}JU+Q9YX>%\F@BJ7K!LY>(ZK$#\VI9\1*Z^96F\1% M]!3BG8AEKB"&P7+H\7:?5 *C*2.(4Q:2IV^,Z\;"_,61T/QAUJ.@V;)B3(21 M0W4,!DNPGIA5>}&%H\PP*WU31.Y*JVV69YL?YNKA9$^!/(KCU"/8I44W.,@ ME^-P2H?,4'9,#LD8CY3\/VTP_%.JN-O85NACI/XV>)T/6(4AU%@;=8JEUI)5 M:Y]*4TL4K0Y/WQ>Q8\$>'&V1Y{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}S%.4^3;15.$>M&#Z(Y!XA*CLWF*78/1,!H4(@;,:2%.]\}#NVB3AL_#Y 9.5/##RG1H(AE& M. &FI08?/7,8SN/H_Y!:,;++6F]@3E+;&GDC"_FE",;+IK"(@(ZLYWZ@$X\4B?.D M:#R-X3,=*9& AL#:(17D? PZY*2:(BW ACD?0T1:1$,7Z[YTB#/H40TS6B04 @WXON<5]_:VR/)O@NE Y(HZP&\J&Y5A)+67D+1>GU(U?$>N?) O)4LL"2C/'Y M++^9S>\W7/"LAC7-_Z,TRT*8SQZ1WS4 +K0[!73/0HA&D=\Q FQYGSM:\>@::_M',] D]XO TT6,]"DA RT]8WGK_OX"X0),YLPX3N$"3.;,,$Z7:#72!6R[40) MR# 8.=!MZ&\FQJ 4)I,RKPGG]R!/-
D&'W9;_(I?,"3=^7A0(#+!U1SD3*"[M1T\5IV!N4KI"04H'@ Y&O3/L$B5B"NWRQ(C76>GQ1/RO"1D\M#1' /M+)W2#-A/[)&(CE/4(//RA;8TPKY=F M_=[_TP2M@65K7AAK%IU0U,/GZ\0PI3N,&=W\}42*PGZ^XHE\W;OT2"#R5'NP M!O(!^6H(P3_Y2YB]3#YG[L^OB@0UP+0_%@(,/NAV@ T'IM/"$RQ<\2JA(3W4 M+_ ABP'M9[0XSV_;N2<-=@G26\.&3&A&"*XD(8<=(6B8BO#KA_.?>WT?J2^1EEM?(B]>7I)7(U9D(LU>T'}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{C.253S-)Z8P<+-^@OD_;!D ?A.#;,$A)"W M-!ORCN<.$,&X;BA4RBF^ JHL#@2I# Q;D:B0;%&=IASA3"6H? W(RW8P*0}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{::MN*A M)@E@:?7* 3LF'X(_TUO'G4;YV1]9BAE:G(OW+(X,]:R%+B;(N M9779K. MVW!MEW@F1!DX(XNF&R0>6P]@QS\L ?HQ_S_ VB&Y5@[JE!M8#I(V7$@.$'9$W3[?8:5BBS; M GE&)0RAT>[8U.Z0:UM"M,VA?CFX==AW69#3D0G$8DH2]G"A"<",PQL!S5*F M^LZ4^V+B$Q/&WY9;5.O1P?NA0:RQ],P0HG ?
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
(*$\0\A@*2QOGB8F!3FWTQH9&I"-M[_C4CY5G"L+UW_"AHX%LESRFRR7=\ARR6^R7-,K(L4#49DP$'56;K;E6FU; M,K0/B?BKU?<;S=-RN]:HKQ'WF)E?-AYH4[?ED^H!D>D8?*KN$:&^M!#;&]67 M37=W5<(B*TA&@EZ]6@_:8H*!Q?/WT4E(T2Z@OP3HIIW MYCAB1#=.N9G,)@=M[,,V8NTMMZ'XFFWT>%)6XP(BJYZ;-W MN[H>>_JK2?%!LZ9E8H8V(#R7 "R.5(MV /JDIE(+#*G1U$#V!G:DB.RK%B!"C-X>_KZ_)QCVM2JPL+LY!EH9$O MRP2"MNL8X)G0NA7P 5"]$$<#5X(){C#:"X6U(R!?K]66S?"JW!2O*F]C3HF\ M7ZZT&\TUXU,"Y7+KXO2TW+Q>H[V9\XY=$_ST%F;(8(QE$D,9H@@OK47"0R^Q W-B74

aemd:AccruedSeparationExpensesMember 2024-06-30 0000882291 aemd:AccruedSeparationExpensesMember 2024-03-31 0000882291 aemd:StockBasedCompensationMember 2024-04-01 2024-06-30 0000882291 aemd:StockBasedCompensationMember 2023-04-01 2023-06-30 0000882291 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0000882291 us-gaap:StockOptionMember 2024-04-01 2024-06-30 0000882291 us-gaap:StockOptionMember 2024-06-30 0000882291 us-gaap:OptionMember 2024-03-31 0000882291 us-gaap:OptionMember 2024-04-01 2024-06-30 0000882291 us-gaap:OptionMember 2024-06-30 0000882291 us-gaap:OptionMember aemd:ExercisePrice1Member 2024-06-30 0000882291 us-gaap:OptionMember aemd:ExercisePrice1Member 2024-04-01 2024-06-30 0000882291 us-gaap:OptionMember aemd:ExercisePrice2Member 2024-06-30 0000882291 us-gaap:OptionMember aemd:ExercisePrice2Member 2024-04-01 2024-06-30 0000882291 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0000882291 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0000882291 us-gaap:OptionMember 2023-04-01 2023-06-30 0000882291 us-gaap:WarrantMember 2024-03-31 0000882291 us-gaap:WarrantMember 2024-04-01 2024-06-30 0000882291 us-gaap:WarrantMember 2024-06-30 0000882291 aemd:OfficeAndLaboratorySpaceMember 2024-04-01 2024-06-30 0000882291 aemd:ManufacturingSpaceMember 2024-04-01 2024-06-30 0000882291 aemd:ManufacturingSpaceMember 2024-06-30 0000882291 aemd:OfficeLabAndManufacturingLeasesMember 2024-06-30 0000882291 aemd:OfficeAndLaboratorySpaceMember 2024-06-30 0000882291 aemd:RestrictedCashMember 2024-06-30 iso4217:USD shares iso4217:USD shares pure false --03-31 2025 Q1 0000882291 10-Q true 2024-06-30 false 001-37487 Aethlon Medical, Inc. NV 13-3632859 11555 SORRENTO VALLEY ROAD SUITE 203 SAN DIEGO CA 92121 619 941-0360 COMMON STOCK, $0.001 PAR VALUE AEMD NASDAQ Yes Yes Non-accelerated Filer true false false 13937327 9072379 5441978 0 277827 478058 505983 9550437 6225788 929306 1015229 813900 883054 963 1100 87506 87506 33305 33305 11415417 8245982 1068134 777862 732518 546434 296093 290565 32203 215038 2128948 1829899 573852 649751 2702801 2479650 0.001 0.001 60000000 60000000 13937327 13937327 2629725 2629725 13937 2629 165844620 160337371 -7773 -6940 -157138168 -154566728 8712616 5766332 11415417 8245982 614082 976638 1254802 1123239 751974 1308283 2620858 3408160 -2620858 -3408160 49418 125981 -2571440 -3282179 -2571440 -3282179 833 994 2572273 3283173 -0.34 -0.34 -1.35 -1.35 7457888 7457888 2431476 2431476 2629725 2629 160337371 -154566728 -6940 5766332 8100000 8100 3531807 3539907 3180000 3180 1841220 1844400 27602 28 -5106 -5078 139328 139328 -2571440 -2571440 833 833 13937327 13937 165844620 -157138168 -7733 8712616 2299259 2299 157426606 -142358555 -6141 15064209 177891 178 1085941 1086119 6397 7 -8379 -8372 250114 250114 -3282179 -3282179 994 994 2483547 2484 158754282 -145640734 -7135 13108897 -2571440 -3282179 86060 90325 139328 250114 1217 -1238 -89872 -146409 323776 334613 0 0 186084 -22907 -1747537 -2482387 -0 230383 0 -230383 3539907 1086119 1844400 0 5078 8372 5379229 1077747 -1290 -186 3630402 -1635209 5529483 14620449 9159885 12985240 28 64 9072379 12897734 87506 87506 9159885 12985240 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION   Aethlon Medical, Inc., or Aethlon, the Company, we or us, is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients, the Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and metastasis, and in life-threatening infectious diseases. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a "Breakthrough Device" for two independent indications: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">· </td> <td style="text-align: justify">the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes or exosomal particles have been shown to participate in the development or severity of the disease; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">the treatment of life-threatening viruses that are not addressed with approved therapies.</td></tr> </table>   We believe the Hemopurifier may be a substantial advancement in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove harmful exosomes and exosomal particles that promote the growth and spread of tumors. In October 2022, we formed a wholly-owned subsidiary in Australia to initially conduct oncology-related clinical research, then seek regulatory approval and commercialize our Hemopurifier in Australia. We are currently working with our contract research organization, or CRO, on preparations to conduct a clinical trial in Australia in patients with solid tumors, including head and neck cancer, and gastrointestinal cancers.   In January 2023, we entered into an agreement with North American Science Associates, LLC, or NAMSA, a world leading medical technology CRO offering global end-to-end development services, to oversee our planned clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA agreed to manage our planned clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors.   We recently completed an in vitro binding study of relevant oncology targets, to provide pre-clinical evidence to support our trial design and translational endpoints. Our study indicated positive results, providing evidence that our Hemopurifier removes extracellular vesicles, or EVs, from plasma. This translational study provides pre-clinical evidence to support our planned phase 1 safety, feasibility and dose-finding clinical trials of our Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. In addition to an interested initial trial site in India, we had three interested sites in Australia that were awaiting our completion of this in vitro binding study. We added the data from this study to our Clinical Investigator Brochure and submitted that brochure to the Ethics Committee of Royal Adelaide Hospital in Australia and in June 2024, we received approval for our proposed phase 1 oncology trial from the Ethics Committee from Royal Adelaide Hospital. We are currently in the process of applying to the Ethics Committees of the two additional interested clinical trial sites in Australia and the site in India.   We also believe that the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.   Additionally, in vitro, the Hemopurifier has been demonstrated to capture H5N1 bird flu virus, H1N1 swine flu virus, Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, Monkeypox virus and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research institutes.   On June 17, 2020, the FDA approved a supplement to our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19, or COVID-19, in a new feasibility study. That study was designed to enroll up to 40 subjects at up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19, be admitted to an ICU and have acute lung injury and/or severe or life-threatening disease, among other criteria. Endpoints for this study, in addition to safety, included reduction in circulating virus, as well as clinical outcomes (NCT # 04595903). In January 2021, the Hemopurifier was used to treat a viremic patient, under our emergency use approval, with a predicted risk of mortality of 80% and the Hemopurifier was able to reduce the patient's SARS-CoV-2 plasma viral load by 58.4%. In June 2022, the first patient in this study was enrolled and completed the Hemopurifier treatment phase of the protocol. Due to the lack of COVID-19 patients in the ICUs of our trial sites, we terminated this study in 2022. However, our IDE for this indication remains open, as we have an active COVID-19 trial in India and wish to preserve the option of enrolling patients if the situation with COVID-19 changes.   Under Single Patient Emergency Use regulations, Aethlon has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated with our Hemopurifier in our COVID-19 clinical trial discussed above.   In October 2022, we launched a wholly owned subsidiary in Australia, formed to conduct clinical research, seek regulatory approval and commercialize our Hemopurifier in that country. The subsidiary will initially focus on the planned oncology trials in Australia.   In August 2024, the Bellberry Human Research Ethics Committee granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia.   In June 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for the same safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia.   We also obtained ethics review board, or ERB, approval from and entered into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi NCR, India, for a COVID-19 clinical trial at that location.   In May 2023, we received ERB approval from the MAMC, for a second site for our clinical trial in India to treat severe COVID-19. MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government.   We now have two sites in India for this trial with the Medanta Medicity Hospital and Maulana Azad Medical College, or MAMC. One patient has been treated to date; however, we have been informed by our CRO that a new COVID-19 subvariant was detected in India recently. Our COVID-19 trial in India remains open in the event that there are COVID-19 admissions to the ICUs at our sites in India.   Additionally, based on preclinical data with acellular kidney perfusates, we believe that the Hemopurifier has potential applications in organ transplantation. We are investigating whether the Hemopurifier, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses, exosomes, RNA molecules, cytokines, chemokines and other inflammatory molecules from recovered organs. We initially are focused on recovered kidneys from deceased donors. We have previously demonstrated the removal of multiple viruses and exosomes and exosomal particles from buffer solutions, in vitro, utilizing a scaled-down version of our Hemopurifier and believe this process could reduce transplantation complications by improving graft function, reducing graft rejection, maintaining or improving organ viability prior to transplantation, and potentially reducing the number of kidneys rejected for transplant.   Successful outcomes of human trials will also be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.   In addition to the foregoing, we are monitoring closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and the surrounding areas, as well as related political and economic responses and counter-responses by various global factors on our business. Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing military conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical research will depend on future developments, as well as the economic impact on national and international markets that are highly uncertain.   We incorporated in Nevada on March 10, 1999. Our executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our website address is www.aethlonmedical.com.   Our common stock is listed on the Nasdaq Capital Market under the symbol "AEMD." <p

style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   During the three months ended June 30, 2024, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024.   REVERSE STOCK SPLIT   On October 4, 2023, we effected a 1-for-10 reverse stock split of our then outstanding shares of common stock. Accordingly, each 10 shares of outstanding common stock then held by our stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock remained at 60,000,000 shares following the stock split. The accompanying unaudited condensed consolidated financial statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred on April 1, 2023. All shares and per share amounts have been revised accordingly.   Basis of Presentation and Use of Estimates   Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended March 31, 2024, included in our Annual Report on Form 10-K filed with the SEC on June 27, 2024. The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements, taken as a whole, contain all adjustments that are of a normal recurring nature necessary to present fairly our operating results, cash flows, and financial position as of and for the period ended June 30, 2024. Estimates were made relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2024 has been derived from the audited consolidated balance sheet at March 31, 2024, contained in the above referenced 10-K. The results of operations for the three months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full year or any future interim periods.   Reclassifications   Certain prior year balances within the unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation, including the impact of the reverse stock split.   LIQUIDITY AND GOING CONCERN   Management expects existing cash as of June 30, 2024 to be sufficient to fund the Company's operations for at least twelve months from the issuance date of these condensed consolidated financial statements. In previous filings, we disclosed substantial doubt about our ability to continue as a going concern due to recurring losses and negative cash flows. We have addressed these concerns by raising $5,379,229, net, through the combination of an equity offering and warrant exercises, combined with our recent financial performance which has shown a significant decrease in expenses and use of cash. For the three-month period ended June 30, 2024, expenses decreased by approximately $787,000 compared to June 30, 2023, accompanied by an approximate $964,000 decrease in cash used in operating and investing activities. As a result of these actions, management believes that the substantial doubt regarding our ability to continue as a going concern has been alleviated.   The accompanying unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business.   Restricted Cash   To comply with the terms of our laboratory and office lease and our lease for our manufacturing space (see Note 10), we caused our bank to issue two standby letters of credit, or L/Cs, in the aggregate amount of $87,506 in favor of our landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs, we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit. We have classified that amount as restricted cash, a long-term asset, on our balance sheet.   REVERSE STOCK SPLIT   On October 4, 2023, we effected a 1-for-10 reverse stock split of our then outstanding shares of common stock. Accordingly, each 10 shares of outstanding common stock then held by our stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock remained at 60,000,000 shares following the stock split. The accompanying unaudited condensed consolidated financial statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred on April 1, 2023. All shares and per share amounts have been revised accordingly.   1-for-10 60000000 Basis of Presentation and Use of Estimates   Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended March 31, 2024, included in our Annual Report on Form 10-K filed with the SEC on June 27, 2024. The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements, taken as a whole, contain all adjustments that are of a normal recurring nature necessary to present fairly our operating results, cash flows, and financial position as of and for the period ended June 30, 2024. Estimates were made relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2024 has been derived from the audited consolidated balance sheet at March 31, 2024, contained in the above referenced 10-K. The results of operations for the three months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full year or any future interim periods.   Reclassifications   Certain prior year balances within the unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation, including the impact of the reverse stock split.   LIQUIDITY AND GOING CONCERN   Management expects existing cash as of June 30, 2024 to be sufficient to fund the Company's operations for at least twelve months from the issuance date of these condensed consolidated financial statements. In previous filings, we disclosed substantial doubt about our ability to continue as a going concern due to recurring losses and negative cash flows. We have addressed these concerns by raising $5,379,229, net, through the combination of an equity offering and warrant exercises, combined with our recent financial performance which has shown a significant decrease in expenses and use of cash. For the three-month period ended June 30, 2024, expenses decreased by approximately $787,000 compared to June 30, 2023, accompanied by an approximate $964,000 decrease in cash used in operating and investing activities. As a result of these actions, management believes that the substantial doubt regarding our ability to continue as a going concern has been alleviated.   The accompanying unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business.   5379229 787000 964000 Restricted Cash   To comply with the terms of our laboratory and office lease and our lease for our manufacturing space (see Note 10), we caused our bank to issue two standby letters of credit, or L/Cs, in the aggregate amount of $87,506 in favor of our landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs, we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit. We have classified that amount as restricted cash, a long-term asset, on our balance sheet.   87506 2. LOSS PER COMMON SHARE   Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded, as their effect would be antidilutive.   As of June 30, 2024 and 2023, an aggregate of 13,523,429 and 2,291,234 potential common shares, respectively, consisting of shares underlying outstanding stock options, warrants, and restricted stock units were excluded, as their inclusion would be antidilutive.   13523429 2291234 <p

id="xdx_807_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zxuNKWxAF4Zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. RESEARCH AND DEVELOPMENT EXPENSES   Our research and development costs are expensed as incurred. We incurred research and development expenses during the three-month periods ended June 30, 2024 and 2023, which are included in various operating expense line items in the accompanying condensed consolidated statements of operations. Our research and development expenses in those periods were as follows: <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_zUXcHvivgZe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of research and development expenses</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%">Three months ended</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630_zOSk4OfTG228" style="width: 13%; text-align: right" title="Research and development expense">414,658</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_c20230401__20230630_zEewrHagq6I3" style="width: 13%; text-align: right" title="Research and development expense">678,922</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_zUXcHvivgZe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of research and development expenses</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%">Three months ended</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_c20240401__20240630_zOSk4OfTG228" style="width: 13%; text-align: right" title="Research and development expense">414,658</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_c20230401__20230630_zEewrHagq6I3" style="width: 13%; text-align: right" title="Research and development expense">678,922</td><td style="width: 1%; text-align: left"> </td></tr> </table> 414658 678922 4. RECENT ACCOUNTING PRONOUNCEMENTS   In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" ("ASU 2023-07"). ASU 2023-07 intends to improve reportable segment disclosure requirements, enhance interim disclosure requirements and provide new segment disclosure requirements for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods with fiscal years beginning after December 15, 2024. ASU 2023-07 is to be adopted retrospectively to all prior periods presented. We are currently assessing the impact this guidance will have on our consolidated financial statements; however, we do not expect a material impact.   In December 2023, the FASB issued Accounting Standards Update 2023-09, Improvements to Income Tax Disclosures ("ASU 2023-09"), which requires enhanced annual disclosures for specific categories in the rate reconciliation and income taxes paid disaggregated by federal, state and foreign taxes. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. The Company is evaluating if the adoption of this new standard will have a material effect on our disclosures.   In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The adoption of ASU No. 2016-13 for smaller reporting companies that did not previously early adopt was January 1, 2023. The Company maintained US Treasury bills with maturities of less than three months and expects zero credit losses from these securities. As a result, the Company did not record an allowance for expected credit losses.   5. EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2024   2022 At The Market Offering Agreement with H.C. Wainwright & Co., LLC   On March 24, 2022, we entered into an At The Market Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, which established an at-the-market equity program pursuant to which we may offer and sell shares of our common stock from time to time, as set forth in the 2022 ATM Agreement.   The offering was registered under the Securities Act of 1933, as amended, or the Securities Act, pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-259909), as previously filed with the SEC and declared effective on October 21, 2021. We filed a prospectus supplement, dated March 24, 2022, with the SEC that provides for the sale of shares of our common stock having an aggregate offering price of up to $15,000,000, or the 2022 ATM Shares.   Under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares by any method permitted by law and deemed to be an "at the market offering" as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the 2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if the sales cannot be effected at or above the price designated by us from time to time.   We are not obligated to make any sales of the 2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate upon the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein.   The 2022 ATM Agreement contains customary representations, warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement.   During the three months ended June 30, 2024, we did <span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_do_c20240401__20240630__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_ztQONUbA2qt8" title="Proceeds from sale of equity">not raise proceeds under the 2022 ATM Agreement. During the three months ended June 30, 2023, we raised net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zoRz3zMemO7k" title="Proceeds from sale of equity">1,086,119, net of $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember__srt--CounterpartyNameAxis__custom--WainwrightMember_zlUhcY49DGJl" title="Payment of stock issuance costs">27,999 in commissions to Wainwright and $<span id="xdx_902_eus-gaap--PaymentsOfDebtIssuanceCosts_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_zN9OGcj0dq11" title="Payment of other stock issuance costs">5,846 in other offering expenses, through the sale of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--ATM2022AgreementMember_ztkIG8Rcd56a" title="Stock issued new, shares issued">177,890 shares of our common stock at an average price of $6.11 per share under the 2022 ATM Agreement.   May 2024 Public Offering   On May 17, 2024, we closed a public offering pursuant to which we sold an aggregate of: (i) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240516__20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJOmea5x40ok" title="Stock issued new, shares">2,450,000 shares of our common stock and accompanying Class A warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantsMember_z3xYU3QEDhfc" title="Warrants issued">2,450,000 shares of common stock and Class B warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantsMember_zi7HaDLkJ1Rh" title="Warrants issued">2,450,000 shares of common stock, at a combined public offering price of $0.58 per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PrefundedWarrantsMember_zlxq3n8rrlJ5" title="Warrants issued">5,650,000 shares of common stock and accompanying Class A warrants to purchase up to 5,650,000 shares of common stock and Class B warrants to purchase up to 5,650,000 shares of common stock, at a combined public offering price of $0.579 per pre-funded warrant and accompanying warrants, which is equal to the public offering price per share of common stock, and accompanying warrants less the $0.001 per share exercise price of each such pre-funded warrant.   All pre-funded warrants issued in the offering were exercised in the quarter ended June 30, 2024. The Class A and Class B warrants each have an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantsMember_zl62mJmB9MLl" title="Warrants exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantsMember_zb4jJ9ETdk6" title="Warrants exercise price">0.58 per share, are immediately exercisable, and, in the case of Class A warrants, will expire on <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantsMember_zA3V9ynWu8Ul" title="Warrants maturity date">May 17, 2029, and in the case of Class B warrants, will expire on <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantsMember_zM59hbt1Gf78" title="Warrants maturity date">May 19, 2025. The exercise price of the Class A and Class B warrants is also subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in such warrants.   Maxim Group LLC ("Maxim"), served as the exclusive placement agent in connection with the offering. We paid Maxim a cash fee of 6.5% of the aggregate gross proceeds raised at the closing of the offering, and reimbursement of certain expenses and legal fees in the amount of $<span

id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_c20240516__20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__srt--CounterpartyNameAxis__custom--PlacementAgentMember_zp74honoGJt2" title="Payment of offering costs">100,000. We also issued to designees of Maxim warrants to purchase up to an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_z8T5Ojy73fgh" title="Warrants issued">324,000 shares of common stock (the "Placement Agent Warrants"). The Placement Agent Warrants have an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zeVZ9m2dWoFf">0.58 per share and have substantially the same terms as the Class A warrants, except the Placement Agent Warrants are not subject to an exercise price reset, are non-exercisable until November 15, 2024, and will expire on <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zPbXOc2CTPM8" title="Warrants maturity date">May 15, 2029.   The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $<span id="xdx_902_ecustom--GrossProceedsFromIssuanceOrSaleOfEquity_dm_c20240516__20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember_zTYxuEm97nPb" title="Gross proceeds from sale of equity">4.7 million. Net proceeds, of the offering, after deducting the placement agent fees and expenses and other offering expenses payable by us, were are approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_dm_c20240516__20240517__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember_zcErkBPDwPfk" title="Proceeds from sale of equity">3.5 million. In June 2024, and holders of Class A and Class B warrants exercised <span id="xdx_900_ecustom--WarrantsExercisedShares_c20240601__20240630__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantsMember_zrkiRkiI6s63" title="Warrants exercised">300,000 shares and <span id="xdx_90A_ecustom--WarrantsExercisedShares_c20240601__20240630__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantsMember_z1HOzXYc3n9d" title="Warrants exercised">2,880,000 shares, respectively, for additional proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_c20240601__20240630__us-gaap--SecuritiesFinancingTransactionAxis__custom--May2024PublicOfferingMember__us-gaap--StatementClassOfStockAxis__custom--ClassAAndClassBWarrantsMember_zLVZkPkTN1g6" title="Proceeds from warrant exercises">1,844,400.   The shares of Common Stock, the Class A and Class B warrants, the pre-funded warrants and the Placement Agent Warrants described above and the underlying shares of Common Stock were offered pursuant to a Registration Statement on Form S-1, as amended (File No. 333-278188) (the "Registration Statement"), which was declared effective by the Securities and Exchange Commission (the "SEC") on May 15, 2024.   Restricted Stock Unit Grants   On April 16, 2024, our Board of Directors approved, pursuant to the terms of the Director Compensation Policy, the grant of the annual RSUs under the Director Compensation Policy to each of the four non-employee directors of the Company then serving on the Board of Directors. The Director Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs at the beginning of each fiscal year for current non-employee directors then serving on the Board of Directors, and for a grant of stock options or $75,000 worth of RSUs for a newly elected non-employee director, with each RSU priced at the average of the closing prices for the five trading days preceding and including the date of grant, or $1.52 per share for the RSUs granted in April 2024. As a result, in April 2024, the four eligible directors were each granted <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240401__20240630__srt--CounterpartyNameAxis__custom--Director1Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0Q7jqEtsvnk" title="RSU's granted"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240401__20240630__srt--CounterpartyNameAxis__custom--Director2Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOpLgWQuRLci" title="RSU's granted"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240401__20240630__srt--CounterpartyNameAxis__custom--Director3Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOuHAmxuVAUh" title="RSU's granted"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240401__20240630__srt--CounterpartyNameAxis__custom--Director4Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFTBWpMWuYWe" title="RSU's granted">32,894 RSUs under the Company's 2020 Equity Incentive Plan, as amended, or the 2020 Plan. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znfLKU50v3Sb" title="Terms of awards">The RSUs are subject to vesting in four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2024, September 30, 2024, December 31, 2024, and March 31, 2025, subject in each case to the director's Continuous Service (as defined in the 2020 Plan), through such dates. Vesting will automatically terminate upon the director's termination of Continuous Service prior to any vesting date.   During the three-months ended June 30, 2024, 27,602 shares were issued upon settlement of 37,779 RSUs.   15000000 0 1086119 27999 5846 177890 6.11 2450000 2450000 2450000 5650000 0.58 0.58 2029-05-17 2025-05-19 100000 324000 0.58 2029-05-15 4700000 3500000 300000 2880000 1844400 32894 32894 32894 32894 The RSUs are subject to vesting in four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2024, September 30, 2024, December 31, 2024, and March 31, 2025, subject in each case to the director's Continuous Service (as defined in the 2020 Plan), through such dates. Vesting will automatically terminate upon the director's termination of Continuous Service prior to any vesting date. 27602 37779 6. RELATED PARTY TRANSACTIONS   During the three months ended June 30, 2024, we accrued unpaid fees of $68,250 owed to our non-employee directors.   As a result of entering into a Separation Agreement effective July 1, 2024 with a former employee, we paid out accrued vacation of $9,688 in the three months ended June 30, 2024. That accrued vacation was previously recorded in the due to related parties account. In addition, pursuant to the terms of the Separation Agreement, we accrued $323,534 for salary and related expenses connected with the Separation Agreement. Accrued separation expenses includes a balance of approximately $186,000 owed to our former Chief Executive Officer, as stipulated in his Separation Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amounts due to related parties were comprised of the following items:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zO1sl5wm8Mdf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of amounts due to related parties</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30,
 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31,
 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left">Accrued Board fees</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_zoboxhtYvwod" style="width: 13%; text-align: right" title="Due to related parties">68,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_zbPR6QzNTrD6" style="width: 13%; text-align: right" title="Due to related parties">68,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued vacation to all employees</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_zjivm5JT9YL7" style="text-align: right" title="Due to related parties">154,816</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_zoe0Eeh1dMA7" style="text-align: right" title="Due to related parties">167,973</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Accrued separation expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedSeparationExpensesMember_zJhlNsTxK7Rb" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties">509,452</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedSeparationExpensesMember_z0augThqpHBf" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties">310,211</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total due to related parties</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240630_zO9Vpmv265lg" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">732,518</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240331_zaTgfzQ9JRx9" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">546,434</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   68250 9688 323534 186000 <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zO1sl5wm8Mdf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RELATED PARTY TRANSACTIONS (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of amounts due to related parties</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30,
 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31,
 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left">Accrued Board fees</td><td style="width: 1%"> </td> <td style="width: 1%; text-align:

left">$</td><td id="xdx_982_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_zoboxhtYvwod" style="width: 13%; text-align: right" title="Due to related parties">68,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_zbPR6QzNTrD6" style="width: 13%; text-align: right" title="Due to related parties">68,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued vacation to all employees</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_zjjvm5JT9YL7" style="text-align: right" title="Due to related parties">154,816</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_zoe0Eeh1dMA7" style="text-align: right" title="Due to related parties">167,973</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Accrued separation expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedSeparationExpensesMember_zJhlNsTxK7Rb" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties">509,452</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20240331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedSeparationExpensesMember_z0augThqpHBf" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties">310,211</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total due to related parties</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240630_zO9Vpmv265lg" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">732,518</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--DueToRelatedPartiesCurrent1_pp0p0_c20240331_zaTgfzQ9JRx9" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">546,434</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 68250 68250 154816 167973 509452 310211 732518 546434 7. OTHER CURRENT LIABILITIES   Other current liabilities were comprised of the following items: <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zC4pud8yQVFc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES (Details)"> <tr style="vertical-align: bottom"> <td> Schedule of other current liabilities</td><td> </td> <td colspan="2" id="xdx_498_20240630_zhvS3DyUEuqh" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_493_20240331_zHvfnJ4TzSY4" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">March 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzgCt_z7NRgL2myCze" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left; padding-bottom: 1pt">Accrued professional fees</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">32,203</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">215,038</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_iTI_pp0p0_mtOLCzgCt_zID3t9KNh5vj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,203</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">215,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zC4pud8yQVFc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of other current liabilities</td><td> </td> <td colspan="2" id="xdx_498_20240630_zhvS3DyUEuqh" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_493_20240331_zHvfnJ4TzSY4" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">March 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzgCt_z7NRgL2myCze" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left; padding-bottom: 1pt">Accrued professional fees</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">32,203</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">215,038</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_iTI_pp0p0_mtOLCzgCt_zID3t9KNh5vj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,203</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">215,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 32203 215038 32203 215038 8. STOCK COMPENSATION   The following tables summarize share-based compensation expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three month periods ended June 30, 2024 and 2023:   <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zaSo4I3Q7JV5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Stock compensation)"> <tr style="vertical-align: bottom"> <td>Schedule of share-based compensation expenses</td><td> </td> <td colspan="2" id="xdx_49E_20240401__20240630_z8snrJcXHVg" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20230401__20230630_znfkOOs1wXSg" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30,
 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30,
 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_z0tGa5u1Kbed" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left; padding-bottom: 1pt">Vesting of stock options and restricted stock units</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">139,328</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">250,114</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_z85vdCBpNxPf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,457,888</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,431,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per common share attributable to stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zS4vzUZcGTek" title="Basic loss per common share attributable to stock-based compensation expense"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_ztk40FgP0iQc" title="Diluted loss per common share attributable to stock-based compensation expense">(0.16</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   All of the stock-based compensation expense recorded during the three months ended June 30, 2024 and 2023, an aggregate of $139,328 and $250,114, respectively, is included in payroll and related expense in the accompanying condensed consolidated statements of operations. Stock-based compensation expense recorded during each of the three months ended June 30, 2024 and 2023 represented an impact on basic and diluted loss per common share of $(0.02) and $<span

id="xdx_904_ecustom--ChangeInEarningsPerShareDiluted_c20230401__20230630_zU21VJDTgdW8" title="Change in earnings per share, diluted">(0.16), respectively.   Stock Option Activity   We did not issue any stock options during the three months ended June 30, 2024 and 2023.   Stock options outstanding that have vested as of June 30, 2024 and stock options that are expected to vest subsequent to June 30, 2024 are as follows: <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zczONfjkzvKj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)"> <tr style="vertical-align: bottom"> <td>Schedule of stock options outstanding</td><td> </td><td colspan="2" style="text-align: right"> </td><td> </td><td> </td><td colspan="2" style="text-align: right"> </td><td> </td><td> </td><td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of
 Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Remaining
 Contractual
 Term in
 Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%">Vested</td><td style="width: 1%"> </td><td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzV64bOLT2I2" style="width: 13%; text-align: right" title="Number of shares vested">61,977</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zO3DkHjtw2e3" style="width: 13%; text-align: right" title="Weighted average exercise price vested">17.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">6.81</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expected to vest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsPKwXAgmC51" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares expected to vest">23,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQGfx0CuEpA8" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price expected to vest">14.60</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWNeim6L46ae" title="Weighted average remaining contractual term in years expected to vest">7.60</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBsDZrxE9hdj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares total">85,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   A summary of stock option activity during the three months ended June 30, 2024 is presented below: <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTOzUrKZS1El" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Option activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of
 Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zt6HFqEFhvrd" style="width: 13%; text-align: right" title="Stock options outstanding, beginning balance">86,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">6.90 - 25.20</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zfu44KSf0WCb" style="width: 13%; text-align: right" title="Weighted average exercise price outstanding, beginning balacne">22.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zR5yHgz6WKn5" style="text-align: right" title="Stock options, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zt51qTCKhdCi" style="text-align: right" title="Weighted average exercise price, granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z62PJ1VKKOki" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options, cancelled/expired">616</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">14.10-1,425.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zZtJ2ScoYRQ" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, cancelled/expired">206.34</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Outstanding June 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zcWPOFEnBpb5" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding, ending balance">85,850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">6.90 - 25.20</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z15XKKqyYh7g" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price outstanding, ending balance">16.60</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Exercisable, June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z1m01TquXFLA9" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options, exercisable">61,977</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">6.90 - 25.20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zQlDupLZ3CT1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable">17.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   There were <span id="xdx_90A_eus-gaap--

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJjZtYVSoAx2">no stock option grants during the three months ended June 30, 2024 and 2023. There were 131,576 RSUs granted during the three months June 30, 2024. The weighted average grant date fair value of RSUs granted during the three months ended June 30, 2024 was $1.52. There were no stock option exercises during the three months ended June 30, 2024 and 2023. On June 30, 2024, our outstanding stock options had no intrinsic value, since the closing share price on that date of $0.50 per share was below the exercise price of our outstanding stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below summarizes nonvested stock options as of June 30, 2024 and changes during the three months ended June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zI1NYH4XYgWd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Nonvested shares)"> <tr style="vertical-align: bottom"> <td>Schedule of non vested stock options</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left">Nonvested stock options at April 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240401__20240630_zzjQVhjMPThg" style="width: 13%; text-align: right" title="Nonvested shares outstanding, beginning balance">28,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240401__20240630_zifjpYwgqWZ6" style="width: 13%; text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, beginning balance">1.44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240401__20240630_zLjaQErs4KPi" style="text-align: right" title="Options vested">(4,700)</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20240401__20240630_z7MVejsdcARe" style="text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, vested">1.62</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_di0_c20240401__20240630_zVvTU46eYxAd" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Nonvested stock options at June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240401__20240630_zCcLKb37Uyvc" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested shares outstanding, ending balance">23,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The detail of the options outstanding and exercisable as of June 30, 2024 is as follows: <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zg0HAyGwUXW3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Options exercisable)"> <tr style="vertical-align: bottom"> <td colspan="2">Schedule of options outstanding and exercisable</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td>

OptionMember_z11Ny11jj5Gb" style="border-bottom: black 2.25pt double; text-align: right" title="Stock options outstanding">85,850</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zLBMK38UNIxa" style="border-bottom: black 2.25pt double; text-align: right" title="Stock options exercisable">61,977</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table>   We recorded stock-based compensation expense related to RSU issuances and to options granted totaling $139,328 and $250,114 for the three months ended June 30, 2024 and 2023, respectively. These expenses were recorded as stock compensation included in payroll and related expenses in the accompanying consolidated statement of operations for the three months ended June 30, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below summarizes restricted stock units as of June 30, 2024 and changes during the three months ended June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zYbOKfgyByv1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - RSU activity)"> <tr style="vertical-align: bottom"> <td>Schedule of restricted stock units restricted stock units</td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 84%">Nonvested RSUs at April 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8utMb1aC31l" style="width: 13%; text-align: right" title="RSUs nonvested">4,885</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaAYLbGFTSf8" style="text-align: right" title="RSU's granted">131,576</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhhi9rUpktt7" style="text-align: right" title="RSU's vested">(27,602</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_iN_di0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrcrrieYGibl" style="border-bottom: Black 1pt solid; text-align: right" title="Tax withholding payments, shares">(10,177</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Nonvested RSUs at June 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_d0_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyLlwskN5Vkb" style="border-bottom: Black 2.5pt double; text-align: right" title="RSUs nonvested">98,682</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our total stock-based compensation for the three months ended June 30, 2024 and 2023 included the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zKbarbGWXCfi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Stockbased compensation)"> <tr style="vertical-align: bottom"> <td>Schedule of stock-based compensation</td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left">Vesting of restricted stock units</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgAx8tSxRz2h" style="width: 13%; text-align: right" title="Stock based compensation">68,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUg4eN5yUKW8" style="width: 13%; text-align: right" title="Stock based compensation">37,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Vesting of stock options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zzMjMOl0uqq9" style="border-bottom: Black 1pt solid; text-align: right" title="Stock based compensation">70,578</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z4TyS6H40jT6" style="border-bottom: Black 1pt solid; text-align: right" title="Stock based compensation">212,614</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Stock-Based Compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630_zrxpsN9BXbNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation">139,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_z33dCcvfDiH5" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation">250,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   We review share-based compensation on a quarterly basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture adjustments for the three months ended June 30, 2024 was insignificant.   On June 30, 2024, our outstanding stock options had no intrinsic value since the closing price on that date of $0.50 per share was below the weighted average exercise price of our outstanding stock options.   At June 30, 2024, there was approximately $310,674 of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of 1.45 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zaSo4I3Q7JV5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Stock compensation)"> <tr style="vertical-align: bottom"> <td>Schedule of share-based compensation expenses</td><td> </td> <td colspan="2" id="xdx_49E_20240401__20240630_z8snrJcXHVg" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20230401__20230630_znfkOOs1wX5g" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30,
 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30,
 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue1_z0tGa5u1Kbed" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left; padding-bottom: 1pt">Vesting of stock options and restricted stock units</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">139,328</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">250,114</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_z85vdCBpNxPf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,457,888</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,431,476</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per common share attributable to stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--

EarningsPerShareDiluted_c20240401__20240630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_z1gY8fmE2G6d" title="Diluted loss per common share attributable to stock-based compensation expense">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.16</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 139328 250114 139328 250114 7457888 7457888 2431476 2431476 -0.10 -0.10 -0.16 -0.16 139328 250114 -0.02 -0.02 -0.16 -0.16 0 0 <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zczONfjkzvKj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure – STOCK COMPENSATION (Details – Options vested and expected to vest)"> <tr style="vertical-align: bottom"> <td>Schedule of stock options outstanding</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of
 Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Remaining
 Contractual
 Term in
 Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%">Vested</td><td style="width: 1%"> </td><td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzV64bOLT2I2" style="width: 13%; text-align: right" title="Number of shares vested">61,977</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQ3DkHjtw2e3" style="width: 13%; text-align: right" title="Weighted average exercise price vested">17.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">6.81</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expected to vest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsPKwXAgmC51" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares expected to vest">23,873</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOGfx0CuEpA8" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price expected to vest">14.60</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">7.60</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBsDZrxE9hdj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares total">85,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 61977 17.37 P6Y9M21D 23873 14.60 P7Y7M6D 85850 <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTOzUrKZS1El" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Option activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of
 Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zt6HFqEFhvrd" style="width: 13%; text-align: right" title="Stock options outstanding, beginning balance">86,466</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">6.90 – 25.20</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zfu44KSf0WCb" style="width: 13%; text-align: right" title="Weighted average exercise price outstanding, beginning balacne">22.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zR5yHgz6WKn5" style="text-align: right" title="Stock options, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zt51gTCKhdCi" style="text-align: right" title="Weighted average exercise price, granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z62PJ1VKKOki" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options, cancelled/expired">616</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">14.10-1,425.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zZtJ2ScoYRQ" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, cancelled/expired">206.34</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Outstanding June 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zcWPOFEnBpb5" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding, ending balance">85,850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">6.90 – 25.20</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z15XKKgyYh7g" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price outstanding, ending balance">16.60</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Exercisable, June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z1m0TquXFLA9" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options, exercisable">61,977</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">6.90 – 25.20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zQlDupLZ3CT1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable">17.37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 86466 6.90 – 25.20 22.40 0 0 616 14.10-1,425.00 206.34 85850 6.90 – 25.20 16.60 61977 6.90 – 25.20 17.37 0 131576 1.52 0 0 0.50 <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zt1NYH4XYgWd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Nonvested shares)"> <tr style="vertical-align: bottom"> <td>Schedule of non vested stock options</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left">Nonvested stock

options at April 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240401__20240630_zzjQVhjMPThg" style="width: 13%; text-align: right" title="Nonvested shares outstanding, beginning balance">28,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240401__20240630_zifjpYwgqWZ6" style="width: 13%; text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, beginning balance">1.44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240401__20240630_zLjaOErs4KPi" style="text-align: right" title="Options vested">(4,780</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20240401__20240630_z7MVejsdcARe" style="text-align: right" title="Weighted average grant date fair value nonvested shares outstanding, vested">1.62</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_di0_c20240401__20240630_zVvTU46eYxAd" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Nonvested stock options at June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240401__20240630_zCcLKb37Uyvc" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested shares outstanding, ending balance">23,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 28653 1.44 4780 1.62 -0 23873 <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zg0HAyGwUXW3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Options exercisable)"> <tr style="vertical-align: bottom"> <td colspan="2">Schedule of options outstanding and exercisable</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="9" style="border-bottom: black 1pt solid; text-align: center">Options Outstanding</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">Options Exercisable</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Exercise Prices</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Number
 Outstanding</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted
 Average
 Remaining
 Life (Years)</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted
 Average
 Exercise
 Price</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Number
 Outstanding</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Weighted
 Average
 Exercise
 Price</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%">$</td> <td style="text-align: right; width: 18%">6.90 - 16.80</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zZvlh9Ru609g" style="width: 13%; text-align: right" title="Stock options outstanding">61,672</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">7.23 years</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zj4FQ7FiWFjj" style="width: 13%; text-align: right" title="Weighted average exercise price, outstanding">13.23</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zK07vMUS07P2" style="width: 13%; text-align: right" title="Stock options exercisable">41,326</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zpNFRgTWmyy1" style="width: 13%; text-align: right" title="Weighted average exercise price, exercisable">13.46</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">25.20</td> <td> </td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zB07yeLLI6pa" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding">24,178</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.52 years</td> <td> </td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zvx3IQHvIaVj" style="text-align: right" title="Weighted average exercise price, outstanding">25.20</td> <td> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zbzW1XZTMBee" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options exercisable">20,651</td> <td> </td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_z6yu2neEwb57" style="text-align: right" title="Weighted average exercise price, exercisable">25.20</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z11Ny1Ljj5Gb" style="border-bottom: black 2.25pt double; text-align: right" title="Stock options outstanding">85,850</td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zLBMK38UNIxa" style="border-bottom: black 2.25pt double; text-align: right" title="Stock options exercisable">61,977</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> 61672 P7Y2M23D 13.23 41326 13.46 24178 P6Y6M7D 25.20 20651 25.20 85850 61977 <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zYbOKfqyBvyl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - RSU activity)"> <tr style="vertical-align: bottom"> <td>Schedule of restricted stock units restricted stock units</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 84%">Nonvested RSUs at April 1, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8utMb1aC31l" style="width: 13%; text-align: right" title="RSUs nonvested">4,885</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaAYLbGFTSf8" style="text-align: right" title="RSU's granted">131,576</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhhi9rUpktt7" style="text-align: right" title="RSU's vested">(27,602</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td

id="xdx_989_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_iN_di0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrcrrieYGibl" style="border-bottom: Black 1pt solid; text-align: right" title="Tax withholding payments, shares">(10,177</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Nonvested RSUs at June 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_d0_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyLlwskN5Vkb" style="border-bottom: Black 2.5pt double; text-align: right" title="RSUs nonvested">98,682</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4885 131576 27602 10177 98682 <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zKbarbGWXCfl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Stockbased compensation)"> <tr style="vertical-align: bottom"> <td>Schedule of stock-based compensation</td><td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 68%; text-align: left">Vesting of restricted stock units</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgAx8tSxRz2h" style="width: 13%; text-align: right" title="Stock based compensation">68,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUg4eN5yUKW8" style="width: 13%; text-align: right" title="Stock based compensation">37,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Vesting of stock options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zzMjMOl0uqq9" style="border-bottom: Black 1pt solid; text-align: right" title="Stock based compensation">70,578</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z4TyS6H40jT6" style="border-bottom: Black 1pt solid; text-align: right" title="Stock based compensation">212,614</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Stock-Based Compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20240401__20240630_zrxpsN9BXbNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation">139,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_z33dCcvfDiH5" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation">250,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 68750 37500 70578 212614 139328 250114 0.50 310674 P1Y5M12D 9. WARRANTS   During the three-months ended June 30, 2024, we issued 16,524,000 warrants in connection with the May 17, 2024 public offering. We did not issue any warrants in the three-months ended June 2023.   A summary of warrant activity during the three months ended June 30, 2024 is presented below: <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zCcdKStA3aUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of warrant activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of
 Exercise
 Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%">Warrants outstanding at March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIpesxhKeJ59" style="width: 13%; text-align: right" title="Warrants outstanding">32,676</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">15.00 - 27.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zc16G6AF6XC2" style="width: 13%; text-align: right" title="Warrants outstanding, weighted average exercise price">20.09</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zplA2oM5iwx5" style="text-align: right" title="Warrants granted">16,524,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsgranted_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTxspTx8U1Wc" style="text-align: right" title="Warrants granted, weighted average exercise price">0.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zruK69UOv2q3" style="text-align: right" title="Warrants exercised">(3,180,000</td><td style="text-align: left">)</td><td> </td><td style="text-align: left">$</td><td style="text-align: right">0.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zhpPahroT0b9" style="text-align: right" title="Warrants exercised, weighted average exercise price">0.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBs6L1R0ZjL6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants cancelled or expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlGoPv9JuQri" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants cancelled or expired, weighted average exercise price">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants outstanding at June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEkm9l37tjN2" style="border-bottom: Black 2.5pt double; text-align: right">13,376,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.58 - 27.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkzjRUMlisIg" style="border-bottom: Black 2.5pt double; text-align: right">0.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Warrants exercisable at June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisable_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6BtSSV5W96f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">13,376,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.58 - 27.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOG12RCnA084" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, weighted average exercise price">0.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zCcdKStA3aUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of warrant activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of
 Exercise
 Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2"

style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%">Warrants outstanding at March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zIpesxhKeJ59" style="width: 13%; text-align: right" title="Warrants outstanding">32,676</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">15.00 - 27.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zc16G6AF6XC2" style="width: 13%; text-align: right" title="Warrants outstanding, weighted average exercise price">20.09</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zplA2oM5iwx5" style="text-align: right" title="Warrants granted">16,524,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsgranted_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTxspTx8U1Wc" style="text-align: right" title="Warrants granted, weighted average exercise price">0.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zruK69UOv2q3" style="text-align: right" title="Warrants exercised">(3,180,000</td><td style="text-align: left">)</td><td> </td><td style="text-align: left">$</td><td style="text-align: right">0.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zhpPahroT0b9" style="text-align: right" title="Warrants exercised, weighted average exercise price">0.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBs6L1R0ZjL6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants cancelled or expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled_d0_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlGoPv9JuQri" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants cancelled or expired, weighted average exercise price"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants outstanding at June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEkm9l37tjN2" style="border-bottom: Black 2.5pt double; text-align: right">13,376,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.58 - 27.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkzjRUMlisIg" style="border-bottom: Black 2.5pt double; text-align: right">0.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Warrants exercisable at June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisable_iE_c20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6BtSSV5W96f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">13,376,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.58 - 27.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable_c20240401__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOG12RCnA084" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, weighted average exercise price">0.63</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 32676 15.00 - 27.50 20.09 16524000 0.58 0.58 3180000 0.58 0.58 0 13376676 0.58 - 27.50 0.63 13376676 0.58 - 27.50 0.63 10. COMMITMENTS AND CONTINGENCIES   LEASE COMMITMENTS   Office, Lab and Manufacturing Space Leases   <span id="xdx_905_eus-gaap--LesseeOperatingLeaseDescription_c20240401__20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratorySpaceMember_zKuWcD6I9RIa" title="Lease description">In December 2020, we entered into an agreement to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement carries a term of 63 months and we took possession of the office space effective October 1, 2021. We took possession of the laboratory space effective January 1, 2022. <span id="xdx_902_eus-gaap--LesseeOperatingLeaseDescription_c20240401__20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingSpaceMember_zbNDYZ44PrKe" title="Lease description">In October 2021, we entered into another lease for approximately 2,655 square feet of space to house our manufacturing operations located at 11588 Sorrento Valley Road, San Diego, California 92121. The term is for 55 months and we took possession of the manufacturing space in August 2022. The current <span id="xdx_908_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20240401__20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratorySpaceMember_zNICCVmpJSGb" title="Lease frequency of periodic payment">monthly base rent under the office and laboratory component of the lease is $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20240401__20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratorySpaceMember_zi8fAFHWFWub" title="Lease periodic payment">14,158. The current <span id="xdx_907_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20240401__20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingSpaceMember_zshz9heziOi7" title="Lease frequency of periodic payment">monthly base rent under the manufacturing component of the lease is $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_c20240401__20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingSpaceMember_zVvsyWSSJHwi" title="Lease periodic payment">12,452. Cash paid in the three months ended June 30, 2024 for amounts included in the measurement of operating lease liabilities in operating cash flows was $<span id="xdx_90C_eus-gaap--OperatingLeaseLiability_iI_c20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingSpaceMember_zPBGp2RZ4Jgk" title="Operating lease liabilities">79,830.   The office, lab and manufacturing leases are coterminous with a remaining term of <span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_zUXDT3aMNcZ" title="Remaining lease term">33 months. The weighted average discount rate is <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_z6tcbVQikqF5" title="Lease weighted average discount rate">4.25%.   As of our June 30, 2024 balance sheet, we have an operating lease right-of-use asset of $813,900 and operating lease liability of $869,945.   In addition, the lease agreements for the new office, lab and manufacturing space required us to post a standby L/C in favor of the landlord in the aggregate amount of $87,506 in lieu of a security deposit. We arranged for our bank to issue standby L/Cs for the new office and lab in the amounts of $<span id="xdx_90E_eus-gaap--LettersOfCreditOutstandingAmount_iI_c20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratorySpaceMember_z7zITPNUmrve" title="Letter of credit">46,726 in the fiscal year ended March 31, 2021 and for the manufacturing space in the amount of $<span id="xdx_90F_eus-gaap--LettersOfCreditOutstandingAmount_iI_c20240630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingSpaceMember_zmVQyWFSKFxb" title="Letter of credit">40,780 in the fiscal year ended March 31, 2022. We transferred like amounts to a restricted certificate of deposit which secured the bank's risk in issuing those L/Cs. We have classified those restricted certificates of deposit on our balance sheet as restricted cash with a balance of $87,506.   Overall, our rent expense, which is included in general and administrative expenses, approximated $102,000 and $105,000 for the three month periods ended June 30, 2024 and 2023, respectively.   LEGAL MATTERS   We may be involved from time to time in various claims, lawsuits, and/or disputes with third parties or breach of contract actions incidental to the normal course of our business operations. We are currently not involved in any litigation or any pending legal proceedings.   In December 2020, we entered into an agreement to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement carries a term of 63 months and we took possession of the office space effective October 1, 2021. In October 2021, we entered into another lease for approximately 2,655 square feet of space to house our manufacturing operations located at 11588 Sorrento Valley Road, San Diego, California 92121. The term is for 55 months and we took possession of the manufacturing space

in August 2022. monthly 14158 monthly 12452 79830 P33M 0.0425 813900 869945 87506 46726 40780 87506 102000 105000 11. SUBSEQUENT EVENTS   Management has evaluated events subsequent to June 30, 2024 through the date that the accompanying consolidated financial statements were filed with the SEC for transactions and other events which may require adjustment of and/or disclosure in such financial statements.   In August 2024, the Bellberry Human Research Ethics Committee granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025. The trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia.   false false false false